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Abstract
Phagocytic cells comprise a central component of the inflammatory response to pathogens, particularly
against extracellular bacteria that proliferate on mucosal surfaces. Mounting evidence suggests that microbes
can manipulate phagocyte function dynamically to shape the persistence and efficacy of antibacterial defenses.
Successful pathogens often restrain inflammatory responses to evade clearance and promote dissemination
within the host. In contrast, commensal bacterial communities have been shown to bolster the functional
capacity of phagocytes throughout the body. Despite the critical role of microbe-phagocyte interactions in
maintaining health and dictating infection outcome, the mechanisms underlying this influence remain
incompletely understood. Here, we examined the impact of pathogenic and commensal microbes on the
functions of neutrophils, monocytes, and macrophages, three phagocyte subsets indispensable for
antibacterial host defense. Using a mouse model of upper airway infection, we found that the bacterial
pathogen Streptococcus pneumoniae (the pneumococcus) exploits molecular mimicry to disarm responding
neutrophils. Phosphorylcholine (ChoP) moieties displayed on the exterior of the pneumococcus and within
the inflammatory phospholipid platelet-activating factor (PAF) allow the microbe to leverage its ChoP-
remodeling enzyme, Pce, to remove PAF from the airway. Neutrophils deprived of PAF signaling fail to
eliminate bacteria effectively, allowing the pneumococcus to persist, disseminate systemically, and transmit
efficiently between hosts. We found that the pneumococcus also manipulates mononuclear phagocyte
responses by stimulating the liberation of macrophage migration inhibitory factor (MIF), a cytokine
responsible for retaining macrophages at sites of inflammation. MIF-driven macrophage responses accelerate
pneumococcal clearance from the upper airway. However, MIF signaling provokes damaging inflammation
and impairs bacterial control during pneumococcal pneumonia, underscoring the tight regulation of
phagocyte responses required for effective host defense. Finally, we studied the impact of signals from the
intestinal microbiota on systemic phagocyte lifespan, a key component of cellular fitness at homeostasis. We
found that a neomycin-sensitive cohort of commensal bacteria augments the survival and circulating lifespan
of neutrophils and inflammatory monocytes. This stimulation required signaling through the intracellular
peptidoglycan sensor Nod1 and liberation of the pro-inflammatory cytokine IL-17A. Together, these data
demonstrate that bacteria modulate phagocyte physiology during infection and health, influencing host
readiness and response to pathogenic threats.
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ABSTRACT 
 
MICROBIAL MANIPULATION OF PHAGOCYTE FUNCTION  
DURING INFECTION AND HEALTH 
 
Christopher B. Hergott 
Jeffrey N. Weiser 
 
Phagocytic cells comprise a central component of the inflammatory response to 
pathogens, particularly against extracellular bacteria that proliferate on mucosal 
surfaces. Mounting evidence suggests that microbes can manipulate phagocyte function 
dynamically to shape the persistence and efficacy of antibacterial defenses. Successful 
pathogens often restrain inflammatory responses to evade clearance and promote 
dissemination within the host. In contrast, commensal bacterial communities have been 
shown to bolster the functional capacity of phagocytes throughout the body. Despite the 
critical role of microbe-phagocyte interactions in maintaining health and dictating 
infection outcome, the mechanisms underlying this influence remain incompletely 
understood. Here, we examined the impact of pathogenic and commensal microbes on 
the functions of neutrophils, monocytes, and macrophages, three phagocyte subsets 
indispensable for antibacterial host defense. Using a mouse model of upper airway 
infection, we found that the bacterial pathogen Streptococcus pneumoniae (the 
pneumococcus) exploits molecular mimicry to disarm responding neutrophils. 
Phosphorylcholine (ChoP) moieties displayed on the exterior of the pneumococcus and 
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within the inflammatory phospholipid platelet-activating factor (PAF) allow the microbe 
to leverage its ChoP-remodeling enzyme, Pce, to remove PAF from the airway. 
Neutrophils deprived of PAF signaling fail to eliminate bacteria effectively, allowing the 
pneumococcus to persist, disseminate systemically, and transmit efficiently between 
hosts. We found that the pneumococcus also manipulates mononuclear phagocyte 
responses by stimulating the liberation of macrophage migration inhibitory factor (MIF), 
a cytokine responsible for retaining macrophages at sites of inflammation. MIF-driven 
macrophage responses accelerate pneumococcal clearance from the upper airway. 
However, MIF signaling provokes damaging inflammation and impairs bacterial control 
during pneumococcal pneumonia, underscoring the tight regulation of phagocyte 
responses required for effective host defense. Finally, we studied the impact of signals 
from the intestinal microbiota on systemic phagocyte lifespan, a key component of 
cellular fitness at homeostasis. We found that a neomycin-sensitive cohort of commensal 
bacteria augments the survival and circulating lifespan of neutrophils and inflammatory 
monocytes. This stimulation required signaling through the intracellular peptidoglycan 
sensor Nod1 and liberation of the pro-inflammatory cytokine IL-17A. Together, these 
data demonstrate that bacteria modulate phagocyte physiology during infection and 
health, influencing host readiness and response to pathogenic threats. 
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CHAPTER 1: 
Introduction 
 
Christopher B. Hergott 
 
Department of Microbiology, University of Pennsylvania,  
Philadelphia, PA, 19104, USA  
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Introduction to Phagocytes in Anti-Bacterial Defense 
In the 133 years since Ilya Metchnikoff’s seminal discovery of immune cells capable of 
engulfing foreign threats, phagocytes have become a central focus in the study of 
inflammatory responses to bacterial infection (323). While most cells in the body bear a 
modest capacity for microbial uptake, a specialized cadre of leukocytes—including 
neutrophils, monocytes, and macrophages—serve particularly crucial roles in clearing 
the host of bacterial pathogens. Termed “professional phagocytes” collectively, these 
cells react swiftly to stimulation by diverse pathogen-associated molecular patterns 
(PAMPs) and employ a potent array of bactericidal mechanisms to digest ingested 
microbes (114). Critically, host protection by phagocytes can commence without 
recognition of pathogen-specific antigens or instruction by the adaptive immune system 
(189). These cells therefore provide essential early control of bacterial growth and 
impede systemic dissemination before subsequent phases of immunity develop. 
 
While each subset of professional phagocytes serve distinct roles in fighting infection, 
they share several fundamental characteristics. Most circulating phagocytes arise 
continuously from hematopoietic myeloid precursors in the adult bone marrow (88).  
The cells egress from the marrow in response to homeostatic cytokine signals from the 
periphery, circulate through the bloodstream, and seed tissues for residence and 
turnover (289). Infection perturbs each component of the phagocyte life cycle: myeloid 
precursors proliferate to spawn more mature phagocytes from the marrow; the lifespan 
of circulating phagocytes extends to enhance their persistence in combating pathogens; 
and inflammatory signals augment the recruitment and bactericidal capacity of 
phagocytes responding to infectious foci (94, 185, 215, 247). Despite these common 
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properties, the functions and regulation of neutrophils, monocytes, and macrophages 
differ substantially and warrant individual examination. 
 
Neutrophils 
Neutrophils, also known as polymorphonuclear phagocytes (PMNs), comprise the most 
abundant leukocyte subset in the human bloodstream. Released from the bone marrow 
at a rate of ~1011 cells per day, these terminally differentiated phagocytes constitute more 
than half of all steady-state hematopoietic output (224). Neutrophils are recruited from 
the circulation upon bacterial infection by a diverse set of pro-inflammatory cytokines 
and chemokines (e.g. tumor necrosis factor α, interleukins 1β and 6, CXCL1 and -2) 
liberated by tissue-resident cells at sites of inflammation (25). Upon reaching the focus 
of infection, neutrophils engulf and destroy invading bacteria, release a multitude of 
antimicrobial proteins from stored granules into the tissue environment, and extrude 
their chromatin in the form of neutrophil extracellular traps (NETs) to impede microbial 
dissemination (38). These mechanisms cooperate to form a vital component of 
antibacterial defense. Accordingly, individuals suffering from defects in neutrophil 
abundance or function exhibit profound immunodeficiency, with increased risks of 
systemic infection by a wide range of bacterial pathogens, sepsis, and death (96, 293).  
 
The life cycle of neutrophils begins with their development from hematopoietic 
progenitors in the bone marrow. While they share a common cellular origin with 
monocytes (termed granulocyte/monocyte progenitors, GMPs), neutrophils diverge from 
the monocytic lineage through the action of granulocyte colony-stimulating factor (G-
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CSF), the key cytokine guiding neutrophil development (200). The maturation of 
granules bearing antimicrobial mediators delineates the subsequent steps in terminal 
neutrophil differentiation. Primary granules, which contain defensins, elastase, serine 
proteases, and myeloperoxidase, form at the early pro-myelocyte stage. Secondary 
granules form in the myelocyte stage that follows, bearing key components of the 
NADPH oxidase enzyme responsible for the bactericidal “respiratory burst,” along with 
lactoferrin and lysozyme. Last, tertiary granules containing cathepsin and gelatinase 
form during the “band stage” directly preceding the emergence of fully mature, 
segmented neutrophils (38-40). It is important to note that the sequence in which these 
granules develop does not reflect the sequence in which they act upon ingested microbes. 
The contributions of granule contents to antimicrobial defense are discussed below. 
 
Following maturation, counterpoised chemokine signals regulate the release of 
neutrophils from the bone marrow. CXCL12, acting through its receptor CXCR4, 
mediates the retention of mature neutrophils in the marrow to maintain a central pool of 
mature phagocytes available to fight infection (38, 100, 145). Opposing this force is 
CXCR2, through which CXCL1 and CXCL2 signal to liberate neutrophils from the 
marrow at homeostasis (99). The balance of these competing influences promotes steady 
peripheral abundance of cells at homeostasis.  In contrast, systemic inflammation 
disrupts the equilibrium of neutrophil mobilization to promote trafficking of phagocytes 
into the periphery en masse.  Systemic infection with Listeria monocytogenes or 
signaling through Toll-like receptors (TLRs) 2 and 4 have been shown to deplete central 
neutrophil stores, indicating that direct detection of pathogens can accelerate phagocyte 
egress (36, 248). Moreover, systemic infections upregulate the circulating levels of 
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cytokines that enhance neutrophil mobilization, including G-CSF, GM-CSF, and IL-6 
(215). While inflammatory mobilization of neutrophils augments the pool of phagocytes 
actively engaged in fighting pathogens, bone marrow exhaustion and host demise can 
result if this response fails to swiftly control bacterial dissemination. 
 
While neutrophils serve an important role in controlling disseminated infections, their 
protective role begins most often in response to localized infections within host tissues. 
Phagocyte trafficking to sites of inflammation requires targeted, efficient exit from the 
vasculature. For neutrophils, this process is governed by sequential interactions with 
endothelial cells lining the blood vessels of inflamed tissue. First, the speed of neutrophil 
transit within the vasculature is slowed by low-affinity interactions with the 
endothelium, causing the cells to roll along the luminal vascular surface. Neutrophil 
rolling is initiated primarily by the binding of E- and P-selectins displayed on the 
endothelia to ligands expressed on the neutrophil surface, including E-selectin ligand 1 
(ESL-1) and P-selectin ligand 1 (PSGL-1) (38, 50, 56). Together, these interactions 
trigger reorganization of neutrophil cytoskeletal structure to enhance display of the β2 
integrins LAF-1 and Mac-1 on the neutrophil surface. Binding of these integrins to their 
ligands on endothelia, Intercellular Adhesion Molecules (ICAM) -1 and -2, permits firm 
adhesion of neutrophils and mediates their transit through the vascular wall and into 
inflamed tissue (110, 358).  
 
After trafficking to infected tissues, neutrophils deploy a plethora of bactericidal 
mechanisms to eliminate the pathogens with which they are now in close proximity. 
These defenses can be divided into two general categories: those requiring pathogen 
6 
 
uptake and degradation (phagocytic) and those requiring release of antimicrobial 
mediators into the extracellular environment (non-phagocytic).  
 
Phagocytic uptake begins with the binding of pathogens to receptors expressed on the 
surface of the neutrophil. Engulfment is accelerated dramatically if microbes are first 
coated with soluble inflammatory factors, such as antibody or complement. These bind 
to antigens exposed on the exterior of microbes and provide a conserved target of 
recognition for uptake receptors in a process termed opsonization (97). Accordingly, 
opsonin receptors comprise the most well-studied molecules governing microbial uptake 
into neutrophils and are upregulated readily by microbial products and inflammatory 
cytokines (186).  Uptake of many bacterial pathogens relies predominantly on   
complement Receptor 3 (CR3, Mac-1)—which recognizes complement component C3b—
and Fc receptors (FcRs), which exhibit specificity for the conserved, basal component of 
antibodies that are bound to microbial surfaces (194). The mechanistic details of 
opsonization are beyond the scope of this discussion and are reviewed extensively 
elsewhere (272, 286). However, despite the diversity of opsonins involved in bacterial 
uptake, engagement of their receptors on neutrophils yields a common result: 
invagination of the neutrophil plasma membrane to engulf microbes in an internal 
compartment called the phagosome. 
 
Phagosome formation within neutrophils is followed swiftly by its fusion with 
membrane-bound granules bearing the enzymes and toxic mediators responsible for 
bacterial killing. In contrast to macrophages and other professional phagocytes, bacterial 
elimination within neutrophils does not require acidification of the phagosomal 
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environment  (159). Neutrophils instead rely on a combination of oxidative and non-
oxidative means to destroy ingested bacteria at neutral pH (292).  
 
Oxidative killing requires the liberation of reactive oxygen species (ROS) within the 
phagosome to attack and degrade microbial structures.  After assembly at the phagosome 
membrane, the multi-subunit enzyme NADPH oxidase begins this “respiratory burst” by 
generating superoxide anions capable of disrupting microbes directly and serving as 
substrates for the generation of other ROS.  Downstream production of hydrogen 
peroxide (through dismutation of superoxide anions), reactive halides (catalyzed by 
myeloperoxidase enzymes), and other oxygen radical species provides the neutrophil 
with a diverse repertoire of bactericidal molecules with which to attack microbial 
structures (74, 292). While the means by which ROS destroy bacteria remain under 
active investigation, proposed mechanisms include disruption of bacterial membrane 
integrity, degradation of essential bacterial enzymes, and damage to bacterial DNA 
(108). Patients who suffer from a congenital absence of NADPH oxidase components 
(termed chronic granulomatous disease, CGD) illustrate the central importance of the 
respiratory burst to bacterial control.  Neutrophils lacking functional NADPH oxidase 
activity exhibit markedly impaired ROS production, resulting in defective microbial 
killing (105). Accordingly, these patients show markedly enhanced susceptibility to 
infections by diverse bacterial pathogens, including many that rarely cause disease in 
immunocompetent individuals (e.g. Klebsiellla species, E. coli, S. aureus, Nocardia 
species) (354).  
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In addition to oxidative mechanisms, neutrophils kill ingested bacteria through the 
action of antimicrobial proteins, introduced to the phagosome through successive 
fusions with cytoplasmic granules. First, secondary granules introduce lysozyme and 
defensins that rupture bacteria, along with proteins like lactoferrin and lipocalin that 
deprive the microbe of requisite nutrients (20, 54). Shortly thereafter, primary granules 
bring pore-forming defensins and serine proteases to the phagosome. These factors 
disrupt the osmotic balance of bacteria and degrade microbial proteins to accelerate 
microbial death (261, 351). Lastly, cathepsins and gelatinase in tertiary granules provide 
further bactericidal pressure through microbial proteolysis (39).  
 
More recently, neutrophils have been shown to kill extracellular bacteria without 
phagocytosis through the liberation of neutrophil extracellular traps (NETs). NETs are 
formed upon neutrophil activation by pathogens through the extrusion of fibers 
composed of neutrophil chromatin, proteases, and anti-microbial peptides. Diverse 
gram-negative and gram-positive bacteria associate with and become enmeshed within 
this NET lattice, inhibiting their growth and accelerating microbial clearance (45).   The 
mechanisms driving NET formation in vivo remain incompletely understood, but are 
thought to involve an orchestrated de-condensation of neutrophil chromatin governed by 
the enzymes peptidyl arginine deaminase type IV (PAD4) and neutrophil elastase (184).  
Further study has revealed that neutrophils can remain vital and exert phagocytosis in 
vivo despite extruding their genomic content in NETs (363).  Thus, neutrophils appear 
to employ multiple, parallel levels of defense against invading bacteria from both within 
and outside the phagocyte cell body. 
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Monocytes and Macrophages 
The mononuclear phagocyte system (MPS) comprises another subset of professional 
phagocytes essential for antibacterial defense. The MPS is composed of monocytes, 
macrophages, and dendritic cells, defined originally by common hematopoietic origins in 
the bone marrow (162). While dendritic cells (DCs) engulf microbes efficiently and are 
considered professional phagocytes, they function primarily to present microbial 
antigens to the adaptive immune system rather than killing bacteria directly (238).  
Therefore, while reviewed extensively elsewhere (237), dendritic cells will not be 
discussed in detail here.  
 
Monocyte and macrophage homeostasis in adults has traditionally been defined as a 
continuum of hematopoietic development, systemic circulation of monocytes, 
differentiation into macrophages, and deposition of macrophages into tissues as resident 
phagocytes (162). However, recent findings challenge this classical dogma. Resident 
macrophages from a number of tissues have been shown to arise from progenitors 
deposited during embryonic life, proliferating locally and without input from the 
hematopoietic system in adult life (127). In turn, monocytes can exit from the circulation 
and survey host tissues without differentiating into macrophages (158). While our 
understanding of the MPS continues to develop and evolve, it remains clear that the 
classical monocyte-macrophage axis continues to replenish macrophages populations 
from many tissues (e.g. the gastrointestinal tract) in adults and is the primary 
mechanism by which these cells proliferate during inflammation (22).  The discussion 
below will therefore focus primarily upon this paradigm of ontogeny. 
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Monocytes develop in the bone marrow as part of normal hematopoiesis.  Arising from a 
progenitor cell shared with neutrophils (granulocyte-monocyte progenitors, GMP), 
monocytes differentiate under the guidance of M-CSF, the cardinal cytokine of 
monopoiesis (125). Accordingly, mice lacking M-CSF or its receptor (M-CSFR) exhibit 
profound defects in the systemic abundance of monocytes and macrophages (63). 
Monocytic lineages differentiate from that of dendritic cells through at least two parallel 
pathways: M-CSF-guided divergence from a precursor cell shared with DCs (monocyte-
dendritic cell precursors, MDPs) and development from independent, committed 
precursor cells called common monocyte progenitors (cMOPs) (116, 146).  Mature 
monocytes emigrate from the bone marrow at homeostasis under the guidance of the 
chemokine CCL2, permitting entry of the cells into systemic circulation (106). Notably, 
CCL2 also drives the accelerated egress of monocytes upon bacterial infection and 
systemic inflammation (295). 
 
Circulating monocytes are divided into two primary subsets, distinguished by differential 
receptor expression and functional roles. In mice, “inflammatory” monocytes express 
high levels of the surface markers Ly6C and CCR2 (the chemokine receptor for CCL2) 
and are the predominant subtype recruited from the marrow in both homeostatic and 
inflammatory conditions. These cells exhibit a brief circulating half-life (18-24 hours) 
and turn over rapidly during health, but also comprise the primary subtype amplified 
and recruited to sites of inflammation during bacterial infection (124). “Classical” or 
“patrolling” monocytes do not express high levels of Ly6C or CCR2, instead upregulating 
the chemokine receptor CX3CR1. Classical monocytes survey blood vessel barriers at 
homeostasis to intercept invading pathogens and guard vascular integrity (16). 
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Exhibiting a longer half-life (5-7 days) than inflammatory monocytes, these cells also 
migrate from the vasculature and are thought to form the immediate precursors to 
resident macrophages and/or an independent population of tissue-resident monocytes 
(124). Interestingly, recent studies have established that classical, Ly6Clo monocytes arise 
chiefly from trans-differentiation of inflammatory, Ly6Chi monocytes in the peripheral 
circulation (364). Thus, unlike neutrophils, monocytic lineages appear to continue 
differentiating after egress from the bone marrow at homeostasis. 
 
During infection, a network of chemokines recruit monocytes from the bloodstream and 
into inflamed tissues. Among bacterial pathogens, this process has been studied most 
closely in the setting of systemic infection by Listeria monocytogenes. Animals lacking 
the chemokine receptor CCR2 exhibit a profound impairment in monocyte recruitment, 
accelerated bacterial outgrowth, and enhanced mortality during Listeria infection, 
indicating that CCR2+ inflammatory monocytes are required for optimal bacterial 
clearance (190, 296). Subsequent work demonstrated that these defects are caused 
mainly by ineffective mobilization of the mature monocyte pool from bone marrow 
stores (295). Other chemokines and cytokines, including CCL7 (a CCR2 ligand) and 
TNFα, act in cooperation with CCL2 to govern optimal recruitment of inflammatory 
monocytes to sites of infection (302).  Classical, CX3CR1+ monocytes also augment this 
process. Selective depletion of CX3CR1+ cells reduces systemic classical monocyte 
abundance and diminishes the recruitment of CCR2+ inflammatory monocytes 
responding to Listeria-infected tissues. (17).  
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Upon arriving at sites of infection, monocytes can contribute to bacterial killing while 
maintaining monocytic identity through production of reactive oxygen/nitrogen species 
and the release of pro-inflammatory cytokines (302, 311). However, macrophages govern 
the bulk of bacterial phagocytosis. While the mechanisms governing microbial uptake by 
macrophages are broadly similar to those of neutrophils, macrophage phagosome 
dynamics after pathogen engulfment are distinct. Macrophage phagosomes mature and 
acquire bactericidal factors through successive fusions with cytoplasmic vesicles and 
lysosomes rather than granules (114). Also in contrast to neutrophils, macrophages 
acidify phagolysosomes to accelerate bacterial killing.  Membrane-bound V-ATPase 
enzymes pump protons into the luminal environment of the phagolysosome in an ATP-
dependent manner to damage microbial structures, inhibit bacterial growth, and 
optimize the function of bactericidal proteases (114, 150). In addition to the reactive 
oxygen species described for neutrophils, macrophages more readily produce reactive 
nitrogen species (RNS) like nitric oxide (NO). Generated by the inducible nitric oxide 
synthase enzyme (iNOS, NOS2), NO attacks microbial proteins, lipids, and nucleic acids 
to accelerate bacterial degradation (319). Macrophages also deploy a number of the 
antimicrobial peptides and proteases described above for neutrophils, though many of 
these proteases function optimally at low pH in adaptation to the acidic environment of 
the macrophage phagolysosome (319). 
 
Principles of Phagocyte Evasion by Bacteria 
Successful microbes must evade phagocytic clearance to persist at mucosal surfaces and 
within host tissues. Accordingly, most bacterial pathogens have evolved a complex 
collection of virulence factors tasked with eluding or disarming each step of phagocyte 
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function. While phagocyte evasion will be discussed in more detail using Streptococcus 
pneumoniae as a model bacterial pathogen, a number of general principles governing 
this process can be illuminated by examining common tactics used by a diversity of 
pathogenic microbes. These include subversion of bacterial recognition by phagocytes, 
uptake into cells, and degradation by phagocyte bactericidal mechanisms.  
 
Bacterial evasion of phagocyte detection often relies upon masking surface structures or 
other immunogenic factors against which the host has evolved sensors or opsonins. 
Many bacteria produce thick polysaccharide capsules to provide this shield. Used with 
particularly high frequency among respiratory pathogens like S. pneumoniae, N. 
meningitidis, H. influenzae, and P. aeruginosa, capsules provide a physical barrier to 
the access of cell wall components and proteins on the exterior of the microbe (285).  
Capsules provide especially potent protection against opsonization by complement, 
which would otherwise facilitate microbe recognition by conserved uptake receptors.  
Complement activation fragments (e.g. C3b) bind poorly to capsular polysaccharide 
lattices and capsules provide suboptimal platforms for the activation of complement 
activation cascades (170).  Accordingly, mutations in capsule production among 
normally encapsulated bacteria accelerate complement deposition and bacterial 
clearance (151).   Many microbes also secrete proteins that bind to complement and 
antibodies, thereby inhibiting their deposition or activation (e.g. S. aureus, S. pyogenes). 
Others produce proteases that cleave complement and immunoglobulins directly (e.g. 
Neisseria spp., H. influenzae, S. pneumonia, S. sanguis) (285). The breadth and depth of 
anti-opsonization strategies among diverse microbes underscore the central importance 
of this step in facilitating phagocytic clearance. 
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In addition to blocking opsonization, many bacteria modify their surface structures to 
evade sensing by pattern recognition receptors (PRRs) and thereby inhibit the 
recruitment and activation of responding phagocytes.  S. typhimurium, P. gingivalis, 
and H. pylori have all been shown to remodel surface lipopolysaccharide structures to 
evade detection by its host receptor, Toll-like receptor 4 (TLR4) (71, 75, 171). C. jejuni 
and H. pylori evade TLR5 similarly through modifications to their flagellar structures 
(11, 285). Together, these mechanisms serve to dampen the inflammatory response to 
infection, thereby reducing the numbers of recruited, activated phagocytes with which 
they must contend. 
 
Upon contact with phagocytes, many bacterial pathogens employ strategies to inhibit 
their uptake into the cells. These include disruptions in host cell signaling essential for 
receptor-mediated internalization or reorganization of the phagocyte cytoskeleton to 
block phagosome formation. For example, Yersinia and Salmonella species inject 
phosphatases into phagocytes to inhibit host tyrosine phosphorylations essential for 
early phagocytic signaling (12, 168). Yersinia and P. aeruginosa, among others, express 
mimetics of host GTPase-activating proteins to terminate intracellular signaling 
important for actin fiber remodeling and phagosome formation (34, 126).  Another tactic 
used commonly to evade internalization is eliminating the phagocytes entirely. A number 
of bacteria, including S. pneumoniae, S. aureus, and S. pyogenes, secrete toxins that 
form pores in the membranes of responding phagocytes, often triggering programmed or 
necrotic cell death (204). 
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Even upon successful internalization, many pathogenic bacteria retain virulence 
strategies to promote their prolonged survival within the intracellular environment. One 
tactic, used by M. tuberculosis and L. pneumophila, relies on reprogramming the 
intracellular trafficking of phagosomes to inhibit their fusion with lysosomal 
compartments and subsequent maturation (114).  L. monocytogenes uses a pore-forming 
toxin, lysteriolysin O, to escape the phagosome altogether, transiting swiftly into the 
phagocyte cytosol (27).  Still others, including Salmonella species and C. burnetti, persist 
within mature phagolysosomes, using acidification as a trigger for the deployment of 
virulence factors (8, 223).  Collectively, these findings have made clear that well-adapted 
bacterial pathogens mount evasion strategies against each step in phagocytic clearance. 
 
Introduction to Streptococcus pneumoniae 
Streptococcus pneumoniae, also known as the pneumococcus, was among the first 
bacterial pathogens studied on a molecular level and among the first for which phagocyte 
evasion strategies were described (345). The pneumococcus is a gram-positive, 
extracellular bacterium that exists as both a common microbial resident of the human 
upper respiratory tract and a highly invasive pathogen capable of dissemination to the 
lungs, bloodstream, and meninges (143). It remains a leading cause of otitis media, 
pneumonia, sepsis, and meningitis worldwide, especially among children, the elderly, 
and immunocompromised individuals. Each year, invasive pneumococcal disease is 
responsible for over 1 million deaths worldwide and accounts for approximately one-
tenth of all deaths among children under five years old (252). In the United States, the 
pneumococcus remains a leading cause of community-acquired bacterial pneumonia 
among adults, causing thousands of deaths annually (283). The historic and ongoing 
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clinical burden exacted by S. pneumoniae has long made it a subject of intensive 
investigation, yielding mechanistic discoveries that have illuminated fundamental 
principles of bacterial virulence and immune evasion. 
 
All pneumococcal infections begin with asymptomatic colonization of the upper 
respiratory tract (348). In addition to serving as the platform from which invasive 
infections arise, pneumococcal colonization is a prerequisite for transmission between 
hosts via respiratory secretions and droplets (244). Carriage is disproportionately 
prevalent in children, where levels can exceed 50% at its peak between ages two and five. 
While the prevalence of colonization in adults is lower (~10%), these rates increase 
among adults in frequent contact with young children (257). Pneumococcal isolates 
circulating in populations are classically characterized by serotype, reflecting variants of 
the polysaccharide capsule that envelops nearly all virulent pneumococcal strains (131).  
Serotypes are delineated by differential reactions with antisera targeted against 
particular groupings of pneumococcal strains, with matched capsule-antisera mixtures 
leading to a characteristic swelling of the capsular polysaccharide upon microscopic 
examination (termed the Quellung reaction) (139). At present, more than 90 
pneumococcal serotypes have been discovered and independently described (143) 
 
Decades of epidemiologic monitoring have revealed that capsular serotypes exhibit vastly 
different invasive capacities and propensities for systemic disease, underscoring the 
critical importance of the capsule in determining pneumococcal virulence (142).  
Accordingly, vaccines developed to combat the pneumococcus use capsular 
polysaccharide from virulent strains as their immunogen. Two variants of vaccines 
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currently hold licenses: the pneumococcal polysaccharide vaccine (PPV) and the 
pneumococcal conjugative vaccine (PCV). Both confer protection through the elicitation 
of systemic antibody responses, facilitating opsonophagocytic clearance of pneumococci 
bearing capsule serotypes present in the vaccine (306, 330). PPV vaccines provide 
effective protection against invasive disease by 23 pneumococcal serotypes, but the poor 
stimulation of immunologic memory inherent to isolated polysaccharide antigen and 
suboptimal efficacy in preventing pneumococcal transmission has reduced the use of this 
vaccine to elderly adults (>65) and immunocompromised individuals (346). In contrast, 
the protein-conjugated PCV vaccine has become the standard of care in vaccinating 
children and provides robust protection against disease, colonization, and transmission 
between hosts (264). The PCV vaccine is presently formulated to include 13 
pneumococcal serotypes, with expansion under active development. Despite the efficacy 
of these vaccines, pneumococcal infections continue to exact a clinical toll worldwide, 
necessitating the need for a mechanistic understanding of how the microbe elicits and 
evades host immunity. 
 
Murine Models and the Host Response to S. pneumoniae 
While humans comprise the sole natural host for Streptococcus pneumoniae, mouse 
models permit mechanistic dissection of host-pathogen interactions and recapitulate the 
cardinal host responses to pneumococcal infection (225). Within 24 hours after the 
acquisition of pneumococcal colonization, the bacteria adhere to the surfaces of the 
nasopharynx and stimulate pro-inflammatory signaling at the mucosa (166). Subsequent 
recruitment of phagocytes to the nasal spaces requires host detection of pneumococcal 
lipoproteins/lipoteichoic acid and peptidoglycan by TLR2 and nucleotide-binding 
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oligomerization domain-containing protein 2 (Nod2), respectively. Mice lacking either or 
both of these pattern recognition receptors exhibit delayed bacterial clearance from the 
upper airway (337). Neutrophils comprise the first wave of recruited phagocytes, 
reaching maximal abundance ~3 days after acquisition. Despite entering the nasal spaces 
and making contact with colonizing pneumococci, these cells are wholly ineffective at 
killing colonizing pneumococci. Systemic depletion of neutrophils from colonized mice 
confers no change in the kinetics of pneumococcal clearance, suggesting that these 
phagocytes are evaded efficiently by the microbe (222). Mice rendered deficient in 
complement component C3 or lacking antibody-producing B cells also exhibit normal 
clearance kinetics, reinforcing that acute inflammation plays little role in protection 
against pneumococcal colonization (227).  
 
Facing little bactericidal pressure by the acute neutrophil response, colonizing 
pneumococci persist in the nasopharynx for 3-4 weeks. Eventual removal of the microbe 
from the upper airway is driven by a sustained influx of macrophages into the nasal 
lumen, and localized depletion of macrophages significantly impairs the kinetics of 
pneumococcal clearance (366). Optimal macrophage recruitment depends upon host 
detection of pneumococcal ligands by Nod2 and TLR2 as described above, the 
development of a robust, IL-17A-producing CD4 T cell response (Th17), and liberation of 
the monocyte/macrophage chemokine CCL2 (87, 366). The repertoire of Th17 cells 
generated during colonization forms the basis of immunologic memory to subsequent 
episodes of pneumococcal colonization, with rapid, IL-17A-driven neutrophil responses 
more swiftly clearing pneumococci upon repeated exposures (205). 
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In comparison with the host response to upper airway colonization, pneumococcal 
pneumonia elicits inflammation that is both more robust and more deleterious to host 
tissues. First, resident alveolar macrophages provide early phagocytic clearance of 
bacteria, though this response is quickly overwhelmed in the context of abundant or 
prolonged pneumococcal burden (93). Within hours, neutrophils and inflammatory 
monocytes are recruited to the lungs in large numbers, attracted by TNFα, IL-1β, CXCL1, 
and CXCL2 released by alveolar macrophages and epithelia (130, 217). The effectiveness 
of this inflammatory response in controlling bacterial abundance governs the balance 
between recovery and systemic dissemination, with the latter leading to host demise 
within days. Intriguingly, neutrophils have been shown to promote bacterial 
dissemination during pneumococcal pneumonia rather than conferring protection, and 
neutropenic mice exhibit reduced rates of sepsis (216). This deleterious impact has been 
attributed to liberation of cytotoxic mediators by the abundant neutrophil response, 
resulting in profound damage to pulmonary tissues. If the host survives this initial 
inflammation and clears the pneumococcus, robust Th17 cellular immunity and 
antibody-dependent clearance contribute to protection from subsequent re-infection of 
the lung (353). 
 
Pneumococcal Strategies for Phagocyte Evasion 
The success of Streptococcus pneumoniae as a respiratory pathogen in the face of a 
robust host defense suggests the microbe has developed well-adapted strategies for 
eluding clearance by phagocytes. The most well-studied among these is the 
pneumococcal polysaccharide capsule. Forming a 200-400 nm thick barrier around the 
exterior of the microbe, the capsule inhibits the deposition of opsonins and prevents 
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phagocytosis by neutrophils and macrophages in the absence of serotype-specific 
antibodies (166). Pneumococcal virulence during invasive infection is directly 
proportional to the thickness of the polysaccharide caspule surrounding the microbe, 
reinforcing the central significance of this protective mechanism (208). However, the 
pneumococcus also employs a number of surface-exposed virulence factors in addition to 
capsule expression, suggesting that capsule alone is likely insufficient to explain the 
totality of phagocyte evasion by the microbe. 
 
The pneumococcus is among the many bacterial pathogens that employ secreted toxins 
to inhibit phagocyte responses. Pneumolysin, the pore-forming toxin produced by the 
pneumococcus, is conserved among nearly all pneumococcal isolates (166). Upon 
binding to neutrophils and macrophages, pneumolysin monomers oligomerize to form a 
barrel-shaped ring capable of forming large pores in the phagocyte membrane (328). 
This can result in direct lysis of responding phagocytes or disruption of migration and 
respiratory burst capacity if the toxin is present at sub-lytic concentrations (259). 
Pneumolysin expression is especially critical for pneumococcal survival in the lungs and 
systemic circulation, where abundant phagocytes readily come into contact with the 
microbe. Bacterial mutants lacking pneumolysin are rapidly cleared from these sites 
(165).  
 
Another paradigm of pneumococcal phagocyte evasion relies upon the decoration of its 
surface with the small molecule phosphorylcholine (ChoP).  ChoP display is a widely 
conserved feature of extracellular bacteria in the respiratory tract, often used to mask  
underlying structures from deposition of antibodies or complement that would otherwise 
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hasten uptake by phagocytes (67). On the pneumococcus, ChoP is covalently linked to 
teichoic and lipoteichoic acids emanating from the gram-positive cell wall. In addition to 
aiding evasion of phagocytosis, ChoP can serve to anchor pneumococci to the mucosal 
surface through binding to host platelet-activating factor receptor (PAFR), mimicking 
the phosphorylcholine moiety also present on the receptor’s cognate host ligand, 
platelet-activating factor (76). Pneumococci lacking ChoP exhibit drastically reduced 
survival during infection of both the upper and lower respiratory tract, reinforcing its 
central role in bacterial virulence (172).  
 
ChoP also serves as a substrate platform to which a number of surface virulence proteins 
adhere (termed choline-binding proteins). Mutation of many of these proteins, including 
LytA, PspA, and Pce, result in fitness defects during the course of pneumococcal 
infection, though the mechanisms driving this accelerated clearance remain largely 
unknown (129). Some evidence suggests choline-binding proteins function to inhibit 
phagocyte responses. LytA functions to auto-lyse the pneumococcal cell wall, potentially 
liberating pneumolysin to attack responding phagocytes (166). PspA, in turn, is thought 
to inhibit complement deposition on the pneumococcal exterior, thereby inhibiting 
opsonization and phagocytic uptake (161). Pce functions to hydrolyze phosphorylcholine 
molecules from the pneumococcal cell wall in a process of continuous turnover to also 
inhibit ChoP-directed opsonin deposition (340). These choline-binding proteins may 
function cooperatively to inhibit phagocytic clearance and promote pneumococcal 
persistence in colonization and disease. 
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Phagocyte Function at the Mucosa: The Roles of PAF and MIF 
While many investigations into factors governing mucosal phagocyte responses focus on 
their effects on cell recruitment, a growing number of inflammatory mediators have been 
shown to alter phagocyte function predominantly after their arrival at sites of 
inflammation. Here, we will discuss two secreted factors, platelet-activating factor (PAF) 
and macrophage migration inhibitory factor (MIF), which stimulate mucosal neutrophil 
and macrophage function respectively and play central roles in phagocyte responses to 
bacterial pathogens. 
 
Platelet-activating factor (PAF) is a secreted, pro-inflammatory phospholipid first 
discovered as a mediator of systemic platelet aggregation (65, 140). Subsequent 
investigations revealed that PAF potently stimulates neutrophil activity after recruitment 
to sites of inflammation (188, 299). PAF is secreted from neutrophils, epithelial cells, 
and macrophages in response to inflammatory stimuli, including bacterial infection 
(269, 303). Through binding to its cognate receptor (PAFR) on activated neutrophils, 
PAF triggers diverse intracellular signaling pathways (e.g. PI3K, PLC, PLA2) to stimulate 
cell viability, upregulation of bacterial uptake receptors, and enhanced phagocytic 
capacity (48, 101, 232, 298). Accordingly, PAFR knockout mice are highly susceptible to 
numerous bacterial pathogens against which neutrophil responses form a key 
component of defense, including K. pneumoniae, P. aeruginosa, and S. pneumoniae 
(310, 334, 338). 
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Macrophage migration inhibitory factor (MIF) is a mammalian cytokine and potent 
activator of macrophage responses (246). Secreted by macrophages and lymphocytes in 
response to diverse inflammatory stimuli, MIF acts in an autocrine and paracrine 
manner to bind its cognate receptors (composed of diverse complexes of CXCR2, 
CXCR4, and CD74) on the surface of monocytes and macrophages (26). While initially 
characterized by its effects on macrophage mobility in vitro (35), subsequent animal 
studies have revealed a central role for MIF in governing innate immunity against 
bacterial pathogens. Mice lacking MIF exhibit enhanced susceptibility to a diverse set of 
infections, including S. typhimurium, K. pneumoniae, and polymicrobial peritonitis 
(183, 265, 278). The mechanism of MIF-mediated macrophage stimulation appears to be 
multi-factorial. Signaling downstream of MIF receptors upregulates the expression of 
pattern recognition receptors (e.g. TLR4) essential for detection of bacterial pathogens 
(277). MIF also suppresses p53 signaling within target cells to prolong the lifespan of 
macrophages recruited to sites of infection and stimulates the capacity of macrophages 
to engulf foreign particles (240, 256). Collectively, these pathways yield macrophages 
that are more activated, persistent, and bactericidal in response to pathogenic threats. 
 
The Microbiota and Systemic Professional Phagocyte Responses 
The evasion or disarmament of professional phagocytes has long been known to be 
essential for the persistence of pathogenic bacteria. In contrast, it has only recently 
become clear that the commensal bacterial flora of the gastrointestinal tract provides 
systemically disseminated signals during health to enhance phagocyte function upon 
infection (69). This suggests that disruptions in the community structure of the gut 
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microbiota, termed dysbiosis, can impair neutrophil, monocyte, and macrophage 
responses to pathogens throughout the body. 
 
Mice raised in the absence of commensal microbes (germ-free) exhibit dysfunctions in 
nearly every component of neutrophil homeostasis.  These mice are neutropenic in the 
steady state, explained at least in part by impaired granulopoiesis in the bone marrow 
(53, 173). Neutrophil migration to sites of inflammation is also impaired because of 
reduced levels of chemoattractant peptides like serum amyloid A (169). Upon arriving at 
infected tissues, neutrophils from germ-free animals exhibit functional defects, including 
impaired phagocytic capacity and reactive oxygen species production (70, 255). 
Accordingly, germ-free mice exert sub-optimal control over a number of extracellular 
bacterial pathogens during infection, including S. pneumoniae, S. aureus, and E. coli 
(70, 91). 
 
The mononuclear phagocyte system is similarly perturbed in the absence of the gut 
microbiota. Systemic abundance of inflammatory monocytes and tissue resident 
macrophages are both reduced in germ-free mice, again correlated with impaired 
development in the bone marrow (69, 173). Tissue-resident macrophages exhibit defects 
in pro-inflammatory gene expression and liberation of inflammatory cytokines upon 
infection, reducing their ability to orchestrate immune responses to pathogens (2, 281). 
Together, these defects correspond with diminished control of infection by L. 
monocytogenes, against which the mononuclear phagocyte system is the predominant 
systemic defense (173).  Impaired antibacterial responses extend to pulmonary 
infections, where reduced production of reactive oxygen species in alveolar macrophages 
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enhances susceptibility to K. pneumoniae among mice with depleted commensal flora 
(68).  
 
As the myriad defects in systemic phagocyte function following disruption of the 
microbiota become clear, attention has turned to understanding the signaling that 
connects commensal microbes with the phagocytes they instruct throughout the body.  A 
number of pattern recognition receptors have been implicated in relaying gut microbial 
signals into systemic, low-level inflammatory responses during health. For example, 
TLR4 and downstream MyD88 signaling have both been shown to be important for 
microbial stimulation of steady-state granulopoiesis in the bone marrow (23, 53) 
Similarly, the cytosolic peptidoglycan receptor Nod1 is required for mediating the 
microbiota’s role in augmenting neutrophil phagocytic capacity (70).  Whether these 
PRRs are detecting microbial products at the intestine or after low-level, systemic 
circulation remains uncertain, though a recent report suggests the cytokine IL-17A serves 
as an intermediate messenger between commensal microbes and alterations of 
neutrophil homeostasis in infant mice (91). Further, the well-established connection 
between Nod1 signaling and the expansion of IL-17A-producing T cells within the 
intestinal lamina propria supports the paradigm of cytokine-dependent relays of 
microbe-driven signals (119). Despite these advances, the mechanistic underpinnings of 
communication between the gut microbiota and systemic professional phagocytes 
remain largely unknown, especially for mononuclear phagocytes.  
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DISSERTATION AIMS 
 
Mounting evidence suggests that microbes can manipulate phagocyte function 
dynamically to shape the persistence and efficacy of antibacterial defenses. Successful 
bacterial pathogens often restrain inflammatory responses to evade clearance and 
promote dissemination within the host (114). In contrast, commensal bacterial 
communities have been shown to bolster the functional capacity of phagocytes 
throughout the body (281). Despite the critical role of microbe-phagocyte interactions in 
maintaining health and dictating infection outcome, the mechanisms underlying this 
influence remain incompletely understood. We hypothesized that continuous 
influence by microbial signals regulates the functional capacity of 
neutrophils and mononuclear phagocytes in both infection and health.  To 
address this overarching hypothesis, we pursued the following specific aims: 
 
Aim 1: Determining whether Streptococcus pneumoniae disarms 
neutrophils via exploitation of phosphorylcholine mimicry. 
Infection by bacterial pathogen Streptococcus pneumoniae begins with asymptomatic 
colonization of the upper respiratory tract. Prolonged carriage depends upon efficient 
evasion of neutrophils recruited to the airway shortly after bacterial acquisition. Using a 
mouse model of upper airway infection, we found that S. pneumoniae exploits molecular 
mimicry of the host-derived molecule phosphorylcholine (ChoP) to disarm responding 
neutrophils and enhance bacterial survival. We determined that ChoP moieties displayed 
on both the bacterial cell wall and the inflammatory phospholipid platelet-activating 
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factor (PAF) allowed the microbe use a hydrolytic surface enzyme, Pce, to remove PAF 
from the airway. Neutrophils deprived of PAF signaling exhibited impaired viability and 
phagocytic capacity, allowing S. pneumoniae to elude acute clearance, disseminate 
systemically, and transmit efficiently between hosts. Use of PAFR knockout mice and 
intranasal treatment with exogenous PAF affirmed that Pce-mediated PAF processing is 
absolutely necessary for neutrophil evasion and prolonged infection of the upper airway 
by S. pneumoniae. 
 
Aim 2: Determining whether Streptococcus pneumoniae governs 
macrophage responses through stimulation of macrophage migration 
inhibitory factor (MIF). 
While a sustained presence of macrophages in the respiratory tract is known to be 
necessary for clearance of Streptococcus pneumoniae, the mechanisms by which this 
response is maintained remained incompletely understood. We found that S. 
pneumoniae stimulates the liberation of macrophage migration inhibitory factor (MIF) 
in the upper airway to promote persistence of the luminal macrophages responsible for 
bacterial clearance. This stimulation required the action of the pore-forming toxin 
pneumolysin, and activation of intracellular p38-MAPK signaling. However, MIF-
mediated macrophage persistence impaired bacterial clearance during infection of the 
lower respiratory tract, accompanied by enhanced neutrophil influx and damage to the 
lung parenchyma. Together, these results underscore the fine regulation necessary to 
efficiently promote bacterial clearance by mononuclear phagocytes. 
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Aim 3: Determining whether the intestinal microbiota regulates the cellular 
lifespan of neutrophils and inflammatory monocytes at homeostasis.  
While the intestinal microbiota is known confer stimulation to phagocytes throughout 
the body, the mechanisms by which this occurs at homeostasis remains less clear. We 
found that a neomycin-sensitive cohort of commensal microbes prolongs the cellular 
lifespan of neutrophils and inflammatory monocytes throughout the body during health. 
Phagocytes deprived of microbial stimulation exhibited accelerated turnover from 
systemic circulation and enhanced rates of apoptosis when cultured ex vivo. Signaling 
through the cytoplasmic peptidoglycan receptor Nod1 was necessary and sufficient to 
detect the microbial signals responsible for regulating phagocyte lifespan, while the 
cytokine IL-17A was necessary to relay Nod1-dependent signals to circulating 
phagocytes.  Together, these results suggest that steady-state signals from the intestinal 
flora modulate the homeostatic turnover of systemic phagocytes, a key component of 
maintaining fitness against infections and other inflammatory insults. 
 
Together, these specific aims will elucidate the mechanisms by which a bacterial 
pathogen modulates phagocyte responses to promote persistence (Aims 1 & 2) and 
through which commensal microbes instruct systemic innate immunity in the absence of 
infection (Aim 3).  
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Abstract 
 
Regulation of neutrophil activity is critical for immune evasion among extracellular 
pathogens, yet the mechanisms by which many bacteria disrupt phagocyte function 
remain unclear. Here, we show that the respiratory pathogen Streptococcus pneumoniae 
disables neutrophils by exploiting molecular mimicry to degrade platelet-activating 
factor (PAF), a host-derived inflammatory phospholipid. Using mass spectrometry and 
murine models of upper airway infection, we demonstrate that phosphorylcholine 
(ChoP) moieties shared by PAF and the bacterial cell wall allow S. pneumoniae to 
leverage a ChoP-remodeling enzyme, Pce, to remove PAF from the airway. PAF 
deprivation corresponds with impaired viability, activation, and bactericidal capacity 
among responding neutrophils. In the absence of Pce, neutrophils clear S. pneumoniae 
rapidly from the airway and impede invasive disease and transmission between mice. 
Abrogation of PAF signaling renders Pce dispensable, reinforcing that the enzyme 
deprives neutrophils of essential PAF-mediated stimulation. Accordingly, exogenous 
activation of neutrophils overwhelms Pce-mediated phagocyte disruption. Haemophilus 
influenzae also employs an enzyme, GlpQ, to hydrolyze ChoP and subvert PAF function, 
suggesting a common paradigm of mimicry-driven immune evasion among respiratory 
pathogens. These results uncover a novel mechanism by which shared molecular 
structures enable microbial enzymes to subvert host lipid signaling, suppress 
inflammation, and ensure bacterial persistence at the mucosa. 
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Introduction  
 
Neutrophils comprise an essential component of the acute inflammatory response to 
pathogens, particularly against extracellular bacteria which reside on mucosal surfaces 
(10). Typically first among leukocytes recruited to sites of infection, neutrophils exert 
potent bactericidal activity, impede microbial dissemination from epithelial barriers, and 
can inhibit bacterial transmission between hosts (214, 292, 304). In turn, opportunistic 
microbes have evolved  strategies to evade the neutrophils they elicit, the mechanisms of 
which have long been the subject of intensive study (285, 333). However, as 
understanding of neutrophil biology has advanced, it has become clear that neutrophil 
bactericidal capacity is regulated dynamically and locally at inflamed sites (282) and that 
some pathogens manipulate phagocyte activation state directly to inhibit microbial 
clearance at sites of infection (211, 312). Our understanding of the mechanisms by which 
neutrophil phagocytic function is suppressed in vivo remains incomplete.  
 
Streptococcus pneumoniae, known as the pneumococcus, was among the first pathogens 
for which neutrophil evasion mechanisms were proposed (180, 356, 357). A leading 
cause of gram-positive bacterial pneumonia, sepsis, and meningitis, the pneumococcus 
causes nearly a million deaths each year worldwide and is estimated to be responsible for 
more than 100,000 hospitalizations in the United States annually (135, 252). All 
pneumococcal infections begin with asymptomatic colonization of the upper airway, and 
clinical studies have observed that progression from benign carriage to invasive infection 
often occurs only a few days after acquisition of upper airway infection (132, 138, 307). 
This coincides with the peak of neutrophil influx to the airway lumen and implies that 
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pneumococcus-neutrophil interactions in the upper airway may govern the balance 
between bacterial clearance and disease (225, 366).  
 
Pneumococcal resistance against neutrophils has traditionally been ascribed to its thick 
polysaccharide capsule, which serves to shield the bacterium from opsonization with 
complement or antibodies that would otherwise hasten phagocytic uptake (128, 236). 
However, in contrast to that in the lungs or bloodstream (164), pneumococcal resistance 
to neutrophils in the upper airway does not rely upon antibody or complement evasion 
(227, 337). Further, colonizing pneumococci express markedly less capsular 
polysaccharide compared to blood and lung isolates, exposing cell wall components long 
known to be targets for immune recognition (175). Together, this suggests capsule-
mediated anti-phagocytosis fails to fully explain pneumococcal neutrophil evasion in the 
upper airway. We sought to determine whether pneumococci instead disarm the 
phagocytic function of neutrophils recruited to the airway lumen, rendering them unable 
to mediate acute bacterial clearance. 
 
Molecular mimicry is among the most widely conserved mechanisms by which bacteria 
evade immunity, exploiting the host’s inability to recognize self-derived molecular 
structures (316). The pneumococcus, like many other airway bacteria, capitalizes upon 
this vulnerability by displaying the host-derived small molecule phosphorylcholine 
(ChoP) on its surface. Decoration of pneumococcal cell wall components with ChoP is 
essential for bacterial fitness and is necessary to inhibit bacterial opsonization (67). 
However, ChoP moieties are found also within a wide range of mammalian 
phospholipids, including those that function as secreted, pro-inflammatory lipid 
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mediators (113). The receptor for one such host lipid, platelet-activating factor (PAF), 
has been shown to be a docking site for pneumococcal ChoP during epithelial cell 
adherence, highlighting that the PAF-PAFR axis may be a particularly important target 
for ChoP mimicry in the airway (76). PAF is secreted rapidly into the airway lumen in 
response to diverse inflammatory stimuli, including bacterial infection (303, 359). 
Though first identified as a mediator of systemic inflammation and platelet aggregation 
(66, 140), PAF was subsequently found to potently stimulate neutrophil phagocytic 
capacity and bactericidal function (178, 299). PAF binding to its G protein-coupled 
receptor on neutrophils triggers multiple intracellular signaling pathways (including 
PI3K, MAPK, PKA, PLC, and PLA2) to stimulate cellular viability, surface expression of 
bacterial uptake receptors, and mobilization of bactericidal machinery (49, 102, 232, 
298). Despite the central role PAF plays in regulating neutrophil function at mucosal 
surfaces, it remains unexplored whether ChoP mimicry can suppress PAF-mediated 
neutrophil activation.  
 
Here, we use a murine upper airway infection model and primary human neutrophils to 
uncover a novel, enzymatic mechanism by which molecular mimicry can be exploited by 
bacteria to modulate innate immunity. In a previously reported screen, we identified pce, 
encoding a cell wall-bound phosphorylcholine esterase (also known as CbpE), as a 
pneumococcal gene potentially contributing to evasion of neutrophil-mediated killing 
(81). We now demonstrate that S. pneumoniae employs Pce to hydrolyze ChoP from 
host-derived PAF in the lumen of the airway. The absence of functional PAF deprives 
infiltrating neutrophils of stimulatory signals necessary for optimal phagocyte activation 
and effective bacterial clearance, allowing pneumococci to persist in the airway, 
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disseminate systemically, and transmit between hosts efficiently. Lastly, we find that this 
exploitation of molecular mimicry is functionally conserved among multiple ChoP-
bearing airway microbes, as the gram-negative pathogen Haemophilus influenzae 
employs a surface-bound phosphodiesterase, GlpQ, to hydrolyze phosphorylcholine and 
subvert PAF-mediated stimulation of acute inflammation. 
 
Results 
 
Neutrophils fail to contribute to mucosal defense during S. pneumoniae 
upper airway infection  
We sought first to determine the contribution of acute inflammation to the control of 
pneumococcal upper airway infection. Mice treated every 4 days with either neutrophil-
depleting (anti-Ly6G) (79) or IgG2a isotype control antibody were inoculated with a 
clinical isolate of S. pneumoniae (serotype 23F) and sacrificed at 4, 14, and 24 days post-
inoculation (p.i.). Neutrophil depletion was verified by flow cytometry (data not shown) 
and pneumococcal CFUs were enumerated at each time point from nasal lavages. 
Consistent with previous observations during early infection (222), we found that 
neutropenic and control mice cleared pneumococci at equivalent rates over 24 days 
(Figure 1A). These results suggested that, despite their rapid influx into the airway lumen 
following acquisition of infection (222), neutrophils failed to exert significant 
bactericidal pressure against S. pneumoniae in the upper airway.  
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Pneumococcal Pce esterase inhibits bacterial clearance and neutrophil 
activation. 
We asked next whether Pce esterase contributes to pneumococcal evasion of acute 
clearance from the airway. Mice inoculated with wild type (WT) or Pce-deficient (Δpce) 
pneumococci were sacrificed and lavaged for bacterial enumeration 1, 3, 4, and 7 days 
p.i., corresponding to the period during which neutrophilic inflammation is most 
prominent (366). While WT bacteria persisted at maximal density over the first week of 
infection, Δpce pneumococci exhibited a survival defect that exceeded 20-fold by day 7 
p.i. (Figure 1B). Notably, WT and Δpce bacterial loads were equivalent at 1 day p.i., 
suggesting differential inoculum retention or impaired establishment of infection were 
unlikely to explain the mutant’s subsequent persistence defect. The poor survival of Δpce 
pneumococci was recapitulated with an independently constructed unmarked, in-frame 
deletion mutant, restored upon genetic correction (Figure 1C), and preserved in a 
distinct serotype 4 isolate (Figure 1D). By day 14 p.i., Δpce bacteria were effectively 
cleared while WT pneumococci persisted at high levels (Figure S1A). Collectively, these 
findings suggested that Pce is necessary for effective pneumococcal persistence during 
acute infection of the upper airway. 
 
We then performed flow cytometry to characterize the acute inflammatory response to 
WT and Δpce bacteria.  Neutrophils dominated the cellular infiltrates elicited by both 
WT and Δpce pneumococci (>95% of CD45+ events, Figure S1C). Despite lower bacterial 
density in the airway, mice inoculated with the Δpce mutant exhibited elevations in the 
maximum density and, more markedly, the duration of neutrophil influx (Figure 1E). 
Congruent with bacterial load measurements, neutrophils persisted in the airway lumen 
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through day 14 p.i. in Δpce-infected mice but were nearly absent in response to WT 
pneumococci (Figure S1B).  
 
The more robust acute inflammatory response observed in the absence of Pce led us to 
hypothesize that the enzyme may perturb the qualitative capacity of neutrophils to 
persist and clear bacteria. Accordingly, we predicted that neutrophils recruited by Δpce 
pneumococci would exhibit greater activation and superior phagocytic capabilities. To 
assess antimicrobial capacity in vivo, we functionally characterized the neutrophils 
responding to WT vs Δpce bacteria by flow cytometry (Figure 1F). Compared to 
neutrophils elicited by WT pneumococci, those elicited by the mutant exhibited 
significantly elevated expression of CD11b (CR3) and CD64 (FcγRI)—which serve as both 
activation markers and bacterial uptake receptors (10, 176, 298)—and >2-fold enhanced 
shedding of CD62L (L-selectin), a marker for inflammation-induced neutrophil 
activation (177, 324). Luminal neutrophils elicited by Δpce bacteria included 
approximately twice as many viable cells compared to those responding to WT, a finding 
consistent with their enhanced persistence in the airway lumen. Lastly, Δpce-elicited 
neutrophils exhibited a ~5-fold increase in reactive oxygen species (ROS) production per 
cell (as detected by CM-H2DCFDA dye staining) over those recruited to WT bacteria, 
underscoring their enhanced bactericidal capacity (292). Together, these findings 
implied that Pce esterase impairs the cellular viability and phagocytic functionality of 
neutrophils upon their arrival in the airway lumen. 
 
Pce promotes invasive pneumococcal disease and bacterial transmission 
between mice. 
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A number of clinical and animal studies have found pneumococcal load in the upper 
airway to be associated strongly with both the onset and severity of subsequent invasive 
disease (7, 307) as well as the risk of pneumococcal transmission between hosts (138, 
304). We asked whether the survival deficit exhibited by Δpce pneumococci during 
infection of the upper airway corresponded with differences in these clinically important 
outcomes. To gauge relative invasive disease risk, we inoculated mice intranasally with 
WT or Δpce pneumococci generated from a mouse-invasive strain (serotype 6A) and 
tracked survival over 9 days (Figure 2A). While approximately 60% of mice infected with 
WT bacteria were moribund within 5 days from pneumococcal sepsis, mice inoculated 
with the mutant were significantly protected, suffering less than 10% lethality over the 
course of the experiment. This difference in survival corresponded with substantial 
attenuation in bacterial invasion to the bloodstream among Δpce pneumococci (Figure 
2B). 
 
Δpce pneumococci were similarly impaired in an infant mouse model of pneumococcal 
transmission (274, 304). Within litters of mice, we inoculated 1-2 “index” pups with 
either WT or Δpce bacteria and quantified the acquisition and load of pneumococci 
among previously uninfected “contact” pups. In line with previous findings (274), litters 
exposed to WT pneumococci exhibited 64% transmission; however, only 6% of contact 
mice from litters exposed to Δpce pneumococci acquired bacteria (Figure 2C). This 
corresponded with >300-fold lower bacterial loads among index mice infected with the 
mutant. Taken together, these data provide evidence that the poor survival of Δpce 
pneumococci in the upper airway crosses a key threshold under which disease and 
transmission are nearly abrogated.  
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Pce prevents accumulation of platelet-activating factor in the upper airway 
lumen. 
Next, we analyzed the mechanism by which Pce esterase impairs neutrophil function in 
the upper airway. Studies using purified, recombinant enzyme have shown that Pce is 
capable of hydrolyzing a wide range of molecules bearing phosphorylcholine (ChoP) in 
vitro, including PAF (144) (Figure 3A, diagram). To quantify directly the impact of Pce 
on airway luminal PAF levels, we inoculated mice with PBS (mock), WT, or Δpce 
pneumococci and pooled lavages from 5 mice per group on day 3 p.i.. After lipid 
extraction and liquid chromatography (LC) to purify PAF, we subjected samples from 
each condition to high-resolution electrospray ionization/mass spectrometry (ESI/MS). 
Lavage fluid from mice inoculated with Δpce bacteria harbored PAF at a concentration of 
approximately 3 nM while mock- and WT-infected mice secreted no PAF detectable by 
LC-ESI/MS (Figure 3A), demonstrating that Pce prohibits the accumulation of PAF in 
the upper airway lumen during pneumococcal infection.  
 
We also examined the expression of genes essential for PAF signaling in the airway 
epithelium, as PAF is known to stimulate the transcription of its own synthetic enzymes 
and receptor via a positive feedback loop (243, 367). At 3 days p.i. with WT or Δpce 
bacteria, we obtained lavages with tissue lysis buffer and quantified mucosal transcripts 
by qRT-PCR in each condition relative to mock-infection. Transcript levels of the PAF 
synthetic enzyme lyso-PAF acetyltransferase (lysoPAFAT) and the PAF receptor (Ptafr) 
were markedly elevated among mice infected with Δpce pneumococci (Figure 3B). In 
contrast, transcription of neutrophil chemokines CXCL1 and CXCL2 trended lower in 
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mice inoculated with the mutant, likely a consequence of lower Δpce bacterial density 
compared to WT. Thus, elevation of PAF-related transcripts was not simply reflective of 
broad up-regulation of inflammatory mediators and Pce-mediated hydrolysis of PAF is 
sufficient to suppress the inflammatory feedback loop driven by PAF signaling. 
 
Neutrophil depletion or inhibition of PAF signaling renders Pce dispensable 
for S. pneumoniae persistence.  
Our data show that S. pneumoniae lacking Pce esterase exhibit a survival defect during 
acute infection of the airway which corresponds with elevated levels of PAF and 
enhanced activation of luminal neutrophils. We asked next whether neutrophils and PAF 
signaling play a causal role in driving the mutant’s rapid clearance. To determine if the 
poor survival of Δpce bacteria could be rescued in the absence of infiltrating neutrophils, 
mice were treated with neutrophil-depleting anti-Ly6G or IgG2a isotype control 
antibodies on days -1, +1, and +4 after inoculation with WT or Δpce pneumococci. 
Effective neutrophil depletion was verified in blood and nasal lavage fluid by flow 
cytometry (Figure 4A) and bacterial CFUs from neutropenic and control mice were 
enumerated from nasal lavages on day 7 p.i. While the Δpce mutant retained a ~20-fold 
survival defect in isotype control-treated animals, its survival was restored to WT levels 
in neutrophil-depleted mice (Figure 4B). This confirmed that neutrophils were required 
for the enhanced clearance of the mutant and that Pce esterase functions to impair 
neutrophil-mediated bactericidal function.  
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To assess whether local PAF signaling contributed to Pce-mediated neutrophil evasion, 
we performed the same 7-day infection with daily intranasal administration of PCA-
4248, a selective antagonist of PAFR (111, 121, 220). Similar to our findings upon 
depletion of neutrophils, local PAFR antagonism restored survival of Δpce pneumococci 
to levels comparable to WT (Figure 4C). PCA-4248 has no direct effect on pneumococcal 
survival or growth in vitro (Figure S2B). Importantly, no additional increase in the 
density of Δpce bacteria was seen upon PCA-4248 treatment of neutrophil-depleted 
mice, underscoring that the predominant impact of elevated airway PAF in the absence 
of Pce is stimulation of neutrophil function. Lastly, we found that bacterial loads on day 
7 p.i. were equivalent among WT and Δpce pneumococci in PAFR-/- mice (Figure 4D), 
providing independent evidence that augmented PAF signaling underlies the enhanced 
clearance of Pce-deficient bacteria. In sum, these results show that Pce esterase governs 
pneumococcal persistence by eliminating PAF from the airway lumen and preventing the 
PAF-mediated activation of neutrophils necessary for efficient pathogen clearance. 
 
Pce esterase hydrolyzes phosphorylcholine and abrogates PAF-mediated 
stimulation of neutrophil function in vitro. 
To further clarify the mechanism by which Pce inhibits PAF-mediated neutrophil 
stimulation, we turned to in vitro studies using mature neutrophils isolated from murine 
bone marrow or human peripheral blood. We began by using neutrophil killing assays 
(80) to determine whether Δpce pneumococci were more sensitive to neutrophils in the 
absence of PAF stimulation. After pre-incubation with complement, WT and Δpce 
bacteria were incubated with increasing concentrations of murine or human neutrophils 
and we measured their survival relative to no-neutrophil controls. At all neutrophil 
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concentrations tested, WT and mutant bacterial survival was equivalent (Figure 5A&B), 
providing evidence that the survival defects seen in vivo were not the result of non-
specific sensitivity to neutrophil uptake. Similarly, WT and Δpce pneumococci were not 
significantly different in growth characteristics in vitro (Figure S2A), sensitivity to 
complement deposition (Figure S3A), capsule expression levels (Figure S3B), or cell 
surface phosphorylcholine (ChoP) accessibility (Figure S3C) as assessed by bacterial flow 
cytometry. 
 
Using recombinant Pce esterase (rPce), we next confirmed that the enzyme bears 
efficient ChoP hydrolysis activity upon incubation with chromogenic substrate p-
nitrophenylphosphorylcholine (pNPPC), which yields p-nitrophenol upon removal of its 
ChoP moiety (Figure 5C) (340). To assess whether rPce directly inhibits PAF-mediated 
stimulation of neutrophils, we pre-treated PAF at a range of physiologic concentrations 
centered around 3 nM (the concentration detected by ESI/MS) with rPce enzyme or PBS 
control. We applied the conditioned PAF media to the phagocytes and quantified up-
regulation of CD11b and CD64 receptor expression on murine neutrophils by flow 
cytometry (Figure 5D). While increasing PAF concentrations correlated with up-
regulation of both receptors in the PBS control condition, no such correlation was seen if 
PAF was pre-incubated with rPce. Similarly, pre-treatment of PAF with rPce abrogated 
the increased killing capacity conferred when PAF was applied to murine or human 
neutrophils (Figure 5D&E). Collectively, these findings reveal that Pce functions to 
hydrolyze ChoP from conjugated substrates and its processing of PAF directly inhibits 
neutrophil activation and phagocytic function.  
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Exogenous stimulation of neutrophils in situ overwhelms Pce-mediated 
immune evasion. 
Having established that Pce inhibits acute clearance of S. pneumoniae in vivo by 
depriving neutrophils of an essential stimulatory ligand, we posited that this immune 
evasion mechanism could be overcome if luminal neutrophils were activated sufficiently. 
We tested this by performing 7-day WT and Δpce pneumococcal infection experiments 
with daily intranasal treatment with an excess of either PAF or N-formyl-Met-Leu-Phe 
(fMLP), a bacterial peptide which stimulates neutrophil chemotaxis and activation 
through pathways independent from that of PAF (120, 298). At day 7 p.i., mice 
inoculated with WT pneumococci and treated with PAF (Figure 6A) or fMLP (Figure 6D) 
exhibited significantly enhanced clearance—such that WT bacterial loads resembled that 
of Δpce—while the mutant’s survival was not substantially affected upon stimulant 
treatment. PAF and fMLP exerted no detectable effect on pneumococcal growth or 
viability in vitro (Figure S2C&D). 
 
Critically, repeating these treatments after systemic neutrophil depletion restored 
survival of both pneumococcal strains to levels seen for WT bacteria in mice treated with 
vehicle controls (Figure 6A&D), reinforcing that neutrophils were responsible for the 
observed increase in clearance. Enhancement of WT pneumococcal clearance upon PAF 
treatment corresponded with an increase in the number of neutrophils in the airway 
lumen to levels similar to those seen during Δpce infection. In contrast, neutrophil 
numbers elicited by Δpce pneumococci were unaffected by PAF administration (Figure 
5B). These results suggested that introduction of excess PAF ligand overwhelmed the 
capability of Pce esterase to mediate immune evasion for WT bacteria, yielding 
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neutrophil phenotypes and bacterial survival that mimicked infection in the absence of 
Pce. Consistent with its known role as a strong chemo-attractant (187), fMLP treatment 
stimulated a substantial elevation in airway neutrophil recruitment, but neutrophil 
numbers were again equalized among WT- and Δpce-infected mice (Figure 5E). Lastly, 
flow cytometric analysis of luminal neutrophils revealed that treatment with PAF or 
fMLP enhanced the relative expression of CD11b and CD64 on cells elicited by WT 
pneumococci to levels seen in those recruited to Δpce, abrogating the relative difference 
in activation observed in the absence of stimulation in situ (Figure 6C&F). Taken 
together, these results serve to reinforce that Pce promotes pneumococcal persistence 
through fine regulation of neutrophil activation and that clearance of WT bacteria can be 
substantially accelerated by stimulating neutrophil function. 
 
Subversion of PAF signaling is conserved in Haemophilus influenzae, 
another ChoP-expressing pathogen of the airway. 
We sought to determine whether exploitation of ChoP mimicry to suppress PAF 
represents a conserved mechanism among other ChoP-expressing bacterial pathogens. 
We focused on Haemophilus influenzae, as it displays phosphorylcholine on surface-
exposed lipooligosaccharide chains (67), it remains an important cause of respiratory 
disease worldwide (284, 329), and could be investigated using a murine model of upper 
respiratory tract infection (368). No direct homologues for pneumococcal Pce were 
apparent in H. influenzae by sequence analysis. However, previous work from our 
laboratory suggested that the highly conserved, surface-bound phosphodiesterase 
lipoprotein GlpQ (also known as Protein D) bears the ability to hydrolyze ChoP 
efficiently from conjugated substrates (107). Previously ascribed a role in bacterial 
44 
 
acquisition of choline from host cells, GlpQ has long been known to be important for 
virulence during mucosal infection, though the nature of its contribution has remained 
incompletely understood (160). We hypothesized that this ChoP-binding enzyme 
functioned analogously to pneumococcal Pce esterase and contributed to the PAF 
evasion during airway infection. 
 
To confirm previous reports that GlpQ contributes to hydrolysis of ChoP (107), we 
applied WT and ΔglpQ H. influenzae to chromogenic pNPPC assays and measured 
absorbance after 120 minutes compared to that generated by WT and Δpce pneumococci 
(Figure 7A&B). Note that GlpQ cleaves phosphorylcholine at the phosphoester bond 
proximal to choline and therefore requires exogenous alkaline phosphatase enzyme 
added to reactions for chromogenic activity in this assay (Figure 7A, arrows). Similar to 
the results for Δpce pneumococci, ChoP hydrolysis activity by H. influenzae was 
significantly impaired in the absence of GlpQ, though some residual activity remained 
(Figure 7B). These results affirmed that native GlpQ hydrolyzes ChoP efficiently. 
 
We asked next whether GlpQ contributes to bacterial persistence in murine upper airway 
infection. Mice inoculated with WT or ΔglpQ H. influenzae were sacrificed on days 1 and 
2 p.i. for bacterial enumeration. By day 2, ΔglpQ bacteria exhibited a survival defect 
exceeding 20-fold (Figure 7C). Flow cytometric analyses of lavage fluid suggested 
enhanced influx of neutrophils during acute infection with the ΔglpQ mutant compared 
to WT (Figure 7D) and neutrophils elicited by the mutant exhibited significantly elevated 
bacterial uptake receptor expression by day 2 p.i. (Figure 7E). To establish whether 
neutrophils drive ΔglpQ persistence defects, we repeated 2-day infections after anti-
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Ly6G or IgG2a isotype antibody treatments on days -1 and +1 after inoculation. Akin to 
results observed with Δpce pneumococci, neutropenia rescued ΔglpQ survival such that 
it resembled that of WT H. influenzae (Figure 7F). ΔglpQ survival was also rescued in 
PAFR-/- mice while littermate control mice recapitulated the mutant defect seen 
previously, indicating that intact PAF signaling is essential for enhanced bacterial 
clearance in the absence of GlpQ (Figure 7G). Importantly, neutropenia did not lead to 
significantly enhanced bacterial survival in PAFR-/- mice, suggesting that PAF 
stimulation plays an important role in regulating neutrophil function during H. 
influenzae infection of the airway. Collectively, these findings reveal that GlpQ is critical 
for limiting neutrophil responses in vivo through inhibition of PAF signaling.  
 
Lastly, we performed neutrophil bactericidal assays in vitro to assess whether pre-
incubation of PAF with H. influenzae bearing GlpQ hindered its ability to stimulate 
neutrophil-mediated phagocytic function when compared to pre-incubation with ΔglpQ 
bacteria. We mixed neutrophils pre-treated with each enzyme-conditioned PAF solution 
with pre-opsonized WT H. influenzae and quantified bacterial survival over a range of 
PAF concentrations compared to no-PAF and no-neutrophil controls (Figure 7H). While 
evidence of PAF-mediated stimulation of phagocytosis remained evident after pre-
treatment in either condition, this enhancement of killing was impaired significantly 
when neutrophils were pre-stimulated with WT bacteria (black bars) compared to ΔglpQ 
mutant (white bars). These results reinforce that glpQ inhibits the effects of PAF on 
neutrophil activity directly. 
 
Discussion 
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Evasion of neutrophil-mediated phagocytosis is essential for the mucosal persistence of 
extracellular bacterial pathogens, and mounting evidence suggests direct suppression of 
neutrophil activation plays an important role in mediating microbial escape from acute 
inflammatory responses. Here, we showed that enzymatic degradation of PAF, driven by 
phosphorylcholine mimicry, underlies neutrophil subversion by S. pneumoniae and H. 
influenzae in the upper airway. As stable infection of the upper airway is a prerequisite 
for the development of pneumonia and sepsis for many respiratory pathogens, a 
mechanistic understanding of immune evasion in this niche is particularly important for 
developing interventions designed to prevent the transition from asymptomatic carriage 
to invasive disease (348).  
 
We found that the surface-bound phosphorylcholine esterase Pce governed the 
exploitation of ChoP mimicry essential for pneumococcal persistence. The near-universal 
conservation of Pce among pneumococcal clinical isolates (90) and results from early 
animal studies (129) support that the enzyme contributes to bacterial fitness during 
airway infection, but the nature of its function in vivo has been less clear. Most studies 
characterizing Pce activity have focused on its ability to remodel the pneumococcal cell 
wall by hydrolyzing ChoP residues from teichoic acid chains, a function associated with 
enhanced adhesion to epithelial surfaces (144, 340). However, Pce-deficient 
pneumococci exhibit essentially unaltered epithelial adherence properties and the 
enzyme is unable to hydrolyze more than 30% of ChoP residues from these substrates, 
even in saturating conditions (129, 148). Our findings reveal that exploitation of shared 
ChoP moieties allows degradation of host-derived PAF, rather than modifications to the 
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cell wall, to be the major contribution of Pce to immune evasion during respiratory 
infection.     
 
Using direct measurement of PAF by high-resolution LC-ESI/MS, we tested the 
hypothesis that Pce restricts PAF accumulation during infection. In upper airway lavage 
fluid, PAF was detectable only from mice infected with Pce-deficient bacteria, at a 
concentration of approximately 3 nM. Even if the dilution inherent to lavage is 
discounted, this concentration exceeded the dissociation constant of PAFR on leukocytes 
(49, 260) and mimicked PAF levels observed in the inflamed human airway (317). 
Together, this reinforced that PAF accumulated to a level sufficient to effectively 
stimulate neutrophils in the airway. The product of PAF hydrolysis by Pce, 1-O-
hexadecyl-2-O-acetyl-sn-glycerol, was not detectable in any condition tested, possibly 
reflecting rapid degradation in vivo. Additionally, we showed that Pce directly 
suppressed PAF-mediated stimulation of human and murine neutrophil bactericidal 
function upon treatment ex vivo with physiologically relevant concentrations of PAF, 
further supporting that Pce limits PAF levels through enzymatic degradation.  
 
We focused our investigations entirely on PAF C16 (1-O-hexadecyl-2-O-acetyl-sn-
glyceryl-3-phosphorylcholine), the most abundant and well-characterized member of a 
diverse set of PAF-like lipids secreted during inflammation. While some PAF-like lipids 
can stimulate neutrophil bactericidal capacity, nearly all bind most avidly to receptors 
other than PAFR (361). A number of studies have shown that even small modifications to 
the molecular structure of PAF significantly disrupts its binding and signaling potency 
through its cognate receptor (267). Since we found that the enhanced neutrophil 
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activation observed during infection with Δpce pneumococci was abrogated entirely 
upon PAFR blockade in vivo or when using PAFR-deficient mice, we concentrated our 
analyses on PAF. Whether other PAF-like lipids are regulated similarly by Pce during 
pneumococcal infection remains a subject of ongoing investigation.   
 
Our work demonstrated that Pce-mediated PAF degradation results in functional 
impairment of neutrophils responding to pneumococcal infection, rendering them 
unable to mediate efficient phagocytosis. Recent studies have suggested that, in addition 
to suppressing clearance, recruiting an ineffective acute inflammatory response can be 
directly beneficial for bacterial fitness. Increased mucus production can provide 
nutrients to stimulate bacterial growth at mucosal surfaces (305), inflammatory influxes 
can enhance bacterial shedding from the nasopharynx to promote transmission between 
hosts (274), and the recruitment of neutrophils can provide an inflammatory milieu 
which may neutralize bacterial competitors among the flora (211). These advantages rely 
upon phagocytes that alter the mucosal environment without presenting significant 
bactericidal pressure. For the pneumococcus, Pce-mediated neutrophil suppression may 
constitute a central mechanism through which inflammation can be utilized to the 
advantage of the microbe. 
 
A wide range of extracellular bacteria display ChoP on their surfaces and express 
enzymes that govern ChoP hydrolysis and turnover, suggesting other pathogens may 
harbor unappreciated strategies for evading clearance through mimicry-driven 
degradation of PAF (67).  Along with the pneumococcus, Haemophilus influenzae, 
Neisseria meningitidis, and Neisseria gonorrhea carry ChoP as surface modifications 
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and most of these pathogens use ChoP to bind PAFR directly, reflecting a common 
strategy of passive, structural mimicry of PAF (24, 349, 350). Our work implies that 
active, enzymatic mechanisms exploiting ChoP mimicry may underlie the well-described 
resistance of these organisms to neutrophils and may expose a broadly applicable target 
for therapeutic intervention. To this end, we investigated neutrophil evasion by H. 
influenzae in the upper airway. Despite bearing no apparent homologues for Pce, we 
found that H. influenzae harbors an analogous mechanism for mimicry-driven, 
enzymatic subversion of PAF through ChoP hydrolysis by the surface-bound 
phosphodiesterase GlpQ. The functional similarity of these structurally unrelated 
esterases, employed by disparate pathogens occupying the same upper airway niche, 
suggests that PAF-mediated inflammation may have necessitated convergent evolution 
(316) aimed at manipulating and neutralizing PAF activity to achieve fitness in the 
airway environment. Our findings also suggest that GlpQ does not govern the entirety of 
ChoP hydrolytic activity mediated by H. influenzae, as some residual enzymatic activity 
persists among ΔglpQ mutants. The identity and functions of these other contributors 
remain under investigation. 
 
The central importance of regulating PAF-mediated inflammation is exemplified further 
by microbes that do not express ChoP but disrupt PAF signaling by means other than 
molecular mimicry. Staphylococcus aureus has been shown to bind leukocytes and 
platelets and directly modulate PAFR signaling (149, 343). Streptococcus pyogenes uses 
a secreted enzyme to cleave acetyl groups from PAF ligand and inhibit neutrophil 
chemotaxis during invasive skin infection (202). It remains conceivable that additional 
mechanisms for PAF disruption exist for S. pneumoniae and H. influenzae independent 
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of ChoP hydrolysis activity. Together, this emphasizes that microbial manipulation of 
PAF signaling may be critical for successful immune evasion and that targeting 
convergent bacterial strategies to this end may be a promising avenue for antimicrobial 
interventions. 
 
The tight regulation of PAF signaling mediated by the pneumococcus and other 
extracellular bacteria suggests that these neutrophil evasion mechanisms could be 
overcome if PAF levels are elevated sufficiently at the site of infection. Accordingly, we 
found that stimulating neutrophils in situ during pneumococcal infection with excess 
PAF restored their activation state and phagocytic capacity, resulting in enhanced 
bacterial clearance. This implies that a threshold concentration of PAF may define the 
balance between effective bacterial evasion and neutrophil-mediated clearance. While 
delivering PAF itself is unlikely to be a clinically tractable method to overcome such a 
threshold, targeting host-encoded negative feedback mechanisms that regulate PAF 
levels may be more promising. Lipoprotein-associated phospholipase A2, also known as 
PAF acetylhydrolase, is secreted by the host, has been shown to mediate PAF hydrolysis, 
and can dampen PAF-mediated inflammation in vivo (231).  It is released into the upper 
airway lumen during respiratory inflammation, has been shown to be upregulated during 
pneumococcal infection, and clinical trials have demonstrated that an antagonist, 
darapladib, is safe in humans (153, 294, 331). While studies aimed to assess the 
effectiveness of targeting PAF acetylhydrolase in combating pneumococcal and other 
bacterial infections are ongoing, this may serve as an important example of how 
mechanistic investigations of bacterial immune evasion may reveal rational targets for 
host-directed antimicrobial therapies. 
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Methods 
 
Bacterial strains. S. pneumoniae strains P1121 (type 23F clinical isolate), TIGR4 (type 4 
isolate), and P1547 (a mouse-virulent type 6A isolate) were grown in tryptic soy (TS) 
broth at 37° C to mid-log phase, as described previously (70, 225, 326). Mutants lacking 
phosphorylcholine esterase (Δpce) were derived for each strain from an insertion-
duplication mutant (340) and used for all experiments except where specified. 
Independently, we created an in-frame, unmarked Δpce deletion mutant and a 
genetically corrected revertant (Δpce::pce) by previously described methods (81). Refer 
to Supplemental Methods for details and Table S1 for primers used in mutagenesis. 
Spontaneously streptomycin-resistant isolates of H. influenzae Eagan (a type b 
encapsulated strain) and an isogenic mutant lacking the surface phosphodiesterase GlpQ 
(ΔglpQ) were used as described previously (107). H. influenzae was grown to mid-log 
phase shaking at 37° C in brain-heart infusion (BHI) broth supplemented with 2% Fildes 
enrichment (Thermo Scientific) and 2 μg/mL β-NAD (Sigma-Aldrich) (sBHI). 
 
Murine model of upper airway infection. Six- to eight-week-old C57BL/6 mice were 
obtained from Jackson Laboratories. Platelet-activating factor receptor-deficient (Ptafr-/-
) mice of C57BL/6 background (Ptafrtm1Eit) were a gift from Dr. Elaine Tuomanen of the 
St. Jude Children’s Research Hospital (47, 270). All knockout mice were bred from 
heterozygotes and compared to littermate controls. For upper airway infection with S. 
pneumoniae or H. influenzae, mice were inoculated intranasally with 107 CFU of mid-log 
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phase bacteria suspended in 10 µL of sterile PBS. To prevent aspiration of the inoculum 
from the upper airway to the lungs, mice were not anesthetized during inoculation. We 
obtained upper airway lavages upon sacrifice through tracheal cannulation and 
expression of 200 μL sterile PBS through the nares. Lavage samples from pneumococcal 
infections were plated on TS agar supplemented with 5-20 µg/mL neomycin and 5,000 
U catalase per plate (Worthington Biochemical). To discern insertion-derived and in-
frame deletion Δpce mutants from wild type pneumococci, plates were supplemented 
with 1 µg/mL erythromycin or 200 µg/mL streptomycin, respectively. Lavage samples 
from mice infected with H. influenzae were plated on sBHI agar supplemented with 100 
µg/mL streptomycin. ΔglpQ mutants were discerned from wild type H. influenzae by 
supplementation with 20 µg/mL kanamycin. CFU counts were enumerated by 
quantitative culture after overnight incubation at 37° C in 5% CO2 (305).  
 
Flow cytometry. Nasal lavages were pelleted at 1,200g for 5 minutes and re-suspended 
in PBS with 1% BSA. FcR blocking was achieved with 1:100 dilution of anti-CD16/32 (BD 
Biosciences, Clone 2.4G2) and cell viability was assessed by staining with Fixable 
Viability Dye eFluor780 (eBioscience) according to manufacturer’s instructions. 
Neutrophils were immunophenotyped by staining with fluorophore-conjugated 
antibodies, diluted 1:150, against the following surface markers: CD45 (eBioScience, 
Clone 30-F11), Ly6G (BioLegend, Clone 1A8), CD11b (Biolegend, Clone M1/70), CD64 
(BioLegend, Clone X54-5/7.1), and CD62L (BioLegend, Clone MEL-14). Neutrophil 
reactive oxygen species (ROS) were quantified after incubation with 10 µM CM-
H2DCFDA (Life Technologies) according to manufacturer’s instructions (193, 230). All 
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cytometry was performed using a BD LSR II flow cytometer and analyzed with FlowJo 
software (Tree Star).  
 
Bacterial transmission model. Infant mouse pneumococcal transmission experiments 
were performed as described previously (274, 304). At day 4 of life, we inoculated 1-2 
“index” pups per litter (approximately 1 in 4) with 2000 CFUs of S. pneumoniae strain 
P1121 in 3 µL PBS. At day 8 of life, all pups were infected intranasally with 2 x 104 TCID50 
Influenza A strain HKx31, as influenza co-infection is required for pneumococcal 
transmission between mice (92). At day 14, all pups were sacrificed and upper airway 
bacterial loads were quantified among index and previously uninfected “contact” mice. 
 
LC-ESI/MS quantification of PAF from the murine upper airway lumen. PAF-C16 was 
extracted and quantified from murine upper airway lavage fluid pooled from 5 mice per 
condition on day 3 of infection (performed in triplicate). Briefly, 0.5 mL of lavage fluid 
was spiked with 2 ng of deuterated PAF-C16-d4 (Cayman Chemical) as a quantification 
standard, extracted in methanol with shaking, and resuspended in 
isopropanol/acetonitrile/water (3:5:2; v/v/v). Reversed phase separations of 3 µL 
injections were conducted using a nano-ACQUITY UPLC system and XBridge BEH130 
C18 column (Waters Corp.) at 1.5 µL/minute. High-resolution LC-ESI/MS quantification 
was performed using a recently calibrated LTQ XL-Orbitrap hybrid mass spectrometer 
(Thermo Scientific) in positive ion mode and with a Michrom captive spray ESI source. 
Data analysis was performed using Xcalibur software (Thermo Scientific) from raw mass 
spectral data.  
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qRT-PCR. RNA was extracted from the upper airway mucosa through lavage with 500 µL 
RLT lysis buffer (Qiagen) (30). After isolation of total RNA (Qiagen RNeasy Kit), cDNA 
was generated using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) and qRT-PCR was performed using 10 ng cDNA, 0.5 µM primers, and SYBR 
Green Master Mixes (Life Technologies). Differential RNA expression was quantified 
using the ΔΔCT method relative to GAPDH transcript levels. qRT-PCR primer sequences 
are listed in Table S1. 
 
Neutrophil depletion and intranasal drug treatments. Systemic depletion of murine 
neutrophils was achieved by intraperitoneal injection of 250 µg anti-Ly6G antibody 
(BioXCell, Clone 1A8) or IgG2a isotype control antibody (Clone 2A3) at the indicated 
time points. Neutropenia was confirmed by flow cytometry and microscopic inspection 
using Shandon Kwik-Diff stains (Thermo Scientific). For intranasal drug treatments, 0.1 
or 1 µg of PAF (Cayman Chemical), PAF receptor antagonist PCA-4248 (Tocris), or fMLP 
(Sigma-Aldrich) were instilled daily (days 1-6), suspended in 10 µL sterile PBS. Vehicle 
control experiments used dilutions of drug solvent (DMSO) in PBS identical to those 
performed for drug dilutions.  
 
Generation of recombinant Pce. Recombinant Pce (rPce) protein was produced as 
described previously (340) with the following modifications. pce was cloned from the 
P1121 S. pneumoniae genome with primers which introduced flanking restriction sites 
for BamHI and SacI (New England BioLabs) (see Table S1). After restriction digest and 
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gel purification, the pce fragment was cloned into pET28a (Novagen) using T4 DNA 
ligase (New England BioLabs) to generate a construct in which pce was flanked with N- 
and C-terminal hexa-histidine tags. Ligated product was transformed into XL-1 Blue 
competent E. coli (Agilent), amplified, and purified by plasmid miniprep (Sigma-
Aldrich). After sequence confirmation, pce-pET28a was transformed into BL21 
(DE3)pLysS competent cells (Promega) and protein expression was induced according to 
manufacturer’s instructions with 1 mM IPTG. Native cell lysis was achieved by sonication 
on ice and lysates were applied to a Ni-NTA purification column (GE Life Sciences) by 
fast protein liquid chromatography (FPLC), followed by dialysis against 20 mM HEPES 
with 3 µM zinc sulfate.   
 
Chromogenic assay for phosphorylcholine hydrolysis. Pce catalytic activity was assessed 
by incubation of 4 µg enzyme with 21 µg of the chromogenic substrate p-
nitrophenylphosphorylcholine (pNPPC, Sigma-Aldrich) at 37° C in 200 µL. Absorbance 
at 415 nm was monitored at the indicated time points to detect phosphorylcholine 
hydrolysis and resultant liberation of p-nitrophenol  (340). For chromogenic assays 
using whole bacteria and isogenic mutants, 50 µL of OD620 1.0-normalized bacteria was 
re-suspended in potassium phosphate buffer (pH 8.0) and incubated with pNPPC as 
above for 120 minutes. For reactions testing H. influenzae strains, 1 U of Shrimp 
Alkaline Phosphatase (Affymetrix) was included in the assays to cleave terminal 
phosphate groups remaining after GlpQ hydrolysis. 
 
Isolation of neutrophils from murine bone marrow and human peripheral blood. 
Mature murine neutrophils were flushed from murine femora and washed with Hank’s 
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Buffer with calcium (Mediatech) containing 0.1% gelatin before enrichment with a 
discontinuous gradient of Histopaque-1077 and -1119 (Sigma-Aldrich). Flow cytometry 
confirmed that >90% of CD45+ cells isolated were Ly6G+CD11b+. Human neutrophils 
were obtained from healthy donors and isolated by Polymorphprep (Axis Shield) 
gradient centrifugation as described previously (314). 
 
Neutrophil activation and bactericidal assays. To assess the impact of Pce on PAF-
stimulated neutrophil function, we performed assays using murine and human 
neutrophils ex vivo. Purified PAF (Cayman Chemical) was incubated in the presence or 
absence of 4 µg recombinant Pce in 100 µL of potassium phosphate buffer (100 mM, pH 
7.4) for 20 minutes at 37° C. Reaction products were applied to 105 murine or 104 human 
freshly isolated neutrophils at a 1:1 dilution and allowed to incubate for 30 minutes. All 
values listed for PAF represent final concentrations after incubation with neutrophils. 
Murine neutrophil activation was assessed by flow cytometric analysis of CD11b and 
CD64 as described above. Assays for neutrophil opsonophagocytic killing were 
performed as described previously (70, 80); 102 bacteria were pre-opsonized for 30 
minutes with baby rabbit serum (BRS) as a complement source and applied to PAF-
treated neutrophils at the indicated bacterium:phagocyte ratios. Refer to Supplemental 
Methods for details on neutrophil bactericidal assays involving H. influenzae. 
 
Statistical analyses. All data are presented as mean ± S.E.M. Data were analyzed using a 
2-tailed Student’s t test for comparisons between 2 groups and ANOVA with Newman-
Keuls post-test for all comparisons of >2 groups. Relative MFI measurements were 
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analyzed using pairwise one-sample t tests relative to a null ratio of 1. For all analyses, p 
< 0.05 was considered statistically significant.  
 
Study approval. All animal experiments were approved by and performed in strict 
accordance with the guidelines of the University of Pennsylvania Institutional Animal 
Care and Use Committee.  
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Figure Legends 
 
Figure 1.  Pce-deficient pneumococci exhibit impaired persistence in the 
upper airway and elicit more activated, viable and durable neutrophils to 
the nasal lumen. 
(A) Bacterial clearance in mice inoculated with wild-type (WT) pneumococci, strain 
P1121 (Type 23F), with (open) or without (black) systemic neutrophil depletion (N = 4-5 
mice per condition, Limit of detection = 2).  (B) Survival of WT P1121 (black) or 
P1121Δpce (grey) pneumococci in the murine upper airway (N = 4-14). (C) Day 7 survival 
of P1121Δpce mutant generated by in-frame, unmarked deletion (Δpce) and with genetic 
correction (Δpce::pce) (N = 5). (D) Day 7 survival of WT and Δpce pneumococci in a 
Type 4 (T4) pneumococcal genetic background (N = 5). (E) Quantification of neutrophils 
(CD45+CD11b+Ly6G+) obtained from the upper airway lumen by nasal lavage before (N = 
3) and after (N = 4-11) inoculation with WT (black) or Δpce (grey) pneumococci. (F) Flow 
cytometric characterization of luminal neutrophils elicited by infection with WT or Δpce 
pneumococci at day 4 p.i. (N = 6-8). MFI = Mean Fluorescence Intensity. Note that not 
all axes are continuous, and gaps in axes represent gaps in time. Dotted lines represent 
limits of detection. Statistical significance was assessed by one-way ANOVA with 
Newman-Keuls post-test for comparisons of >2 conditions (Panels A, B, & E), Student’s t 
test for 2-group comparisons (Panels C & D), and one-sample t test relative to null = 1 for 
relative MFI measurements (Panel F).  NS = not significant, * = p < 0.05, *** = p < 
0.001. 
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Figure 2.  Pce promotes invasive pneumococcal disease and bacterial 
transmission between mice. 
(A) Survival of adult mice inoculated intranasally with WT (black) or Δpce (grey) 
pneumococci of invasive strain P1547 (Type 6A) (N = 12 mice per condition from 3 
independent experiments). Statistical significance was assessed by Mantel-Cox Test. (B) 
Enumeration of CFUs in the blood of mice infected with WT or Δpce P1547 pneumococci 
as above (N = 5, Limit of detection (LOD) = 14). (C) Infant murine transmission. Upper 
airway lavage CFUs enumerated from index (open circles, N = 3-4) and contact (closed 
circles, N = 14-18) pups on day 14 of life, after index mice were inoculated with WT 
(black) or Δpce (grey) pneumococci on day 4 of life and all pups were infected 
intranasally with influenza on day 8. Numerical values above contact mice columns 
represent percent acquisition (LOD = 10). Transmission data reflect 3 independent 
experiments. In Panels B & C, statistical significance was assessed by one-way ANOVA 
with Newman-Keuls post-test. ** = p < 0.01, *** = p < 0.001. 
 
Figure 3.  Pce prevents accumulation of platelet-activating factor in the 
lumen of the upper respiratory tract and its absence stimulates 
transcription of genes important for PAF signaling. 
(A) Diagram of PAF with phosphorylcholine moiety (ChoP) labeled (and site of Pce-
mediated hydrolysis marked with black arrow). Detection of PAF levels in the upper 
airway lumen by LC-ESI/MS (Limit of quantification = 0.066 nM, dashed line), 
quantified from pooled nasal lavages obtained from 5 mice at 3 days p.i. with PBS 
(open), WT (black), or Δpce (grey) P1121 pneumococci. Averages reflect 3 independent 
biological replicates of 5 pooled mice each. Statistical significance was assessed by one-
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way ANOVA with Newman-Keuls post-test. For representative LC traces from lavage 
fluid of mock-, WT-, Δpce-infected mice: top row displays PAF detected at 8.6 min. 
retention, bottom row displays 2H4-PAF C16 spiked control samples.  (B) qRT-PCR 
analyses measuring relative gene expression of the PAF synthetic enzyme lysoPAFAT, 
PAFR (Ptafr), and chemokines Cxcl1 and Cxcl2 from nasal lavages obtained at 3 days p.i. 
from mice colonized with PBS, WT, or Δpce P1121 pneumococci (N = 6-10 mice per 
condition). All transcripts were normalized to GAPDH controls and are displayed 
relative to mice mock-infected with PBS (dotted lines). Statistical significance was 
assessed by Student’s t test. NS = not significant, * = p < 0.05 
 
Figure 4.  Pce is dispensable for pneumococcal persistence in the absence of 
infiltrating neutrophils or intact PAF signaling in the upper airway. 
(A) Confirmation of neutrophil depletion. Mice were treated with neutrophil-depleting 
antibody (α-Ly6G, Clone 1A8) or IgG2a isotype control (250 µg, i.p.) on days -1, +1, and 
+4 post-inoculation (p.i.) with PBS (open), WT (black) or Δpce (grey) P1121 pneumococci 
(N = 3-4 mice per condition). On day 7 p.i., depletion was confirmed by flow cytometry 
of whole blood and nasal lavage. (B) Enumeration of WT (black) or Δpce (grey) 
pneumococcal CFUs obtained from nasal lavages on day 7 p.i after treatment of mice (N 
= 5-11 mice per group) with neutrophil-depleting α-Ly6G or IgG2a isotype control 
antibodies. (C) Enumeration of bacterial CFUs on day 7 p.i. after daily intranasal 
treatment with 0.1 or 1 µg of PAF receptor antagonist PCA-4248 (or 1% DMSO vehicle), 
from day +1 to +6 p.i (N = 5-12). The experiment was repeated with neutrophil depletion 
as described in (A). (D) WT and Δpce bacterial loads were enumerated in lavages 
obtained from PAFR-/- and littermate controls on day 7 p.i. (N = 5-11). Statistical 
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significance was assessed by one-way ANOVA with Newman-Keuls post-test for all 
panels. NS = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
 
Figure 5.  Pce esterase hydrolyzes phosphorylcholine (ChoP) from 
conjugated substrates and directly inhibits PAF-mediated stimulation of 
neutrophil activation and function in vitro.  
Killing of WT (black) or Δpce (grey) P1121 pneumococci in vitro by murine (A) or human 
(B) neutrophils, at the indicated neutrophil:bacterium ratios, after pre-opsonization with 
baby rabbit serum. HI = heat-inactivated. Bacterial survival was measured relative to 
control assays in the absence of neutrophils (dotted line). (C) Kinetic time-course of p-
nitrophenol liberation (absorbance at 415 nm) after incubation of p-
nitrophenylphosphorylcholine (pNPPC) with recombinant Pce enzyme (rPce, black line). 
Assays were repeated in the absence of Pce enzyme, pNPPC substrate, or in the presence 
of 250 mM EDTA. (D) Mean fluorescence intensity (MFI) quantification of bacterial 
uptake receptors CD11b and CD64 on murine neutrophils treated with PAF that was pre-
incubated with rPce (black) or PBS (open). PAF stimulation assays were repeated with 
10-5 M PAF receptor antagonist PCA-4248 as a specificity control. Killing assays using 
WT pneumococci were performed after PAF-mediated murine (D) or human (E) 
neutrophil stimulation in the presence (black) or absence (open) of rPce. Top dotted line 
denotes 100% bacterial survival; bottom dotted line denotes average survival in the 
absence of PAF. For all panels, data averages reflect at least 3 independent experiments 
(3-4 independent biological replicates for cellular assays). Statistical significance for all 
pairwise comparisons was assessed by Student’s t test. * = p < 0.05, ** = p < 0.01, *** = 
p < 0.001. 
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Figure 6.  Exogenous stimulation of neutrophils in situ overwhelms Pce-
mediated immune evasion. 
(A) Enumeration of WT (black) or Δpce (grey) pneumococcal CFUs obtained on day 7 p.i. 
and after daily (+1 to +6) intranasal treatments with 1 μg PAF or vehicle control (1% 
DMSO in PBS). The experiment was repeated after treatment with neutrophil-depleting 
α-Ly6G or IgG2a isotype control antibody (see Figure 4B) (N = 5-10 mice per condition). 
(B) Quantification of neutrophils elicited to WT (black) or Δpce (grey) P1121 
pneumococci in nasal lavages of vehicle- or PAF-treated mice on day 7 p.i. (N = 5 per 
group). (C) Relative mean fluorescence intensity (MFI) of uptake receptor expression on 
luminal neutrophils elicited to WT or Δpce pneumococci (Δpce/WT) after daily 
treatment with vehicle (black) or 1 μg PAF (open), as described in (A) (N = 5). (D) 
Enumeration of bacterial CFUs as in (A), with and without daily intranasal treatments 
with 1 μg fMLP or vehicle (N = 5-7). (E) Quantification of elicited neutrophils as in (B) 
with or without treatment with fMLP (N = 5). (F) Relative uptake receptor MFI on 
neutrophils elicited to WT or Δpce pneumococci (Δpce/WT) after daily treatment with 
vehicle (black) or 1 μg fMLP (open), as in (C) (N = 5). Statistical significance was 
assessed by one-way ANOVA with Newman-Keuls post-test except for Panels C & F, 
wherein significance was assessed by one-sample t test relative to a value of 1. NS = not 
significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
 
Figure 7.  Haemophilus influenzae GlpQ hydrolyzes phosphorylcholine and 
contributes to evasion of PAF-mediated neutrophil defense of the airway. 
(A) Diagram of p-nitrophenylphosphorylcholine (pNPPC). Black arrow denotes site of 
63 
 
hydrolysis by S. pneumoniae Pce; white arrow indicates that by H. influenzae GlpQ. (B) 
P-nitrophenol liberation after incubating pNPPC with WT (black) or mutant (grey) S. 
pneumoniae (Sp) or H. influenzae (Hi) (N = 5). (C) Survival of WT (black) or ΔglpQ 
(grey) Hi during infection of the murine upper airway. (N = 5-8 mice per group, Limit of 
detection (LOD) = 4). (D) Quantification of neutrophils obtained from mice inoculated 
with WT or ΔglpQ bacteria (N = 4). (E) CD11b and CD64 relative MFI on neutrophils 
elicited by WT or ΔglpQ bacteria, d2 post-inoculation (p.i.) (N = 4). (F) Enumeration of 
day 2 WT or ΔglpQ Hi CFUs after treatment with α-Ly6G antibody or IgG2a isotype 
control. (N = 5, LOD = 4). (G) WT and ΔglpQ bacterial loads from PAFR-/- mice, 
littermate controls, or neutropenic PAFR-/- mice on day 2 p.i. (N = 3-9, LOD = 10). (H) 
Bacterial killing assay of WT Hi by 1000:1 murine neutrophils pre-treated with 
increasing concentrations of conditioned PAF media; PAF was pre-incubated with heat-
killed WT (black) or ΔglpQ (white) bacteria before mixing with neutrophils prior to 
killing assays. Average values represent 3 biological replicates. Top dotted line: 100% 
bacterial survival; Bottom dotted line: average survival in the absence of PAF. Statistical 
significance was assessed by Student’s t test for pairwise comparisons (Panels B & H), 
one-way ANOVA with Newman-Keuls post-test for multi-group comparisons (Panels C, 
D, F, & G), and one-sample t test relative to null = 1 for relative MFI measurements 
(Panel E). NS = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
 
Figure S1.  Clearance of Pce-deficient pneumococci on day 14 post-
inoculation (p.i.) and upper airway luminal neutrophil gating strategy. 
(A) Enumeration of WT (black) or Δpce (grey) P1121 pneumococcal CFUs obtained from 
nasal lavages on day 14 p.i. (N = 14). (B) Quantification of luminal neutrophils elicited 
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WT or Δpce pneumococci on day 14 p.i. (N = 5). (C) Gating strategy used to identify 
CD45+CD11b+Ly6G+ neutrophils from infiltrating immune cells during upper airway 
infection. Representative data represents neutrophils elicited by Δpce pneumococci on 
day 4 p.i. Statistical significance was assessed by Student’s t test. NS = not significant, * 
= p < 0.05. 
 
Figure S2.  Assessment of the direct effects of PCA-4248, PAF, and fMLP on 
pneumococcal growth and viability in vitro.  
Growth curves (OD620) of WT (black) and Δpce (grey) P1121 pneumococci in tryptic soy 
(TS) broth and grown either alone (A) or with increasing concentrations of PCA-4248 
(B), PAF (C), or fMLP (D). Concentrations of drugs: PBS vehicle (circles), 2 nM 
(squares), 0.2 µM (diamonds), and 200 µM (triangles). Values represent three 
independent experiments. Statistical significance was assessed by Student’s t test; all 
comparisons were not significant. 
 
Figure S3.  Quantification of complement deposition, capsule expression, 
and phosphorylcholine (ChoP) levels by bacterial flow cytometry. 
Graphs and representative histograms for mean fluorescence intensity (MFI) of: (A) 
Complement component C3 deposited on WT (black) and Δpce (grey) P1121 
pneumococci after 30 minutes incubation with 66% murine serum.  Experiments were 
also performed using heat-inactivated (HI) murine serum (white) and P1121Δcap lacking 
capsule expression (light grey). (B) P1121 capsule expression on WT and Δpce P1121 
measured by deposition of anti-23F capsular antibody. (C) Accessibility of surface ChoP 
among P1121Δcap and P1121ΔpceΔcap pneumococci measured by deposition of anti-
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phosphorylcholine antibody. Values represent duplicated independent experiments. 
Statistical significance was assessed by one-way ANOVA with Newman-Keuls post-test. 
NS = not significant, ** = p < 0.01. 
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Table S1 
 Description Sequence (5’ to 3’) Reference 
pce amplification 
primers 
P1, F GGGGAATTCAGAATGAAAAAGAAATTAAC (340) 
 PCE-2, R 
TATGGATCCCTACTGTTCTGATTCCGATTT
GTTTAC 
(340) 
    
Janus cassette 
insertion into pce 
   
 SP_0930 Upstream, F TCTGCGTCCAGGGATTGTTC This Study 
 SP_0930 Upstream, R 
CATTATCCATTAAAAATCAAACGCATCACT
GCCACCTTCTTG 
This Study 
 Janus Cassette, F 
CAAGAAGGTGGCAGTGATGCGTTTGATTT
TTAATGGATAATG 
(321) 
 Janus Cassette, R 
CACTCGTTTCAGAGCTTTGTGACTTTCCTT
ATGCTTTTGGAC 
(321) 
 SP_0930 Downstream, F 
GTCCAAAAGCATAAGGAAAGTCACAAAGC
TCTGAAACGAGTG 
This Study 
 SP_0930 Downstream, R AAGGTCTGCTTGGACCATCG This Study 
    
Unmarked pce 
deletion 
   
 SP_0930 Upstream Del., F GTCCAGGGATTGTTCACCGT This Study 
 SP_0930 Upstream Janus Fusion, R 
GAAGGCCCTAAAACCTTCTTTTCTATCTTA
CTTTCTCAATCTCTCCAAGGTTTCC 
 
This Study 
 SP_0930 Downstream Janus Fusion, F 
GGAAACCTTGGAGAGATTGAGAAAGTAAG
ATAGAAAAGAAGGTTTTAGGGCCTTC 
 
This Study 
 SP_0930 Downstream Del., R CTTCCAACAAAAGCCCCTGC This Study 
    
pce cloning     
 
Pce cloning primer, F  
(BamHI site) 
ATCGGATCCGCACTTGTAGGCGCTTTT This Study 
 
Pce cloning primer, R  
(SacI site) 
ATCGAGCTCACACTCGTTTCAGAGCTTTG
TG 
This Study 
    
qRT-PCR  Lyso-PAF Acetyltransferase, F GCCCAGGTGGCTTTCATGACGT (209) 
 Lyso-PAF Acetyltransferase, R CCAGCAAACCACATGGTGCGC (209) 
 PAF Receptor, F CTGGACCCTAGCAGAGTTGG (196) 
 PAF Receptor, R GCTACTGCGCATGCTGTAAA (196) 
 CXCL1, F CTGGGATTCACCTCAAGAACATC (245) 
 CXCL1, R CAGGGTCAAGGCAAGCCTC (245) 
 CXCL2, F CGCTGTCAATGCCTGAAG (258) 
 CXCL2, R GGCGTCACACTCAAGCTCT (258) 
 GAPDH, F TGCACCACCAACTGCTTAG (245) 
 GAPDH, R GGATGCAGGGATGATGTTC (245) 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure S1 
 
  
75 
 
Figure S2 
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Figure S3 
 
  
77 
 
Supplemental Methods 
 
Generation of an insertion-duplication Δpce mutant. A PCR product containing pce 
interrupted by an erythromycin resistance cassette was amplified from the R36AΔpce S. 
pneumoniae genome (a gift from Dr. Alexander Tomasz) using primers “P1” and “PCE-2” 
(see Table S1) (340). The product was transformed into the indicated wild type isolates, 
selected with 1 µg/mL erythromycin. Correct cassette insertion was verified by 
sequencing and lysates from all transformed mutants were incubated for 60 minutes 
with chromogenic p-nitrophenylphosphorylcholine to ensure no Pce enzymatic activity 
remained (see Methods). 
 
Generation and correction of an in-frame Δpce deletion mutant. Deletion of pce was 
achieved through insertion and subsequent deletion of a bicistronic Janus construct 
bearing kanamycin resistance and streptomycin trans-sensitivity cassettes in 
spontaneously streptomycin-resistant bacteria, as detailed previously (81, 321).  To 
insert the Janus cassette, an overlap-extension PCR product was created from three 
independent PCR reactions: First, a ~650 bp fragment upstream of pce was amplified 
from the pneumococcal genome using primers “SP_0930 Upstream, F&R”; the ~1.8 kb 
Janus cassette was amplified using primers “Janus Cassette, F&R”; and a ~640 bp 
fragment downstream of pce was amplified from the genome using primers “SP_0930 
Downstream, F&R” (See Table S1). All three PCR products were then column-purified 
together (Qiagen) and extended using shared homology in a PCR reaction lacking 
primers. A final PCR using outside flanking primers “SP_0930 Upstream, F” and 
“SP_0930 Downstream, R” was performed to generate a product of approximately 3 kb. 
After purification, the product was transformed into wild type pneumococci and 
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transformants were selected with 500 µg/mL kanamycin before sequence verification.  A 
similar procedure was performed to create a construct to delete the Janus-bearing pce 
gene, wherein 2 PCR products were generated by: 1) “SP_0930 Upstream Del., F” & 
“SP_0930 Upstream Janus Fusion, R”; and 2) “SP_0930 Downstream Janus Fusion, F” 
& “SP_0930 Upstream Del., R.” These products were sewn together as described above 
and used to transform Janus-bearing pce mutants. Clones were selected with 500 µg/mL 
streptomycin and sequenced to confirm in-frame deletion of pce. Lastly, a genetically 
corrected (Δpce::pce) strain was generated by transforming Janus-bearing Δpce mutants 
with a ~3 kb PCR product containing wild type pce using primers “SP_0930 Upstream, 
F” and “SP_0930 Downstream, R” before selection with 500 µg/mL streptomycin and 
sequence verification. 
 
In vitro bacterial growth and toxicity assays. Kinetic bacterial growth assays were 
performed as described previously (89); 96-well plates bearing 190 µL of TS broth 
supplemented with 10 µL catalase per well (30,000 U/mL) (Worthington Biochemical) 
were inoculated with wild type or Δpce pneumococci at OD620 0.1. Bacterial growth and 
viability were monitored at 15-minute intervals over 10 hours in the presence of PBS 
(vehicle control), PAF (Cayman Chemical), PAF receptor antagonist PCA-4248 (Tocris), 
or fMLP (Sigma-Aldrich) at the indicated concentrations.  
 
Complement deposition assays. Complement component C3 deposition assays were 
adapted from Dalia et al., 2010 (80). Approximately ~106 PBS-washed, mid-log-phase 
bacteria were incubated at 37° C for 30 minutes in 66% fresh murine serum (in Hank’s 
Buffer with calcium). After a subsequent wash, bacteria were stained with 1:150 FITC-
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conjugated, monoclonal anti-mouse complement component C3 antibody (Accurate 
Chem.) and detected by flow cytometry. Assays were repeated with serum heat-
inactivated for 60 minutes at 65° C as negative controls and bacteria lacking capsule 
served as positive controls for C3 deposition. 
 
Quantification of bacterial capsule and surface phosphorylcholine. To quantify 
pneumococcal polysaccharide capsule by flow cytometry, PBS-washed bacteria were 
incubated with 1:500 Type 23F polyclonal typing sera (Statens Serum Institut) for 30 
minutes, washed, then stained with 1:150 AF647-conjugated anti-rabbit IgG (Life 
Technologies). Capsule-deficient pneumococci served as negative controls. To quantify 
surface phosphorylcholine, WT and Δpce bacteria lacking capsule (Δcap) were incubated 
as above with 1:500 monoclonal anti-phosphorylcholine IgA (TEPC-15, Sigma-Aldrich) 
before staining with 1:100 FITC-conjugated anti-mouse IgA (Sigma-Aldrich).  
 
H. influenzae neutrophil bactericidal assays. Bacterial killing assays were performed to 
assess whether pre-incubation of PAF with GlpQ phosphodiesterase inhibits PAF-
stimulated neutrophil bactericidal function. Increasing concentrations of PAF were pre-
incubated for 60 minutes with 25 µL heat-killed WT or ΔglpQ H. influenzae re-
suspended in PBS from OD620 1.0-normalized culture. Conditioned PAF solution was 
then centrifuged at 3,000g for 10 minutes to isolate supernatants, which were plated to 
confirm the absence of viable bacteria. Conditioned media from each condition was then 
applied to bone marrow-derived mature murine neutrophils, 105 phagocytes per 
reaction.  After an additional 30-minute incubation, 102 CFU wild type H. influenzae 
(pre-opsonized in 66% baby rabbit serum) was added to the treated neutrophils in each 
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reaction well. Bacterial survival was quantified in each condition by dilution plating after 
45 minutes of incubation and compared to controls lacking neutrophils or PAF in pre-
incubation steps. 
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Abstract 
 
Human genetic polymorphisms associated with decreased expression of macrophage 
migration inhibitory factor (MIF) have been linked to the risk of community-acquired 
pneumonia (CAP).  Since Streptococcus pneumoniae is the leading cause of CAP and 
nasal carriage a precursor to invasive disease, we explored the role of MIF in the 
clearance of pneumococcal colonization in a mouse model.  MIF-deficient mice (Mif -/-) 
showed prolonged colonization with both avirulent (23F) and virulent (6A) 
pneumococcal serotypes compared, to wild-type animals.  Pneumococcal carriage led to 
both local upregulation of MIF expression and systemic increase of the cytokine.  
Delayed clearance in the Mif -/- mice was correlated with reduced numbers of 
macrophages in upper respiratory tract lavages as well as impaired upregulation of 
monocyte chemotactic protein-1 (MCP-1/CCL2).  We found that primary human 
monocyte derived macrophages as well as THP-1 macrophages produced MIF upon 
pneumococcal infection in a pneumolysin-dependent manner.  Pneumolysin-induced 
MIF production required its pore-forming activity and phosphorylation of p38-MAPK in 
macrophages, with sustained p38-MAPK phosphorylation abrogated in the setting of 
MIF-deficiency.  Challenge with pneumolysin-deficient bacteria demonstrated reduced 
MIF upregulation, decreased numbers of macrophages in the nasopharynx, and less 
effective clearance.  Mif -/- mice also showed reduced antibody response to pneumococcal 
colonization and impaired ability to clear secondary carriage.  Finally, local 
administration of MIF was able to restore bacterial clearance and macrophage 
accumulation in Mif -/- mice.  Our work suggests that MIF is important for innate and 
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adaptive immunity to pneumococcal colonization and could be a contributing factor in 
genetic differences in pneumococcal disease susceptibility. 
 
Introduction 
 
Despite the availability of vaccines and antimicrobial therapy, the burden of disease 
caused by Streptococcus pneumoniae, or the pneumococcus, remains significant 
worldwide.  Among children <5 years, there are 14 million cases of serious pneumococcal 
disease annually with almost 1 million deaths, concentrated largely in developing nations 
(252).  According to the Active Bacterial Core surveillance, 40,000 cases of invasive 
pneumococcal disease (meningitis, bacteremia, and bacteremic pneumonia) occurred the 
United States in 2010 (64).  Additionally, the pneumococcus is estimated to be a 
contributing organism in 20-60% of cases of community acquired pneumonia (CAP), 
which leads to almost 600,000 annual hospitalizations, and is a leading cause of death 
among persons >65 years (157).   
 
Carriage of the pneumococcus in the nasopharynx is a risk factor for aspiration into the 
lungs and a well-established to be a precursor to pneumonia and invasive disease with 
the colonizing serotype (6, 37).  Pneumococcal carriage begins within the first six months 
of life and sequential colonization is prevalent throughout childhood (132).  Immune 
mediators of colonization, their contribution to disease, and whether they can be 
assessed to understand disease risk and modulated in vaccination strategies are 
important areas for study.  Cell-mediated immunity appears to be more important than 
humoral immunity in effecting primary pneumococcal clearance from the nasopharynx 
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(226, 227).  Evidence of the contribution the CD4 T cell response is suggested by the 
greater incidence of both pneumococcal colonization and disease among HIV-infected 
compared to uninfected subjects (210).  In addition to Th1 immunity, animal as well as 
human studies have implicated the Th17 response in pneumococcal clearance (205, 366).   
 
Although neutrophils are the first cell type to be recruited after colonization, the peak of 
their presence in the nasopharynx does not correlate with initiation of clearance, and 
their depletion does not seem to affect bacterial burden during carriage (222, 227, 249).  
Recently, a critical role for the sustained presence of macrophages in pneumococcal 
recognition and clearance, as well as coordination of the adaptive response, has been 
reported.  Mice deficient in pattern recognition receptors show limited ability to generate 
local chemokine responses to enable recruitment and retention of macrophages in the 
upper airway and impaired pneumococcal clearance (87, 222, 366).   
 
Defining the genetic determinants of immunity to pneumococcal disease risk is an area 
of active investigation.  Some familial immune defects are known to confer profound risk 
for pneumococcal infection (262).  However, the finding of increased susceptibility to 
pneumococcal disease in certain ethnic groups, despite controlling for disparities in 
socioeconomic status, suggests that there may be a broader genetic basis for 
susceptibility (55).  Studies examining host genetics in both pneumococcal colonization 
and disease cohorts have proposed polymorphisms which may play a role, including a 
number affecting macrophage function (46, 342).   
 
Recently, an examination of host genetics in a cohort of 1700 older adults with CAP 
implicated two commonly-occurring polymorphisms conferring increased expression of 
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an innate mediator, macrophage migration inhibitory factor (MIF), in protection from 
disease (362).  Microbiologic diagnosis is often challenging in CAP, but older age and 
community origin of the patients make the pneumococcus a likely pathogen in a majority 
of cases.  The functional significance of these MIF variants, a tetranucleotide repeat in 
the promoter (-794 CATT) and a linked single nucleotide polymorphism (SNP, -173 
G/C), in regulating macrophage response to various infectious and inflammatory stimuli 
has been demonstrated (82, 83, 273, 313).  As pneumococcal carriage is a precursor to 
disease and macrophage responses are important in clearance, we chose to explore the 
role of MIF in a murine model of nasopharyngeal colonization. 
 
MIF was the first cytokine discovered and named for its activity of retaining 
macrophages at the site of inflammation, making it an important factor to examine in 
pneumococcal colonization (35, 85).  The expression of MIF by both immune cells 
(macrophages and lymphocytes) and epithelial cells (of the lung, gut, and skin) highlight 
its role in host-pathogen interaction (19, 57).  MIF has been demonstrated to mediate 
recognition of gram-negative bacteria and mycobacteria by regulating macrophage 
expression of molecular pattern recognition receptors (82, 277, 278).  Additionally, MIF 
promotes production of a variety of inflammatory cytokines by enabling nuclear 
translocation of NFκB and sustaining the activation of intracellular mitogen-activated 
protein (MAP) kinases (84, 240, 241).  Studies with MIF-deficient (Mif -/-) mice have 
shown that the role of MIF (detrimental vs. beneficial) in different bacterial infections is 
dependent on the nature of the pathogen and the type of immunity induced.  For 
instance, Mif -/- mice are protected from overwhelming inflammation in LPS or 
superantigen-induced shock but are more susceptible to infection with Salmonella 
typhimurium and Mycobacterium tuberculosis (58, 82, 183). 
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Early studies attributed the accumulation of alveolar macrophages in rabbit models of 
pneumococcal pneumonia to the activity of MIF (59).  Thereafter, the role of MIF in 
infections with gram-positive pathogens which do not produce a superantigen, such as 
the pneumococcus, has received less attention.  Additionally, the role of MIF in mucosal 
immunity or how it may mediate immune responses to the pneumococcus as a 
commensal as well as an agent of disease remains to be explored.  
 
Methods 
 
Mice.  C57BL/6 (WT) mice were obtained from the Jackson Laboratory at 6–8 weeks of 
age.  Mif -/- mice in the C57BL/6 background, backcrossed 10 generations, were obtained 
as previously described (82).  WT and Mif -/- mice were age and sex matched in all 
experiments. All procedures were performed in accordance with the Institutional Animal 
Care and Use Committee protocols at the University of Pennsylvania. 
 
Bacterial strains and culture conditions.  The P1121 strain of pneumococcus was utilized 
for nasal colonization experiments because it is a minimally passaged serotype 23F 
isolate obtained from the nasopharynx of a subject in a human carriage study (227).  
Another clinical isolate for serotype 6A also was used (276).  23F pneumococci as well as 
the previously described pneumolysin deletion (23Fply–), point mutant (23FplyW433F), and 
revertant (23Fply-→ply+) strains were also utilized for macrophage infections where 
indicated (87).  All bacteria were grown in tryptic soy broth (TS, Life Technologies) at 
37°C and 5% CO2 until cultures reached mid-log phase, OD600 between 0.45 and 0.50.   
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Murine model of pneumococcal colonization.  All bacterial strains were animal passaged 
prior to use in experiments and stored at –80°C in 20% glycerol.  Inocula consisted of 
10^7 mid-log-phase PBS-washed bacteria in 10μl PBS and were plated to confirm dose.  
They were delivered to the nares of unanesthetized mice as previously described (360).  
At the indicated time points, mice were sacrificed, their trachea cannulated, and 200μl 
PBS instilled.  Lavage fluid was collected from the nares and serially diluted in PBS for 
plating on TS agar plates supplemented with catalase (Worthington Biochemicals). The 
lower limit of detection was either 100 CFU/ml or 20 CFU/ml lavage fluid, depending on 
the experiment.  Blood was collected by cardiac puncture and the serum separated.  
Serum and lavages were assayed for mMIF by specific ELSIA.  Serum was additionally 
assayed for anti-pneumococcal IgG as previously described (87). 
 
Recombinant murine MIF (rMIF) was produced as described previously and ensured to 
be LPS-free (32).  PBS was used to dilute the rMIF to the indicated concentration.  As 
dimethyl sulfoxide (DMSO) was present in the rMIF preparation, an identical amount of 
DMSO was added to PBS for the vehicle control treatment.  Either rMIF or vehicle 
control were administered in a 10μl volume to the nares of unanesthetized mice for the 
frequency and duration described. 
 
RNA Extraction and RT-PCR.  RNA was isolated from the upper respiratory tract 
following a lavage with 300μl RNA lysis buffer using an RNeasy Mini Kit (QIAGEN) 
according to manufacturer’s protocol. Complementary DNA was reverse transcribed 
using a high-capacity reverse transcription kit (Applied Biosystems).  Approximately 
25ng cDNA was used as a template in reactions with 0.5μM of forward and reverse 
primers for MIF, GAPDH, and CCL2 and SYBR Green (Applied Biosystems), according 
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to the manufacturer’s protocol and as previously described (82, 87).  Reactions were 
carried out using the StepOnePlus Real-Time PCR system, and quantitative comparisons 
were obtained using the ΔΔCT method (Applied Biosystems).  Mock-infected WT mice 
were set as the reference to which relative comparisons were made. 
 
Flow cytometry.  The nasal lavages of 5 mice from each group were pooled, centrifuged 
to obtain a cell pellet, and resuspended in PBS with 1% bovine serum albumin.  
Nonspecific binding was blocked using a rat anti-mouse antibody directed against the 
FcγIII/II receptor (CD16/CD32) (BD Biosciences), and the cells were stained with the 
following rat anti-mouse cell surface antibodies: Ly6G, Ly6C, CD11b, CD11c, Siglec-F, 
and F4/80 (BD Biosciences).  All samples were fixed in 4% paraformaldehyde before 
analysis.  Data were acquired using the FACSCalibur flow cytometer (BD Biosciences) 
and analyzed using FlowJo software (Tree Star). 
 
Macrophage culture and stimulation.  Human macrophages were prepared from 
peripheral blood mononuclear cells (PBMCs) isolated by Ficoll-Hypaque gradient 
centrifugation.  The cells were resuspended in RPMI 1640 medium supplemented with 
20% human AB serum (Gemini) and plated.  After 2 h of culture, the adherent cells were 
washed extensively with PBS and cultured for 1 week with human serum supplemented 
media to allow differentiation into monocyte-derived macrophages.  THP-1 monocytes 
(ATCC) were differentiatedinto macrophages by adding 50ng/mL of phorbol 12-
myristate 13-acetate (PMA; Sigma-Aldrich) to RPMI supplemented with 10% fetal calf 
serum culture (FCS) medium for 16 hours.   
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Both human monocyte derived macrophages and THP-1 cells were infected at a 
multiplicity of infection (MOI) ratio of 10 bacteria per macrophage.  The bacteria were 
spun onto the macrophages by centrifuging at 1500 X g for 10 minutes.  Invasion was 
allowed for 1 hour at 37°C, 5%CO2, then extracellular bacteria were washed away, and 
gentamicin-supplemented culture media was added.  Conditioned supernatants were 
collected at the indicated time points.  Cell viability was confirmed by light microscopy 
and lactate dehydrogenase release assay (Roche).  Macrophages were treated with the 
p38-MAP kinase inhibitor, SB203580 (Cell Signaling), at a concentration of 10μM added 
to the culture media throughout the course of the experiment (or control DMSO 
supplemented culture medium) where indicated.  Supernatants were assayed for huMIF 
by specific ELISA. 
 
Bone marrow derived macrophages (BMDMs) were prepared by differentiating cells 
flushed from the femur/tibias of C57BL/6 mice of the appropriate genotype (WT or Mif -
/-) in the presence of supernatant from L929 cells as a source of M-CSF (in DMEM and 
10% FCS) for 1 week.  The macrophages were harvested and replated for infection 
experiments.  For BMDM experiments, infected macrophages were placed into the 
incubator immediately after centrifugation and lysed on ice with cold RIPA buffer (Cell 
Signaling) supplemented with protease inhibitor (Roche) and phosphatase inhibitor 
(Sigma-Aldrich), at the indicated time points. 
 
Western Blotting.  Cell lysates were separated on a 10% polyacrylamide gel (Bio-Rad) 
and proteins were transferred to polyvinylidene difluoride membranes.  Membranes 
were probed first for phospho p38-MAPK using a rabbit monoclonal antibody (Cell 
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Signaling).  The same membrane was then stripped and re-probed for total p38-MAPK 
(rabbit monoclonal, Cell Signaling). 
 
Statistics.  Statistical comparisons were computed using the Mann-Whitney U test (non-
parametric, 2-tailed t test) or one way analysis of variance as indicated in the figure 
legends (Prism 4, GraphPad Software). A P value of less than 0.05 was considered 
significant. 
 
Results 
 
MIF is required for the clearance of pneumococcal colonization from the 
nasopharynx. 
We found WT and Mif -/- mice to be colonized to a similar degree after inoculation with 
23F pneumococci, a clinically relevant serotype which is not associated with pneumonia 
or invasive disease in mice.  By 7 days post-challenge, when bacterial clearance is 
initiated, a two-fold higher bacterial load was noted in the nasopharynx of the Mif -/- 
mice compared to their WT counterparts (Figure 1A).  In the WT animals, clearance 
progressed rapidly and was largely complete by 14 days.  In contrast, the Mif -/- mice had 
prolonged colonization through day 28, but were able to clear the infection by day 42 
(data not shown).  As expected, no symptoms of pneumococcal disease were observed in 
either group of animals. 
 
To ensure that the clearance defect in Mif -/- mice was not a phenomenon unique to 
serotype 23F pneumococci, we tested a serotype 6A isolate, which colonizes the murine 
nasopharynx and also causes bacteremia and sepsis.  The Mif -/- mice demonstrated 
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almost a log higher bacterial load in their nasal washes at 7 days compared to their WT 
counterparts (Figure 1B).  Perhaps as a consequence of the greater bacterial burden, Mif -
/- animals also demonstrated greater mortality from sepsis compared to WT (54% vs. 
26%, p=0.05).   
 
Pneumococcal colonization leads to both local and systemic MIF expression. 
We next explored whether exposure to pneumococci in the nasopharynx could induce 
expression of MIF.  At 3 days post colonization, MIF expression in the nasopharynx was 
assayed by qRT PCR performed on RNA extracted from a nasal wash with lysis buffer.  
We found a basal level of MIF expression in the nasal wash (compared to Mif -/- control, 
Figure 2A).  Upon pneumococcal colonization, the MIF expression was upregulated 2.5-
fold.  Our attempts to detect MIF protein in the nasopharynx were limited by dilution in 
the volume required for nasal lavage.  Local exposure to pneumococci in the nasal 
mucosa led to a rise in the circulating level of MIF at 3 days, without any evidence of 
bacterial dissemination (Figure 2B).  Notably, both local upregulation and systemic 
increase of MIF at 3 days preceded the onset of bacterial clearance, which began at 7 
days and accelerated thereafter. 
 
Cellular recruitment and chemokine expression are impaired in the absence 
of MIF. 
Macrophage recruitment to the nasopharynx has been demonstrated to effect 
pneumococcal clearance and to be dependent on bacterial recognition and local MCP-1 
(CCL2) induction and signaling (87, 366).  When we compared the cellular composition 
of nasal washes from WT and Mif -/- mice over the course of pneumococcal colonization, 
we observed reduced numbers of macrophages (CD11b-, F4/80+ cells) in the Mif -/- 
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animals at both 3 and 7 days (Figure 3A).  Nasopharyngeal macrophages lacked 
expression of CD11c, Ly6C, Ly6G, and Siglec-F.  The presence of macrophages in the 
nasopharynx of WT animals at 3 days correlated with transcriptional upregulation of 
MIF, and preceded the initiation of pneumococcal clearance.  The MIF-dependent defect 
in macrophage numbers was sustained thereafter and could be detected at 14 days post 
colonization.  The defect seemed to be specific to macrophages as neutrophil infiltration 
in the nasopharynx was unaffected in the absence of MIF (Figure 3B).   
 
We also found that Mif -/- animals were impaired in their ability to induce transcription 
of MCP-1 (CCL2) in the nasopharynx during pneumococcal colonization (Figure 3C).  
While WT mice upregulated expression of the macrophage chemoattractant almost 10-
fold compared to uninfected, this was reduced ~60% in the Mif -/- mice.  Once again, 
dilution in the nasopharyngeal lavage precluded our ability to explore the differences in 
MCP-1 (CCL2) on the protein level. 
 
Pneumolysin mediates the action of MIF in the nasopharynx 
We next sought to examine the role of bacterial factors in mediating inflammatory 
macrophage responses in the nasopharynx.  We focused on the pneumococcal pore-
forming toxin, pneumolysin, which in addition to its role as a cytolysin has been 
demonstrated to be important for bacterial recognition by the innate immune system, 
subsequent initiation of the inflammatory cascade, and bacterial clearance (213, 234, 
337, 355).  Sensing of pneumolysin has been proposed to occur through TLR4, NLRP3, 
as well as pore-formation and osmotic gradient-dependent mechanisms (271).  When we 
compared the kinetics of pneumococcal clearance using pneumolysin sufficient and 
deficient pneumococci, we found that carriage was more dense and prolonged in the 
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setting of pneumolysin deficiency in both the WT and Mif -/- animals (Figure 4A).  
However, the MIF-dependent defect in pneumococcal clearance was eliminated during 
colonization with pneumolysin deficient pneumocci, suggesting that the role of MIF in 
pneumococcal clearance requires pneumolysin.  We also found macrophage recruitment 
to the nasopharynx to be reduced and local upregulation of MIF to be impaired in the 
setting of colonization with pneumolysin-deficient pneumococci (23Fply-, Figure 4B and 
C).   
 
Pneumolysin-stimulated phosphorylation of p38-MAPK is important for 
cytokine production and impaired in the absence of MIF. 
Bacterial infection is known to induce the production of MIF from a variety of cell types, 
and MIF has been proposed to modulate host-pathogen interactions by regulating 
macrophage expression of pattern recognition receptors such as TLR4 and dectin-1 (82, 
277, 278).  We first confirmed robust MIF production from human macrophages 4 hours 
after infection with pneumococci (Figure 5A).  Next, we examined the requirements of 
MIF production using a model of pneumococcal infection in human THP-1 monocytes 
differentiated into macrophages.  Since pneumococci have been implicated in the lysis of 
host cells, we examined MIF production early in the course of infection and confirmed 
cell viability to exclude death as a source of MIF.    
 
We observed no induction of MIF after infection of the cells with 23Fply- bacteria 
compared to mock infected controls, consistent with our findings on the role of 
pneumolysin in the nasopharynx.  Genetic correction of the mutation, in the 23Fply-→ply+ 
strain, restored MIF production.  We concluded that pneumolysin is required for 
pneumococcal-induced MIF production from macrophages.   
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To dissect the basis of the macrophage-pneumolysin interaction, we explored the role of 
TLR4 in this process.  We hypothesized that if TLR4 is crucial for pneumolysin-
dependent inflammatory cytokine production, reduced TLR4 in the Mif -/- mice may 
underlie their abrogated response to pneumococcal colonization.  To test this, we utilized 
a 23FplyW433F mutant, which expresses a pneumolysin that can activate TLR4 but is 
deficient in its ability to form functional membrane pores.  Osmotic stress from 
pneumolysin pores has been proposed to activate inflammation by an alternative 
mechanism – inducing phosphorylation of p38-MAPK (213, 271).  Phosphorylation of 
MAPKs is known to be to an upstream event in the induction of a number of 
inflammatory cytokines.  We found no MIF production from THP-1 macrophages 
infected with the 23FplyW433F pneumococci, suggesting that MIF’s effects in pneumococci-
induced inflammation are TLR4-independent and may be related to an alternate 
mechanism such as pore formation and p38-MAPK phosphorylation.  To evaluate this, 
we treated macrophages with SB203580, a p38-MAPK inhibitor (MAPKi), and assayed 
MIF production.  As SB203580 inhibits all isoforms of p38MAPKs, there is a potential 
for off-target effects with its use.  We found MIF production to be diminished in the 
macrophages treated with the MAPKi compared to vehicle control treated cells (Figure 
5B). 
 
Phosphorylation of p38-MAPK is involved in the secretion of inflammatory cytokines 
from immune cells (271).  Therefore, we next explored phosphorylation of p38-MAPK in 
WT and Mif -/- BMDMs after pneumococcal infection.  Phospho p-38 MAPK was 
demonstrated immediately after infection in the WT cells and sustained over the course 
of the experiment (Figure 5C).  By contrast, although some phospho p-38 MAPK was 
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noted at early after infection (2 min) in the Mif -/- cells, it was not observed thereafter (5 
or 10 mins).  Interestingly, MAPK phosphatase 1 (MKP1), which has been postulated to 
be involved in the resolution of inflammatory responses, is observed to be 
downregulated by MIF and found to be constitutively active in the setting of MIF-
deficiency (3). 
 
MIF is involved in the generation of the adaptive immune response to 
pneumococcal colonization. 
Given the important role of macrophages in coordinating the adaptive immune response, 
we next examined the role of MIF in generation of antibody responses to pneumococcal 
colonization and secondary bacterial clearance (87).  After six weeks of colonization, 
when WT and Mif -/- animals were clear of pneumococci in the nasopharynx, serum was 
obtained and analyzed for total anti-pneumococcal IgG titers by ELISA.  We found Mif -/- 
mice to have 10-fold lower antibody titers compared to their WT counterparts (Figure 
6A), despite more prolonged bacterial exposure.  To evaluate the consequences of an 
impaired adaptive response, we re-inoculated WT and Mif -/- mice with the colonizing 
inocula of 23F pneumococci 6 weeks after primary challenge.  Prior studies of secondary 
challenge in previously colonized WT mice demonstrated rapid pneumococcal clearance 
(366).  We noted that Mif -/- mice remained colonized with ~10^4 pneumococci 5 days 
after secondary challenge compared to WT mice which had <10^3 bacteria recovered 
(Figure 6B).  These results demonstrate that the MIF-dependent macrophage effects 
during pneumococcal colonization also impact downstream adaptive immune responses. 
 
Nasopharyngeal treatment with rMIF restores the MIF-dependent defects in 
pneumococcal clearance. 
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Finally, we sought to rescue MIF effects on pneumococcal clearance by replacing the 
cytokine in Mif -/- mice.  Mif -/- mice were dosed with 100ng of rMIF or vehicle control in 
the nasopharynx every other day after pneumococcal inoculation for a period of 2 weeks.  
The rMIF-treated mice had a 1.5 log reduction in their nasopharyngeal bacterial load 
compared to vehicle control treated animals (Figure 7A).  We also evaluated the cellular 
composition of the nasopharyngeal lavage from the Mif -/- animals with and without MIF 
treatment.  We found MIF administration to be associated with an accumulation of 
macrophages to a level similar to that observed in WT animals (Figure 7B).  Taken 
together, the results of our MIF replacement experiments confirm that the presence of 
MIF in the nasopharynx has a direct effect on the recruitment and retention of 
macrophages, which enables them to promote pneumococcal clearance. 
 
Discussion 
 
We show herein that MIF is expressed by macrophages upon pneumococcal infection in 
a pneumolysin-dependent manner, via a mechanism that requires the phosphorylation 
of p38-MAPK.  Additionally, we demonstrate that MIF promotes the MCP-1 (CCL2)-
mediated recruitment and retention of macrophages in the nasopharynx to allow for 
clearance of primary carriage, and also is required for the generation of adaptive 
responses - antibody production and clearance after repeat pneumococcal challenge.  
Taken together with our finding that administration of rMIF to the MIF-deficient 
animals recovers these defects, our studies indicate that MIF is both necessary and 
sufficient for the accumulation of macrophages in the nasopharynx and subsequent 
pneumococcal clearance. 
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Our work in the mouse model suggests that a setting of relative MIF deficiency may be 
associated with inability to clear pneumococcal carriage.  Although it was not possible to 
demonstrate a correlation between higher nasal colonization and pneumonia in the 
animal model using the 23F serotype, clinical data correlating colonization burden to 
pneumonia suggests that in humans, relative MIF deficiency may confer a propensity for 
downstream disease.  These results are in support of the clinical findings reported by 
Yende and colleagues reporting older adults with the low-expresser MIF genotype to be 
more likely to develop CAP as well as suffer adverse outcomes (362).  The functionality 
of human MIF polymorphisms in the response to infectious stimuli has been 
demonstrated in gram-negative bacterial infection as well as in tuberculous and 
meningococcal disease (82, 83, 273).  One study also has suggested that MIF mRNA 
upregulation in peripheral blood mononuclear cells upon pneumococcal infection is 
influenced by MIF genotype (325).  Further investigation is necessary to analyze the 
MIF-genotype effect on nasopharyngeal and systemic pneumococcal responses.  
Additionally, genetic examinations of dedicated patient cohorts will be required to 
ascertain the impact of immune factor polymorphisms on the risk for pneumococcal 
colonization and disease.  Reduced ability to clear primary colonization or develop 
adequate adaptive responses to deal with subsequent challenge, both of which were 
affected by MIF in our model, are risk factors for pneumococcal disease in children and 
adults (112). 
 
Genetic examinations thus far suggest a dual role for MIF in infection with gram-
negative pathogens – promoting pathogen elimination in some scenarios but causing 
inflammatory damage in others.  In meningococcal disease, the low-expresser MIF 
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genotype is associated with mortality from disease but protective from its occurrence 
(273).  High-expression of MIF is correlated with morbidity and mortality in sepsis but 
protects older adults from developing gram-negative bacteremia (83, 195).  In lower 
respiratory tract infection with Pseudomonas aeruginosa, the absence of MIF protected 
mice from neutrophil-dependent inflammatory pathology, and genetic low-expressers of 
MIF among individuals with cystic fibrosis were protected from pseudomonas 
pneumonia (42, 263).  Fewer studies have examined the role of MIF in the response to 
gram-positive pathogens, and work is underway to determine whether MIF is beneficial 
or detrimental in host responses to pneumococcal infection in the lower respiratory 
tract.  A preliminary genetic examination of patients with pneumococcal disease found 
meningitis to be associated with high-expression MIF genotypes, suggesting that MIF 
may play divergent roles depending on depending on the anatomic site of host-
pneumococcal interaction and whether the inflammatory response is beneficial or 
detrimental to the host (95). 
 
MIF appears to be critical for the control of infections where recruitment and retention 
of macrophages plays a central role in mounting an effective immune response.  The 
source of the macrophages in the nasopharynx is an active area of investigation.  Studies 
to date have implicated embryologically divergent origins for the circulating monocytes 
and alveolar macrophages in the lung; whether there are analogous populations of cells 
in the nasopharynx is unknown (137).  The absence of CD11b on both alveolar and 
nasopharyngeal macrophages suggests phenotypic similarities, but the relatively small 
number of cells in the latter group make their immunologic characterization challenging.  
MIF may play a role in the migration of circulating monocytes into tissues in an MCP-1 
(CCL2) dependent manner, setting up a positive-feedback loop as more cells are 
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recruited (134).  Additionally, some of the seminal studies of MIF described its ability to 
inhibit migration and promote retention of alveolar macrophages (59).  Recruitment of 
circulating monocytes or retention of tissue macrophages may serve as the mechanism 
by which MIF promotes nasopharyngeal macrophage accumulation in pneumococcal 
colonization.  We found no MIF-dependent defects in uptake or killing of pneumococci 
in vitro by BMDMs (data not shown), leading us to the conclusion that it is MIF’s role in 
the recruitment/retention of macrophages in the nasopharynx which underlie its 
importance in clearance of colonization. 
 
This study also highlights the immunomodulatory properties of pneumolysin, which 
serves as a virulence factor for in invasive pneumococcal disease, but has been found to 
promote bacterial clearance from the nasopharynx (33, 337).  We report that TLR4-
independent stimulation of macrophages to effect inflammatory cytokine production 
requires phosphorylation of p38-MAPK, a process which had been previously reported in 
epithelial cells, both in vitro and in vivo (29, 271).  The action of a bacterial cytolysin to 
promote pattern recognition receptor-independent cytokine production in innate 
immune cells has been described with the β-hemolysin of another gram positive 
pathogen – group B streptococcus (28).  A potential mechanism for MAPK-dependent 
secretion of MIF may be through the binding of the transcription factor, specificity 
protein (Sp) 1, to the MIF promoter (279). 
 
Investigating host and bacterial factors which effect immunity in the nasal mucosa 
contributes to the understanding of how the pneumococcus is able to exist as a 
commensal in the upper airways but cause invasive disease in the lower tract (347).  
Although the role of MIF in pulmonary immune responses has been examined, this work 
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is the first examination of its function in the upper airways.  MIF production has been 
observed in human gastric and intestinal mucosa upon gram-negative bacterial infection 
(109, 207).  We demonstrate a role for MIF in development of respiratory mucosal 
immunity – macrophage retention and chemokine production - required for 
pneumococcal clearance.  We focused on MIF production from macrophages in the 
pneumococcal response, but further studies are necessary to determine whether there 
are additional cellular sources (e.g. dendritic cells or epithelial cells).  Finally, our work 
adds pneumolysin-mediated phosphorylation of p38-MAPK to pattern recognition 
receptor activation as a mechanism of macrophage activation in response to 
pneumococcal challenge.  Further investigations of the role of MIF in mucosal immunity 
will be important to the understanding local protective responses in response to 
vaccination as well as the contribution of host genetics to the risk of pneumococcal 
disease. 
 
Figure Legends 
 
Figure 1.  MIF is important for the clearance of pneumococcal colonization. 
Wild type (WT) and MIF-deficient (Mif -/-) mice were inoculated intranasally with 107 
CFU pneumococci.  Lavages of the upper respiratory tract were performed thereafter to 
determine colonization density (CFU/ml). WT mice (black squares) display accelerated 
clearance of 23F pneumococci compared to Mif -/- mice (open squares, A).  The MIF-
dependent defect in colonization is evident using both 23F and 6A strains of 
pneumococci at 7 days (B).  N≥5 mice per experiment, at least two experiments.  The 
dashed line indicates the limit of detection. Error bars represent S.D. and horizontal 
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lines indicate mean values.   Y-axis units depicting CFU/ml are on a log base 10 scale. *P 
< 0.05, **P < 0.01, Mann-Whitney U test.  
 
Figure 2.  Pneumococcal colonization leads to local upregulation and 
systemic production of MIF in WT mice.  
Upper respiratory tract lavages were obtained 3 days after inoculation using RNA lysis 
buffer.  RNA was isolated and reverse transcribed, and MIF expression level was 
measured by quantitative RT-PCR relative to GAPDH controls.  Baseline MIF expression 
and MIF upregulation after colonization was noted in WT (A).  Serum was obtained by 
cardiac puncture at 3 days post-colonization and analyzed for MIF by specific ELISA.  
Increased circulating MIF was noted in WT mice (B). Values are relative to mock-
colonized WT mice ± SD (n≥10 mice per group). *P < 0.05, **P < 0.01, unpaired t test.  
 
Figure 3.  MIF is required for the macrophage influx and MCP-1 
upregulation in response to pneumococcal colonization.  
Upper respiratory tract lavages were obtained 3 and 7 days after inoculation and the 
composition of the cellular infiltrate was determined by flow cytometry. Numbers of 
macrophages (F4/80+, CD11b–, A) and neutrophils (Ly6G+, CD11b+, B) are shown in 
WT (gray bars) and Mif -/- mice (white bars). Each bar represents the average number of 
events ± SD in 4 experiments, each with 5 mice.  MCP-1 upregulation in the WT mice 
was demonstrated by quantitative RT PCR of RNA from nasal lavages and found to be 
reduced in the Mif -/- mice (C). RT PCR values are relative to mock-colonized WT mice ± 
SD (n≥10 mice per group). *P < 0.05, **P < 0.01 Mann-Whitney U test or unpaired t 
test.  
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Figure 4.   Pneumolysin mediates the effect of MIF on pneumococcal 
colonization.    
Colonization experiments were performed in WT (close squares) and Mif -/- (open 
squares) mice using 107 CFU of strain 23F and strain 23Fply-.  Nasal lavage was obtained 
at 14 days. 23Fply- (pneumolysin-deficient ) pneumococci colonized both WT and T Mif -/- 
mice to a greater degree than 23F.  The MIF-dependent defect in pneumococcal 
clearance was eliminated in the absence of pneumolysin (A).  Macrophage influx, 
quantified by flow cytometry, was greater in WT mice colonized with strain 23F 
compared to 23Fply- (B).  MIF upregulation, assessed using quantitative RT PCR of nasal 
lavage was present in strain 23F colonization and absent in and 23F ply- colonization (C).  
Flow cytometry, mean ± SD, n=5 mice per experiment, 4 experiments.  RT-PCR, relative 
to mock-colonized WT mice ± SD, n≥10 mice per group.  Y-axis units depicting CFU/ml 
are on a log base 10 scale. *P < 0.05, **P < 0.01, Mann-Whitney U test or unpaired t 
test.  
 
Figure 5.  MIF is produced from macrophages in a process that requires the 
pore-forming function of pneumolysin.   
Human macrophages differentiated from PBMCs were infected with 23F pneumococci at 
an MOI of 10:1 and their culture supernatant assayed for MIF production by specific 
ELISA (A).  THP-1 macrophages, differentiated by PMA,  were infected with the 
indicated strain of pneumococci.  MIF production after infection was diminished in the 
23Fply- and 23FplyW433F strains compared to 23F, and restored in the revertant 23Fply-→ply+ 
strain (B).  MIF production was abrogated by inhibition of p38MAPK phosphorylation 
by treatment with SB203580 (a specific MAPKi, C).  Phosphorylation of p38MAPK was 
observed by western blotting after infection of cultured bone marrow derived 
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macrophages (BMDMs) from WT mice with 23F pneumococci, and quantified by 
densitometry.  p38 MAPK phosphorylation was diminished in BMDMs of Mif -/- mice 
(D).  Mean ± SD values depicted from 4 independent experiments.  Representative 
western blot shown and densitometry performed from 4 independent experiments.  
*P<0.05, **P < 0.01, ***P<0.001, one-way ANOVA. 
 
Figure 6.  MIF promotes the generation of adaptive responses to 
pneumococcal colonization.  
Mice were inoculated intranasally with 107 CFU of 23F pneumocci and 21 days after 
inoculation, were sacrificed, serum was isolated, and levels of anti-pneumococcal serum 
IgG determined by ELISA. Values are expressed as geometric mean titers. WT mice 
(black squares) had circulating higher antibody titers to pneumococcus compared to Mif -
/- mice (open squares, A).  Mice were allowed to clear primary colonization for 6 weeks, 
and then re-challenged with 107 CFU 23F pneumococci.  Nasal lavage was obtained at 5 
days. Mif -/- mice had higher levels of colonization compared to WT (B).  N≥5 mice per 
experiment, at least two experiments. .  Y-axis units depicting CFU/ml are on a log base 
10 scale.  **P < 0.01, Mann-Whitney U test.  
 
Figure 7.  Nasopharyngeal treatment with rMIF recovers the MIF-dependent 
defect in macrophage recruitment and pneumococcal clearance.   
Mif -/- mice were colonized with 107 23F pneumococci, and treated every other day with 
either 100ng of rMIF in PBS or vehicle control.  Nasal lavage was obtained at 14 days.  
MIF treatment let to greater clearance of  pneumococcal colonization compared to 
control (A).  Macrophage influx, quantified by flow cytometry, was also greater in the 
rMIF treated mice compared to vehicle treated controls (B).  Horizontal lines indicate 
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mean values, dashed line is the limit of detection. Flow cytometry, mean ± SD, n=5 mice 
per experiment, 3 experiments.  Y-axis units depicting CFU/ml are on a log base 10 scale.  
*P < 0.05, **P < 0.01, Mann-Whitney U test.  
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Abstract 
 
Mortality from pneumococcal pneumonia remains high despite antibiotic therapy, 
highlighting the pathogenic potential for host inflammation.  We demonstrate that 
macrophage migration inhibitory factor (MIF), an innate immune mediator, is 
detrimental for survival as well as lung pathology, inflammatory cellular infiltration, and 
bacterial burden in a mouse model of pneumococcal pneumonia despite being necessary 
for clearance from the nasopharynx.  Treatment of animals with a small molecule 
inhibitor of MIF improves survival by reducing inflammation and improving bacterial 
control.  Our work demonstrates that MIF modulates beneficial vs. detrimental 
inflammatory responses in the host-pneumococcal interaction and is a potential target 
for therapeutic modulation. 
 
Introduction 
 
Mortality from invasive pneumococcal infection remains at 10% today.  Even with 
appropriate antibiotic administration mortality is still a concern in the treatment of 
pneumonia, implicating a pathogenic component of the host response (18, 64).  
Development of novel, antibiotic-independent, therapeutic strategies are needed to 
address the disease burden associated with pneumococcal lung infections. 
 
The pathogenesis of pneumococcal pneumonia is governed by the interplay of 
inflammatory responses - some are required to control bacterial growth whereas others 
are dispensable or detrimental and result in inflammatory pathology.  After infection, 
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sensing of the pneumococcus by epithelial and resident immune cells leads to the 
production of cytokines and chemokines, which recruit innate effector cells, neutrophils 
and monocytes, to the lung.  Neutrophils and monocytes/macrophages are agents of 
pneumococcal killing, but their role in the regulation of inflammation has recently come 
to light.  Depletion of neutrophils in pneumonia improves survival and lung pathology 
without compromising bacterial control (216).  Additionally, IL-1 signaling in monocytes 
and epithelial cells promotes expression of the neutrophil chemoattractants KC/CXCL1 
and MIP-2/CXCL2, resulting in increased pulmonary neutrophilia and exacerbated 
disease (217).  The importance of cooperation between monocytes and neutrophils is 
highlighted by findings that mice lacking either macrophages or components of the 
macrophage apoptosis machinery demonstrate increased neutrophil recruitment and 
impaired pneumococcal control (217, 275). 
 
We recently reported that macrophage migration inhibitory factor (MIF), a cytokine 
expressed abundantly by both immune and epithelial cells at sites of host-pathogen 
interaction, retains macrophages in the nasopharynx in response to pneumococcal 
colonization and is required for bacterial clearance (224).  This supports the observation 
that older adults who are low-expressers of MIF, by way of a commonly occurring genetic 
polymorphism, are at greater risk for community-acquired pneumonia (362).  However, 
given that host-pathogen interactions may vary in different regions of the respiratory 
tract, we next sought to define the role of MIF in pulmonary immunity during 
pneumococcal pneumonia.   
 
Methods 
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Mice.  Adult C57BL/6 (wild type, WT) mice were age/sex matched with MIF-deficient 
(Mif-/-) mice in the C57BL/6 background for all experiments (224).  Procedures were 
performed in accordance with the Institutional Animal Care and Use Committee 
protocols of the University of Pennsylvania. 
 
Model of pneumococcal colonization and pneumonia.  An animal-passaged serotype 3 
strain of Streptococcus pneumoniae (ATCC 6303) was used for all experiments.  
Cultures were grown in tryptic soy broth (TS, Life Technologies) at 37°C to mid-log 
phase, OD620~1.0.  For colonization experiments, 107 mid-log phase bacteria in 10μl of 
PBS were delivered to the nares of awake mice (224).  At the indicated time points, mice 
were sacrificed, their trachea cannulated, and lavage fluid collected from the nares for 
bacterial enumeration.Pneumonia was modeled by administering 104 mid-log phase 
bacteria in 80μl of PBS to the nares of isoflurane-anesthetized mice (Santa Cruz 
Biotechnology).  During survival experiments animals were monitored twice a day for 
signs of illness such as decreased activity and labored breathing, and euthanized if they 
were in extremis.  Otherwise, they were sacrificed by CO2 asphyxiation at the indicated 
times.   
 
For MIF replacement experiments, 100ng of endotoxin-free recombinant MIF (rMIF) 
dissolved in 80μL of PBS, or PBS alone, was administered to the nares of anesthetized 
mice (224).  For MIF-inhibition, 40mg/kg of 3-(3-hydroxybenzyl)-5-methylbenzooxazol-
2-one, designated MIF098, dissolved in PEG 400 plus (2-hydroxypropyl)-β-cyclodextrin 
vehicle, or vehicle alone, was administered i.p. twice daily beginning on the day of 
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infection (320).  MIF098 did not directly inhibit pneumococcal growth, even at ten-fold 
the concentration used in vivo. 
 
Bronchoalveolar lavage was performed with 1ml of cold PBS for protein analysis or 3ml 
for flow cytometry.  Fluid was centrifuged to pellet cells prior to protein determination 
(bicinchoninic acid (BCA) assay, Thermo Scientific) and ELISAs (eBioscience).  Blood 
was obtained by cardiac puncture and diluted 1:10 in PBS before plating.  For bacterial 
enumeration, the right lung lobes were collected in PBS, mechanically disrupted, and 
serial dilutions plated.  Histologic examination was performed on hematoxylin and eosin 
(H&E) stained sections of the left lung.  Pathology was scored as follows: 0-no 
involvement; 1-localized infiltrates of neutrophils in alveoli, no bacteria; 2-dense 
infiltrates of neutrophils in airways with involvement of adjacent alveoli, no bacteria; 3-
consolidation of neutrophil inflammation in bronchioles and alveoli, lobar pneumonia, 
with intact visible bacteria; 4, overwhelming infection with bacteria greater than 
inflammatory cells in alveoli or bronchioles. 
 
Flow cytometry.  Single cell suspensions were prepared by incubating minced tissue (left 
lung) with collagenaseIV (Worthington Biochemicals) and DNaseI (Sigma-Aldrich) for 1 
hour at 37°C. The digest was disrupted by passing through a cell-strainer (BD 
Bioscience).  Red blood cells were lysed and cells were washed in DMEM/FBS (Life 
Technologies).  Cells were counted after trypan blue staining using an automated counter 
(Life Technologies). Cells were stained with CD11b-PerCP, Gr-1/Ly6G-PE, Ly6C-APC-
Cy7, Siglec F-BV421, MHCII-AF700, CD11c-PE-Cy7, CD45-650NC (BD Biosciences), 
Annexin V-APC and Zombie Yellow Fixable Viability Dye (BioLegend) according to the 
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manufacturers’ protocol.  Samples were fixed prior to analysis.  Data was acquired using 
the LSR II flow cytometer (BD Biosciences), and analyzed using FlowJo (Tree Star). 
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Results 
 
MIF is detrimental for survival and lung injury in pneumococcal 
pneumonia. 
In our serotype 3 pneumonia model, mice developed severe illness that resulted in death 
beginning at 2 days post-infection, with 90% of the WT animals succumbing by 7 days 
(Figure 1A).  As is the case in human pneumococcal disease, bacteremia was noted in a 
majority (60%) of ill-appearing mice.  They also had significant pulmonary pathology, 
with alveolar and bronchial inflammation (overall pathology scored as 3, Figure 1B).   
 
Mif-/- animals had improved survival during pneumococcal pneumonia, with 46% 
mortality and no bacteremia (Figure 1A).  Overall, the Mif-/- animals demonstrated fewer 
clinical signs of illness and lost less weight than their WT counterparts.  The lungs of the 
Mif-/- mice had reduced parenchymal infiltration and their airways remained free of 
inflammatory cells (overall pathology scored as 1, Figure 1B). 
 
MIF-related pathology is associated with greater pulmonary bacterial load, 
inflammatory cell infiltrate, and cytokine/chemokine production. 
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There was 100-fold bacterial growth over 2 days in WT animals.  Mif-/- animals, in 
contrast, were better able to control bacterial proliferation, correlating with their 
increased survival and attenuated lung pathology (Figure 1B and D).  Since our 
observations seemed to indicate opposing roles for MIF in pneumonia vs. colonization, 
we repeated carriage experiments with the same serotype 3 isolate.  This strain colonized 
the murine nasopharynx effectively and did not produce symptomatic illness.  While the 
WT mice began clearing the bacteria after 7 days, Mif-/- mice showed no change in 
burden by 14 days (Figure 1C).   
 
In order to better understand the role of inflammation in pneumonia, we next 
characterized the pulmonary cellular infiltrate in WT and Mif-/- mice over the course of 
disease.  WT and Mif-/- animals demonstrated a progressive infiltration of neutrophils 
into the lung parenchyma, but Mif-/- mice had approximately 5-fold fewer neutrophils 
than WT at 2 days (Figure 1E).  Additionally, Mif-/- animals had approximately 1.5-fold 
fewer monocytes/macrophages in the lung than WT.  While total numbers of alveolar 
macrophages in BAL remained similar between groups (data not shown), we observed a 
significant increase in early apoptosis in these cells in Mif-/- mice, which correlated with 
a later increase in dead cells (Figure 1F).  These differences in apoptosis were not 
observed among neutrophils or monocytes/macrophages. 
 
Next, we compared the chemoattractant microenvironment of the lungs between WT and 
Mif-/- mice.  Similar to our observations in nasal colonization, local MIF production in 
lungs was induced early during pneumococcal infection and sustained over the course of 
the experiment (Figure 2A) (224).  Higher protein levels were present in the 
bronchoalveolar lavage (BAL) fluid obtained from the WT compared to the Mif-/- 
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animals, indicating higher levels of inflammation in the WT group.  Finally, levels of the 
specific chemoattractants of neutrophils and monocytes/macrophages, IL-1β and MCP-
1/CCL2 respectively, were significantly higher in BAL obtained from WT compared to 
Mif-/- mice. 
 
Modulation of MIF regulates outcome in pneumococcal pneumonia. 
In order to investigate whether the presence of MIF was both necessary and sufficient to 
induce detrimental inflammation in pneumococcal pneumonia, we delivered rMIF to the 
lungs of Mif-/- mice.  We found that local administration of rMIF decreased survival over 
the course of pneumonia and increased the pulmonary bacterial burden 48h after 
infection, compared to PBS administration (Figure 2B and C).  Next to assess the role of 
MIF inhibition in pneumococcal pneumonia along with its therapeutic potential, we 
treated WT mice with either the small molecule receptor antagonist for MIF, MIF098, or 
vehicle control, over the course of infection (320).  Survival in the WT vehicle treated 
animals mirrored that seen in the untreated mice (Figures 1A and 2B).  Treatment with 
MIF098 both delayed initiation of mortality and improved overall survival from 10% to 
>50%, identical to that observed in Mif-/- mice.  When we examined pulmonary bacterial 
loads 2 days after infection, we found a 100-fold reduction in burden in the MIF098 
treated animals compared to vehicle control (Figure 2C).  The bacterial burden in 
MIF098 treated mice was similar to Mif-/- animals treated with vehicle control.  Finally, 
we demonstrated a reduction in both the numbers of infiltrating neutrophils and 
inflammatory monocytes/macrophages with MIF098 treatment (Figure 2D&E). 
 
Discussion 
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We show herein that MIF is detrimental for survival in pneumococcal pneumonia.  Mice 
deficient in MIF have improved survival with reduced lung pathology, more effective 
bacterial control, and decreased infiltration of the lungs by innate immune cells 
compared to their WT counterparts, which may be mediated by enhanced apoptosis of 
alveolar macrophages in the absence of MIF.  These findings are in contrast to 
pneumococcal colonization of the nasopharynx where MIF is required for bacterial 
clearance.  Taken together, our experiments suggest that MIF-mediated inflammation 
plays a defining role in the outcome of the host-pneumococcal interaction in the upper 
vs. lower respiratory tract.  Additionally, we demonstrate that modulation of 
inflammation by a small molecule antagonist of MIF improves outcomes in 
pneumococcal pneumonia. 
 
There are parallels between the innate immune responses elicited by the presence of 
pneumococci in the nasopharynx and the lung.  While neutrophils are recruited early to 
both sites, their relative contribution to bacterial control has been shown to be limited 
(216, 222).  Mice lacking IL-1 receptor have decreased pulmonary neutrophilia and 
bacterial dissemination in pneumococcal disease (217).  Previous work in a model of 
Toxoplasma gondii infection confirms our observation of reduced IL-1β production in 
the setting of MIF-deficiency, but its mechanism remains to be determined (115).  
Additionally, neutrophil-mediated lung pathology is associated with failure of 
pneumococcal control; whether the predominance of neutrophils or enhanced 
inflammation in the WT animals may be a cause of the greater bacterial growth in these 
animals compared to Mif-/- remains to be investigated (339). 
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During colonization, MCP-1/CCL2 upregulation in WT mice correlates with the 
sustained presence of macrophages in the nasopharynx required for pneumococcal 
clearance, all of which are impaired in MIF-deficiency (87, 224).  In pneumonia, 
CCL2/MCP-1 levels are also higher in the BAL of WT mice compared to Mif-/- mice and 
are associated with the increased number of monocytes/macrophages in the tissue.  MIF 
may promote the migration and retention of circulating monocytes into tissues in a 
MCP-1/CCL2 dependent manner, setting up a positive-feedback loop as more cells are 
recruited (134).  Additionally, MIF is known to prolong the survival of inflammatory cells 
by inhibiting p53 dependent apoptosis (287); the enhanced apoptosis we observed in 
alveolar macrophages may underlie improved outcomes in Mif-/- mice by promoting the 
resolution of inflammation. 
 
Few host factors have been examined systematically in both pneumococcal colonization 
and disease.  But studies examining the response to the pneumococcal cytolysin, 
pneumolysin, in host-bacterial interaction provide another example of differing roles of 
inflammation in the nasopharynx vs. the lung.  Pneumolysin-deficient pneumococci are 
better able to persist in models of carriage because of an attenuated inflammatory 
response but are less virulent in pneumonia where they induce decreased recruitment of 
innate immune cells (224, 339). 
 
Our observations on the detrimental role of MIF implicate it as a target for 
immunomodulation in pneumococcal pneumonia.  While therapeutic potential of MIF 
inhibition has been evaluated for regulating inflammatory pathology in rheumatologic 
disease, this is the first examination of the use of a small molecule inhibitor of the 
cytokine in response to bacterial infection (52). Future work is needed to determine the 
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timing and duration of MIF inhibition necessary for an optimal impact on the excess 
morbidity and mortality caused by inflammation in pneumococcal pneumonia. 
 
Figure Legends 
 
Figure 1.  Macrophage migration inhibitory factor (MIF) is detrimental to 
survival and lung pathology in a murine model of pneumococcal 
pneumonia.  
(A) Pneumonia was induced in WT (closed squares) and Mif-/- (open squares) mice by 
intranasally inoculating anesthetized mice with 1x104 CFU of Type 3 pneumococci in 
80μl of PBS.  WT mice demonstrated reduced survival than their Mif-/- counterparts.  (B) 
When lungs from the mice were examined by H&E staining at 48 hours post infection, 
WT animals demonstrated greater lung pathology (cellular infiltrates of the parenchyma 
and airways) compared to Mif-/-.  While Mif -/- mice have impaired ability to clear Type 3 
pneumococcal colonization from the nasopharynx (modeled by inoculating awake mice 
with 1x107 CFU pneumococci in 10μl of PBS, C), they have reduced lung bacterial 
burdens during pneumococcal pneumonia (D).  (E) WT mice demonstrate increased 
numbers of pulmonary neutrophils as well as monocytes compared to their Mif -/- 
counterparts during pneumonia (48h).  Cellular composition assessed by flow cytometry, 
where Ly6C+Ly6G+ are designated as neutrophils and Ly6C+Ly6G- cells as monocytes, 
per 10^5 CD45+ live cells counted.  (F) Mif-/- mice have increased ratio of alveolar 
macrophages undergoing early apoptosis at 12h, which correlates with increased 
numbers of dead alveolar macrophages at 48h.  Cellular composition of BAL assessed by 
flow cytometry, where Siglec F+CD11c+ cells are designated as alveolar macrophages, 
with Annexin V and Zombie yellow viability dye used to determine early apoptosis and 
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cell death.  N≥10 mice per group in survival experiments, and ≥4 mice per group in all 
others.  *P<0.05, **P < 0.01, ***P<0.001, log-rank test for survival curves, Mann-
Whitney U test for CFU and cell number comparisons.  
 
Figure 2.  Modulation of MIF regulates inflammation, influencing both 
bacterial load and survival in pneumococcal pneumonia.   
(A) MIF was produced locally in the lung during the course of pneumococcal pneumonia.  
Increased MIF was associated with greater general inflammation in the lungs assessed 
by total BAL protein in the WT vs. Mif-/- animals.  Specific cytokine attractants of both 
monocytes and neutrophils (MCP-1 and IL-1β, respectively) were greater in the WT mice 
compared to their Mif-/- counterparts.  MIF, MCP-1, and IL-1 β were assessed by specific 
ELISAs and total protein determined by BCA assay. (B) Mif-/- mice receiving local MIF 
supplementation (by delivery of 100ng rMIF in 80μL of PBS to the airways beginning 
from the day prior to infection, and continuing daily thereafter) had decreased survival 
compared to their counterparts receiving PBS alone.  (C) Additionally, they had higher 
bacterial burdens than their PBS-receiving Mif-/- counterparts.  Conversely, when MIF 
was inhibited in the WT mice using a small molecule inhibitor (MIF-098, dosed at 
40mg/kg i.p., twice daily, beginning on the day of infection), the mice had greater 
survival compared to those receiving vehicle control (VC, B).  Additionally, greater 
survival in the MIF098 treated animals was associated with reduced pulmonary bacterial 
load compared to VC treated WT animals (C).  (D&E)  Pharmacologic MIF inhibition also 
reduced both neutrophil and monocyte infiltration compared to VC treatment. All 
experiments performed at 48h, unless otherwise stated.  N≥10 mice per group in survival 
experiments, and ≥4 mice per group in all others.  *P<0.05, **P < 0.01, ***P<0.001, log-
124 
 
rank test for survival curves, Mann-Whitney U test for cytokine, CFU, and cell number 
comparisons.  
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Abstract 
 
Homeostatic regulation of myeloid cell abundance and function rely upon continuous 
turnover of circulating phagocytes from the bloodstream. While growing evidence 
suggests that these cells possess intrinsic mechanisms driving spontaneous senescence 
and apoptotic cell death, it remains largely unknown whether environmental signals 
influence myeloid cell turnover in vivo.  Here, we show that the gut microbiota regulates 
the steady-state cellular lifespan of neutrophils and inflammatory monocytes, the two 
most abundant circulating myeloid cells and key contributors to inflammatory 
responses. Treatment of mice with broad-spectrum antibiotics increases the expression 
of surface markers previously linked to phagocyte senescence, accelerates cellular 
turnover, and increases the rate of spontaneous apoptosis among myeloid cells while 
leaving lymphoid lifespan unperturbed. The gut-restricted aminoglycoside neomycin can 
fully recapitulate the impact of broad-spectrum antibiotic treatment on phagocyte 
viability, corresponding with reduced abundance of bacterial taxa that express the 
peptidoglycan dipeptide γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP). 
Administration of iE-DAP is sufficient and its intracellular receptor, Nod1, is necessary 
to mediate the influence of the gut flora on systemic myeloid cell lifespan. Systemic 
neutralization of interleukin 17A (IL-17A), a key regulator of myeloid cell longevity 
stimulated by Nod1 signaling, eliminates the stimulatory effects of the microbiota on 
myeloid cell persistence. Together, these results uncover a novel microbial influence on a 
central component of myeloid homeostasis and suggests perturbations of commensal 
communities can influence systemic, steady-state regulation of cell fate.  
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Introduction 
 
Each day, approximately 1011 mature neutrophils emerge from the bone marrow and 
enter systemic circulation, comprising the most abundant leukocyte subset in the human 
bloodstream (15). These terminally differentiated phagocytes migrate swiftly into 
inflamed tissues following infection or injury, where they eliminate invading pathogens, 
release an array of inflammatory mediators, and help orchestrate subsequent phases of 
immunity (10, 38, 214). To maintain tissue and immune homeostasis in the absence of 
inflammation, steady-state production of neutrophils must be counterpoised by 
continuous elimination in the bone marrow, spleen, and liver (206, 341). The uniquely 
brief lifespan of these cells, averaging less than 24 hours, is essential for replenishing the 
pool of circulating phagocytes and averting the vascular and tissue damage risked by 
their potent cytotoxic capacity (118, 229). Peripheral clearance also regulates neutrophil 
abundance indirectly by restraining systemic concentrations of IL-17A and IL-23, 
cytokines that drive development of neutrophils in the bone marrow (315). However, 
pathologically enhanced neutrophil turnover has been linked to congenital neutropenia 
and a wide range of immunodeficiency syndromes, illustrating the stringent regulation of 
cell survival required to maintain immunologic fitness (122, 179, 250). Despite the 
central role played by cell turnover in regulating phagocyte homeostasis, the factors that 
influence neutrophil lifespan during health remain incompletely understood. 
 
Steady-state turnover of neutrophils follows a program of spontaneous cell senescence 
(termed neutrophil “aging”), exit from circulation, and programmed cell death (289). 
Aged neutrophils that have resided longest in the bloodstream shed the surface selectin 
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CD62L and enhance display of the chemokine receptor CXCR4, changes which facilitate 
extravasion and homing to tissue-resident macrophages for uptake (62, 218).  
Simultaneously, accumulating oxidative damage and metabolic dysregulation cooperate 
to trigger spontaneous apoptosis upon the exit of neutrophils from the bloodstream (123, 
181, 182, 288). Tight coordination of these processes allow efficient and immunologically 
quiescent clearance of expiring phagocytes.  While the mechanisms of cell death in 
neutrophils have long been subject to intensive study, previous work has focused largely 
on the diverse cell-intrinsic pathways governing constitutive neutrophil apoptosis (123, 
308). Comparatively less attention has been paid to extrinsic factors influencing 
neutrophil viability in the steady state. 
 
Extension of neutrophil lifespan during inflammation highlights the ability of 
environmental signals to modulate phagocyte turnover kinetics. Numerous viral and 
bacterial pathogens prolong neutrophil survival to stabilize a replicative niche or to 
promote tissue damage that facilitates microbial growth (254, 291, 309). Moreover, 
enhanced viability can augment neutrophil responses to some bacterial infections, driven 
by pro-inflammatory cytokines like IL-1β, TNFα, and IL-17A (72, 77). Neutrophils 
obtained from patients with systemic inflammatory disease, including rheumatoid 
arthritis, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, gout, and 
cystic fibrosis, also exhibit delayed apoptosis, as do neutrophils exposed to hypoxic 
injury (229, 327). The stimulatory impact of microbial and cytokine signals are thought 
to expand the window in which recruited neutrophils can exert optimal inflammatory 
function, strengthening their contribution to host defense.  Whether similar signaling 
influences neutrophil lifespan in the absence of inflammation remains unclear. 
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A growing body of evidence suggests signals emanating from the gut microbiota prime 
systemic innate immunity in health and regulate phagocyte homeostasis (69). Germ-free 
mice show steady-state reductions in the abundance of both neutrophils and 
mononuclear phagocytes, changes ascribed previously to defects in hematopoietic 
development (23, 53, 173). However, mature phagocytes from animals raised germ-free 
or treated with antibiotics also exhibit a range of functional defects, including impaired 
trafficking to tissues, production of reactive oxygen species, and bactericidal capacity 
(70, 169, 255). Given that the commensal flora can influence phagocyte function in the 
periphery, we hypothesized that steady-state microbial signals may enhance the lifespan 
of circulating neutrophils and that this effect may extend to other short-lived, circulating 
phagocytes. 
 
Here, we use in vivo cell-tracking and ex vivo cell viability assays to demonstrate that a 
distinct, neomycin-sensitive cohort of intestinal microbiota continuously regulates the 
death and turnover rates of neutrophils and Ly6C+ inflammatory monocytes in healthy 
mice.  We show that signaling through nucleotide-binding oligomerization domain-
containing protein 1 (Nod1), a cytoplasmic peptidoglycan sensor which recognizes the 
dipeptide structure γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP), is necessary and 
sufficient to mediate the microbial influence on phagocyte longevity. Lastly, we find that 
the inflammatory cytokine IL-17A is required to transmit the Nod1-dependent microbial 
signal to neutrophils and inflammatory monocytes throughout the body, illuminating a 
signaling axis through which commensal microbes regulate systemic immune cell fate at 
homeostasis. 
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Methods 
 
Mice.  Six- to eight-week-old wild type C57BL/6 mice were obtained from Jackson 
Laboratories and maintained in strict accordance with a protocol approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee (IACUC). 
Congenic Nod1-/-,Tlr4-/-, and Nod2Tlr2-/- mice were described previously (70, 87). Germ-
free C57BL/6 mice were obtained from the University of Pennsylvania Gnotobiotic 
Mouse Facility and maintained in germ-free conditions until sacrifice. All mice were 
sacrificed by CO2 inhalation followed by cardiac puncture. 
 
Antibiotic treatment.  All antibiotics were administered in drinking water ad libitum.  
Mice received sterile-filtered tap water supplemented with either a broad-spectrum 
antibiotic cocktail (1 g/L each of neomycin (Fisher), vancomycin (Santa Cruz), 
metronidazole (Sigma), ampicillin (Corning), and gentamicin (Life Technologies)), 1 g/L 
of neomycin or metronidazole alone, or control tap water. Water was changed every 3-4 
days and the treatment regimen was maintained for 3-4 weeks. 
 
Tissue processing and cell isolation.  Bone marrow parenchyma was flushed from the 
femora and tibia of mice with RPMI 1640 (Corning) supplemented with 5% fetal bovine 
serum (FBS) (GIBCO). Murine blood was obtained from retro-orbital sinuses following 
induction of anesthesia by isoflurane (Santa Cruz) or by cardiac puncture for terminal 
bleeds. Blood samples were anticoagulated with 0.1 M EDTA (Invitrogen) and 
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erythrocytes were lysed with ACK lysis buffer (Life Technologies) for 5 minutes at room 
temperature before flow cytometric analyses. Splenocytes were isolated by 
homogenization over 40 µm nylon cell strainers (Falcon) into RPMI 1640 + 5% FBS.  
 
Flow cytometry.  After resuspension of cells in PBS with 1% BSA, FcR blocking was 
performed with 1:100 dilution of anti-CD16/32 (BD Biosciences, 2.4G2). Cellular 
viability/integrity was assessed by Fixable Viability Dye eFluor780 (eBioscience). Surface 
marker staining was performed for 30 minutes at 4° C, antibodies diluted 1:150, against: 
CD45 (eBioscience, 30-F11); CD11b (M1/70), CD11c (N418), Ly6G (1A8), Ly6C (AL-21), 
F4/80 (BM8), CXCR4 (L276F12), CD62L (MEL-14), CD4 (GK1.5), CD8 (53-6.7), and 
B220 (RA3-B26) (all from BioLegend). All cytometry was performed on a BD LSRII flow 
cytometer and analyzed using FlowJo software (Tree Star). 
 
Ex vivo apoptosis assays.  To measure the duration of cellular viability and kinetics of 
spontaneous apoptosis ex vivo, we applied freshly isolated splenic or bone marrow 
parenchyma to 96-well plates, with ~105 cells and 200 μL RPMI + 5% FBS per well. No 
antibiotics or cytokines were added to ex vivo culture media. Plates were incubated at 
37° C and removed at the indicated time points before examination by flow cytometry. 
Apoptosis among each cell population gated during analysis was measured by staining 
with Annexin V (1:20) in Annexin V Binding Buffer (BioLegend) for 15 minutes at room 
temperature. Viable cells were identified as Annexin V- Fixable Viability Stain-. 
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BrdU pulse-chase assays.  5-bromo-2-deoxyuridine (BrdU) incorporation was measured 
as described previously (364) with the following modifications: Mice were given 3 
intraperitoneal (i.p.) injections of 2 mg BrdU (Life Technologies), spaced 3 hours apart, 
in 100 μL PBS. After circulating leukocytes were obtained by retro-orbital bleeding 
(~100 µL), BrdU incorporation was measured by flow cytometry (BioLegend, Bu20a, 
1:20) at the indicated time points post-injection after fixation and permeabilization per 
manufacturer’s instructions. Decreases in the proportion of BrdU+ cells were fit to a one-
phase exponential decay equation, N(t)=N(0)e-γt, where N represents the BrdU+ fraction 
over time t and the rate constant γ is solved. 
 
16S rDNA collection, quantification, and sequencing.  Stool samples were collected from 
neomycin-treated and control mice on days 7, 14, and 21 after initiation of antibiotic 
treatment, with ileum contents also collected on day 21. Samples were flash-frozen at -
80° C and DNA was extracted using Zymo ZR Fecal Miniprep Kits. 16S rDNA copy 
number was quantified by qRT-PCR, relative to a standard curve constructed from a 
TOPO vector containing E. coli 16S rDNA. PCR reactions were performed in triplicate as 
previously described (147) using the following 16S rDNA-specific primers: Forward, 5’-
AGAGTTTGATCCTGGCTCAG-3’; Reverse, 5’-CTGCTGCCTYCCGTA-3’; Probe, 5'-FAM-
TAA+CA+CATG+CA+AGT+CGA/3BHQ1-3' (“+” precedes position of LNA base). 16S 
rDNA metagenomic sequencing was performed as described previously on the Illumina 
HiSeq platform, using bar-coded primers aligned to the V1V2 region (301). Data was 
analyzed and quality-controlled using the QIIME pipeline v.1.8 and phylogenetic trees 
were constructed using FastTree v.2.1.3 with default parameters (60, 268). 
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Ligand treatments and cytokine neutralization.  To stimulate Nod1 signaling in vivo, we 
injected mice i.p. with two doses of 100 µg C12-iE-DAP (InvivoGen), an acylated 
derivative of the minimal Nod1 dipeptide ligand iE-DAP. Injections were given 12 and 2 
hours before sacrifice for ex vivo apoptosis assays and at 48 and 72 hours after BrdU 
injections for in vivo myeloid cell turnover experiments. Neutralization of IL-17A was 
achieved through two i.p. injections of 100 µg anti-IL-17A monoclonal antibody 
(BioXCell, 17F3) or IgG1 isotype control antibody (MOPC-21), performed at 12 and 2 
hours before sacrifice for ex vivo apoptosis assays and at 48 and 72 hours after BrdU 
injections for in vivo myeloid cell turnover experiments. 
 
Statistics.  Data are displayed as mean ± SEM. Except where indicated otherwise, 
statistical significance was assessed by 2-tailed Student’s t test for pairwise comparisons 
and ANOVA with Newman-Keuls post-test for comparisons of >2 groups. For all 
analyses, p < 0.05 was considered statistically significant. 
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Results 
 
Antibiotic treatment accelerates turnover of circulating phagocytes from the 
bloodstream. 
Turnover of phagocytes from circulation begins with a coordinated program of cell 
senescence, defined recently in neutrophils to include shedding of CD62L and up-
regulated CXCR4 expression (62). To determine whether the microbiota influences the 
display of these aging markers, we collected blood from mice treated for 4 weeks with 
broad-spectrum antibiotics (ABX) and evaluated neutrophils (CD45+CD11b+Ly6C+Ly6G+ 
cells, see Figure S1) by flow cytometry compared to conventionally treated mice (CNV). 
To control for diurnal oscillations in receptor expression, we collected all blood for 
phagocyte aging analyses at zeitgeber time 5 (ZT5), 5 hours after initiation of ambient 
light (62). Neutrophils from antibiotic-treated mice showed significant elevation of 
CXCR4 expression and decreased CD62L levels, suggesting a signature of accelerated cell 
turnover in mice depleted of intestinal flora (Figure 1A). Neutrophils from mice treated 
only with neomycin (NEO) resembled those from mice treated with broad-spectrum 
antibiotics, indicating that a neomycin-sensitive cohort of intestinal microbes may 
accelerate the intravascular aging of bloodstream phagocytes. 
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We next performed BrdU pulse-chase assays to assess directly whether the observed 
changes in surface markers corresponded with accelerated turnover of phagocytes from 
circulation. After pulsing mice intraperitoneally (i.p.) with BrdU, we measured the 
fraction of BrdU+ neutrophils (PMNs) and inflammatory monocytes (IMs, 
CD45+CD11b+Ly6C+Ly6G-, Figure S1) in the bloodstream over time (Figure 1B). Previous 
studies have shown that BrdU is not mitogenic at these doses, is incorporated most 
readily into the numerous late precursors giving rise to mature phagocytes in the bone 
marrow, and that circulating phagocytes reach saturation with BrdU approximately 2 
days after its administration (73, 322, 364). Accordingly, we found that nearly 100% of 
bloodstream PMNs (Figure 1C) and IMs (Figure 1D) were BrdU+ at 2 days post-injection. 
This saturation occurred irrespective of antibiotic treatment. To assess whether the 
microbiota instead influences the circulating longevity of labeled phagocytes, we tracked 
the contraction of BrdU+ cells from the blood of antibiotic-treated and control mice over 
the next 3 days. In contrast to the equivalent frequencies of labeled cells at Day 2, 
treatment with broad-spectrum antibiotics significantly accelerated the elimination of 
BrdU+ PMNs and IMs from circulation (Figure 1C&D), portrayed quantitatively by 
enhanced decay kinetics when set to one-phase exponential decay equations (Figure 1E).   
Neomycin was again sufficient to reproduce the impact of the broad-spectrum antibiotic 
cocktail on phagocyte longevity. This corresponded with modest but significant 
decreases in the frequencies of total PMNs and IMs in the bone marrow (Figure 1F) and 
spleen (Figure 1G) of mice treated with neomycin alone, comparable to differences 
observed previously with broad-spectrum antibiotics and germ-free mice (91, 173). 
Taken together, these data provide evidence that the neomycin-sensitive gut microbiota 
augments the circulating lifespan of bloodstream phagocytes in vivo. 
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Antibiotic treatment corresponds with impaired phagocyte survival ex vivo. 
Following exit from the bloodstream, senescent phagocytes undergo spontaneous 
apoptosis before clearance by tissue-resident macrophages (4, 206). We asked whether 
the microbiota influences the duration of phagocyte viability and resistance to 
spontaneous cell death. Since apoptotic cells are cleared immediately in vivo and do not 
accumulate at steady state (266), we determined the lifespan of neutrophils and 
inflammatory monocytes ex vivo in cultures lacking growth factors or cytokines. At 6 or 
24 hours after harvest of bone marrow or splenic parenchyma, we measured the 
proportion of phagocytes that remained viable and excluded Annexin V, a stain that 
detects early apoptosis by binding surface-exposed phosphatidylserine (Figure 2A, 
representative gating for neutrophils). In concordance with their accelerated turnover 
from the bloodstream, PMNs and IMs from mice treated with broad-spectrum 
antibiotics or neomycin entered apoptosis more rapidly than controls (Figure 2B). 
Accelerated cell death occurred in cells from both the bone marrow and spleen, was 
apparent at 6 hours, and expanded at 24 hours post-harvest. In contrast, neomycin 
treatment had no measurable impact on the apoptosis of splenic lymphocytes, 
fibroblasts, or endothelial cells (Figure S2A). Splenic macrophages exhibited apoptosis 
kinetics similar to that of IMs, likely reflecting the monocytic origin of some of these cells 
(Figure S2B) (1). 
 
To verify that the depletion of microbes was responsible for accelerated phagocyte 
apoptosis rather than a direct effect of antibiotics, we repeated the ex vivo apoptosis 
assays using germ-free mice. Similar to the effects observed upon treatment with 
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antibiotics, germ-free mice trended toward lower frequencies of PMNs and IMs in the 
bone marrow (Figure 2C) and spleen (Figure 2D) and exhibited accelerated apoptosis 
when incubated ex vivo (Figure 2E&F). In contrast, treating mice solely with 
metronidazole, which preferentially targets anaerobes had no impact on phagocyte 
viability (data not shown) (203). Thus, a distinct, neomycin-sensitive cohort of microbes 
regulates the cellular lifespan of mature phagocytes in addition to their turnover from 
the bloodstream. 
 
Treatment with neomycin stably alters the community structure of the gut 
microbiota. 
Since neomycin was sufficient to recapitulate the impact of broad-spectrum antibiotics 
on phagocyte turnover, we sought next to characterize the impact of this gut-restricted 
aminoglycoside on the murine intestinal microbiota (13, 192). After collecting weekly 
fecal samples and harvesting ileal contents 21 days after initiation of treatment, we 
extracted genomic material and performed 16S rDNA qPCR to quantify changes in 
intestinal microbial abundance. In contrast to reductions described previously with 
broad-spectrum antibiotics (352), we observed no significant differences in fecal or ileal 
16S rDNA copy number between neomycin-treated and conventional mice (Figure 3A). 
However, metagenomic sequencing of intestinal contents revealed stable and 
reproducible shifts in microbial community architecture at both sample sites, beginning 
within 1 week after the onset of treatment (Figure 3B&C). Most notably, 
Lactobacillaceae-family bacteria dropped from approximately 25% of fecal microbes 
among conventional mice to less than 10% with neomycin, paired with a ~40% increase 
in anaerobic S24-7-family Bacteroidetes species (Figure 3B). This redistribution concurs 
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with previous reports showing sensitivity among lactobacilli and resistance among 
anaerobes to aminoglycosides in vitro (51, 78). Clostridiaceae and Turicibacter species, 
while comprising only ~4% and ~10% of microbes in control mice respectively, were 
effectively absent in neomycin-treated mouse feces.  
 
The ileal microbiota exhibited changes broadly similar to those observed in fecal samples 
(Figure 3C). However, given the previously described immunoregulatory role of 
segmented filamentous bacteria (SFB) residing within the small intestine (155), we 
queried directly whether neomycin induced changes in the abundance of SFB species 
(e.g. Candidatus Arthromitus). We detected no SFBs in control or treated mice, a finding 
consistent with previous analyses of mice acquired from Jackson Laboratories (156). 
While the effects of antibiotics on the intestinal microbial ecosystem are complex (242), 
these results suggest that the impact of neomycin on phagocyte lifespan corresponds 
with a discrete and stable signature of altered commensal flora. However, the nature of 
the microbial signal connecting gut commensals to phagocyte homeostasis remained 
unclear.  
 
Nod1 mediates the microbial influence on phagocyte lifespan at 
homeostasis. 
We previously described a role for the intracellular peptidoglycan sensor Nod1 in driving 
microbiota-mediated stimulation of neutrophil phagocytic capacity ex vivo (70).  As the 
peptidoglycan of members of the Lactobacillaceae family depleted by neomycin 
treatment bear iE-DAP and stimulate Nod1 in vitro (21, 31), we hypothesized that the 
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microbiota stimulates this cytoplasmic sensor to regulate phagocyte homeostasis in the 
absence of infection. To determine whether Nod1 signaling stimulates the viability of 
neutrophils and inflammatory monocytes, we repeated ex vivo phagocyte apoptosis 
assays using Nod1-/- mice. PMNs and IMs from both the bone marrow (Figure 4A) and 
spleen (Figure 4B) of Nod1-/- mice entered apoptosis significantly more rapidly than 
those of wild type controls, instead resembling phagocytes from neomycin-treated mice. 
Treating Nod1-/- mice with neomycin produced no additional increase in the kinetics of 
phagocyte apoptosis, reinforcing that Nod1 is responsible for relaying the stimulatory 
signal from the flora into changes in cellular viability. In contrast, the lifespan of 
phagocytes from Nod2Tlr2-/- and Tlr4-/- mice resembled those of wild type controls 
despite well-described roles for these sensors in regulating granulopoiesis and phagocyte 
activation (53, 163, 191). To assess whether signaling through Nod1 was sufficient to 
recapitulate the impact of the microbiota on cellular lifespan, we repeated the apoptosis 
assays after injecting mice i.p. with the acylated Nod1 ligand C12-iE-DAP (332). Ligand 
treatment rescued the viability of phagocytes from neomycin-treated mice such that their 
lifespan was indistinguishable from conventional mice while conferring only a modest 
survival benefit to the conventional cells.  
 
To ascertain whether Nod1 signaling plays a similarly central role in regulating 
phagocyte turnover in vivo, we subjected Nod1-/- mice to BrdU pulse-chase assays 
(Figure 4C). Congruent with their impaired survival ex vivo, PMNs and IMs disappeared 
from circulation more quickly in knockout mice than in controls and knockout phagocyte 
turnover kinetics were indistinguishable from that of neomycin-treated animals (Figure 
4D). Further, administration of C12-iE-DAP markedly delayed turnover of both PMNs 
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and IMs from the blood and equalized the longevity of phagocytes from conventional and 
neomycin-treated mice (Figure 4C&D). Together, these data reveal that recognition of 
iE-DAP by Nod1 is both necessary and sufficient to mediate the stimulatory impact of the 
flora on phagocyte lifespan. 
 
Neutralization of IL-17A abrogates the role of the microbiota and Nod1 on 
phagocyte lifespan. 
While Nod1-mediated sensing of peptidoglycan from the microbiota is essential for the 
maintenance of gut mucosal immunity (41), how these signals are transmitted to instruct 
systemic immune homeostasis remains poorly understood. Nod1 signaling drives 
systemic responses to infection primarily through the liberation of cytokines that recruit 
and activate phagocytes (219). We predicted that similar signaling regulate phagocyte 
lifespan in the steady state. We focused our studies on IL-17A, a key cytokine 
orchestrating myeloid cell development, function, and survival (91, 199, 235), because its 
production has been shown to be stimulated by both the gut microbiota and Nod1 
signaling (14, 119, 156). Neutralization of IL-17A markedly impaired the survival ex vivo 
of PMNs and IMs from the bone marrow (Figure 5A) and spleens (Figure 5B) of 
conventionally treated mice. However, the blockade had limited impact on cells from 
neomycin-treated or Nod1-/- animals, resulting in equal cellular viability across all groups 
in the absence of IL-17A signaling. BrdU pulse-chase assays revealed similar results in 
vivo, with neutralization of IL-17A phenocopying neomycin treatment or lack of Nod1 in 
accelerating the turnover of PMNs and IMs from the bloodstream (Figure 5C&D). 
Collectively, these results demonstrate that neomycin-sensitive microbes, Nod1, and IL-
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17A comprise requisite components of a common signaling axis that governs systemic 
phagocyte lifespan at homeostasis. 
 
Discussion 
 
Cell turnover is a key component of immune homeostasis, and accumulating evidence 
suggests that failure to properly regulate the lifespan of circulating phagocytes can 
impair host defense. Here, we showed that the gut microbiota governs the viability and 
circulating lifespan of neutrophils and inflammatory monocytes at steady state. Our 
observations highlight how broad-spectrum antibiotic therapy may negatively impact the 
availability of circulating myeloid cell populations. As disruptions of commensal 
microbial communities are associated with a growing set of inflammatory, infectious, 
and neoplastic diseases, mechanistic understanding of the microbial influence on innate 
immunity during health may reveal actionable therapeutic targets when this relationship 
is disturbed (281).  
 
We found that treating mice with broad-spectrum antibiotics accelerated each of the 
fundamental steps in neutrophil turnover: senescence, extravasion, and apoptotic cell 
death. Driven by our previous findings linking the microbiota to stimulation of 
neutrophil bactericidal capacity ex vivo (70), we hypothesized that microbial signals may 
regulate a broader set of fundamental properties among mature neutrophils at 
homeostasis. We focused on cell turnover because, in addition to regulating cell 
abundance directly, mounting evidence suggests neutrophil elimination drives 
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regulatory circuits that feed back on other components of myeloid homeostasis in vivo, 
including neutrophil development in the bone marrow. Phagocytosis of apoptotic 
neutrophils by macrophages has been shown to suppress IL-23 production in these cells, 
thereby inhibiting IL-17A liberation by tissue-resident lymphocytes and suppressing 
granulopoiesis and neutrophilia (315). More recently, Casanova-Acebes et al. have shown 
that rhythmic migrations of senescent neutrophils to the bone marrow modulate the 
hematopoietic niche to more broadly disfavor progenitor cell retention and maturation 
(62). Therefore, while alterations of the microbiota have been linked to defects in 
myeloid cell development previously (23, 173), whether this is a primary phenomenon or 
secondary to enhanced turnover remains an area of active investigation.  
 
In addition to neutrophils, the stimulatory effect of the flora on cell longevity extended to 
Ly6C+ inflammatory monocytes, the second-most abundant and short-lived circulating 
phagocyte (364). The potential fates of inflammatory monocytes are more diverse than 
that of neutrophils and considerably less is known about the mechanisms guiding their 
turnover. Ly6C+ inflammatory monocytes have been shown to differentiate into long-
lived Ly6C-CX3CR1+ monocytes that patrol vascular endothelia and resident macrophages 
and dendritic cells populating some tissues (22, 125, 162, 364). However, recent evidence 
suggests that, in addition to inhabiting the first stage of a developmental sequence of 
mononuclear phagocytes, inflammatory monocytes emerge from the bone marrow and 
turn over in tissues at homeostasis while maintaining Ly6C+ monocyte identity (158). In 
contrast, tissue-resident macrophages and dendritic cells arise from a number of cellular 
origins, including non-hematopoietic cells seeded during embryonic development (364).  
We focused our investigations on circulating neutrophils and inflammatory monocytes 
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because their short lifespans contrast with the more persistent nature of tissue-resident 
phagocytes and were therefore more likely to be regulated dynamically by tonic 
microbial signals. 
 
Our finding that neomycin recapitulates the impact of broad-spectrum antibiotics on 
phagocyte lifespan has precedence in other investigations on the immunomodulatory 
effects of the microbiota, namely in regulating antiviral responses to influenza infection 
in the lungs (152). Despite its ongoing clinical utility (44, 117), the precise nature and 
kinetics of neomycin-induced shifts in commensal community structure have not been 
explored previously.  We found that neomycin treatment suppressed the abundance of 
lactobacilli in the murine intestine, a family of microbes previously shown to express 
Nod1 ligands and activate Nod1 in vitro (21, 31). This decrement was matched with a 
compensatory increase in the abundance of Bacteroidetes species, many of which also 
express Nod1 ligands.  However, detailed analyses of the radial distribution of microbes 
in the gut suggest that obligate anaerobic bacteria, including Bacteroidetes species, 
reside predominantly in the luminal center of the intestinal tract (5). In contrast, 
lactobacilli and other oxygen-tolerant bacteria often reside in closer contact with the 
mucosal surfaces, where oxygen tension is greater and microbial products are sensed 
more readily by the epithelium (251, 344). This redistribution may explain the decrease 
in Nod1 signaling observed upon neomycin treatment. 
 
Our results also indicate that the pro-inflammatory cytokine IL-17A connects microbial 
detection by Nod1 to systemic changes in phagocyte lifespan. IL-17A has been shown to 
delay the apoptosis of neutrophils and mononuclear phagocytes largely through 
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stimulation of downstream cytokines, including G-CSF and GM-CSF (43, 235). Since the 
signaling pathways downstream of IL-17A diverge by target cell type and may have 
overlapping or redundant functions, we chose to focus on IL-17A as the most proximal 
cytokine driving phagocyte survival and therefore the most likely to be amenable to 
therapeutic intervention. The division of function for downstream cytokines to survival 
of neutrophils and inflammatory monocytes remain an area of ongoing investigation. 
 
As disruptions of the intestinal microbiota are associated with a broad range of 
inflammatory and infectious disease, efforts to manipulate the flora directly and attain a 
healthful commensal community have developed rapidly over the past decade. These 
include transplantation of exogenous microbial communities into the gut environment, 
which has been shown to improve disease outcomes in some severe intestinal infections 
(197). Our findings imply these interventions may improve the persistence and function 
of phagocytes that monitor for foreign threats throughout the body, providing systemic 
benefits from local manipulations of microbial communities. Furthermore, growing 
understanding of the central importance of apoptosis and cell turnover to immune 
homeostasis has spurred an increase in the development of therapeutics designed to 
target this component of phagocyte physiology directly. For example, inhibitors of cyclin-
dependent kinases have been shown to improve resolution of pathogenic pulmonary 
inflammation by hastening the apoptosis of infiltrating neutrophils (280). Our results 
suggest that the makeup of intestinal commensal communities may modulate the 
efficacy of this therapy and others like it, potentially providing an opportunity for 
adjuvantive therapies targeting the gut microbiota directly to improve the outcome of 
patients with diverse inflammatory diseases. 
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Figure Legends 
 
Figure 1.  Antibiotic treatment accelerates turnover of circulating 
phagocytes from the bloodstream. 
(A) Quantification of mean fluorescence intensity (MFI) for CD62L and CXCR4 on 
neutrophils from the blood of mice treated with tap water (CNV, black), broad-spectrum 
antibiotics (ABX, open), or neomycin (NEO, grey). (B) Representative flow cytometry 
plots from BrdU pulse-chase assays. Events represent CD45+CD11b+Ly6C+ cells stained 
for intracellular BrdU content and Ly6G (neutrophils: Ly6G+; inflammatory monocytes: 
Ly6G-) on days 2 and 4 after BrdU injection, compared to no-BrdU controls. (C) 
Frequency of BrdU+ events among blood neutrophils (PMNs) and inflammatory 
monocytes (D, IMs) assessed on days 2-5 after BrdU administration. (E) Rate constants 
(k, day-1) for one-phase exponential decay quantified from BrdU+ frequencies depicted in 
(C) and (D).  (F) Steady-state cell frequencies (% of CD45+ events) of PMNs and IMs 
measured from the bone marrow and spleens (G) of CNV- and NEO-treated mice. All 
data presented as mean ± SEM with ≥ 5 mice per group. Statistical significance was 
assessed by Student’s t test for pairwise comparisons and one-way ANOVA with 
Newman-Keuls post-test for comparisons of >2 conditions. NS = not significant, * = p < 
0.05, ** = p < 0.01, *** = p < 0.001. 
 
Figure 2.  Antibiotic treatment corresponds with impaired phagocyte 
survival ex vivo.  
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(A) Representative flow cytometry plots of neutrophils (PMNs, gated on 
CD45+CD11b+Ly6C+) obtained from bone marrow (BM) and spleens and allowed to 
incubate ex vivo for 0, 6 or 24 hours before staining with Annexin V to detect apoptotic 
cells.  Non-apoptotic, viable cells were quantified by gating on Annexin V- events (SSC = 
side scatter). (B) Assessment of Annexin V- event frequency (% Viable) among PMNs and 
inflammatory monocytes (IMs) obtained from the BM and spleens of conventional 
(CNV), broad-spectrum antibiotic-treated (ABX, open), and neomycin-treated (NEO, 
grey) mice following 6 or 24 hours incubation ex vivo. (C) Steady-state cell frequencies 
(% of CD45+ events) of PMNs and IMs obtained from the bone marrow and spleens (D) 
of CNV (black circles) and germ-free mice (GF, open circles). (E) Survival ex vivo of 
neutrophils and inflammatory monocytes from the bone marrow (24 hours) and spleens 
(F, 6 hours) of CNV and GF mice. All data presented as mean ± SEM with ≥ 3-5 mice per 
group. Statistical significance was assessed by Student’s t test for pairwise comparisons 
and one-way ANOVA with Newman-Keuls post-test for comparisons of >2 conditions. 
NS = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
 
Figure 3.  Metagenomic analysis of the murine intestinal microbiota upon 
treatment with neomycin. 
(A) Quantitative real-time PCR analysis of 16S rDNA copy number from the intestinal 
contents of mice treated with conventional water (CNV, black) or neomycin (NEO, grey). 
Fecal samples were collected and analyzed on days 0, 7, 14, and 21 after initiation of 
neomycin treatment. Ileal contents were collected on day 21. (B) Family-level 
phylogenetic analyses of fecal bacterial sequences from conventional and neomycin-
treated mice. Frequencies of significantly altered bacterial taxa in feces were compared 
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individually at day 21. (C) Family-level phylogenetic analysis of ileal contents taken at 
day 21, with individual frequency comparisons of significantly altered taxa.  All data 
represent averages from 8 mice in each treatment condition, housed as pairs in 4 
separate cages.  Box-and-whisker plots depict medians ± inter-quartile range. Statistical 
significance for all comparisons was analyzed by Kruskal-Wallis tests with correction for 
false discovery rate (FDR).  * = p < 0.05, ** = p < 0.01. 
 
Figure 4.  The intracellular peptidoglycan sensor Nod1 is necessary and 
sufficient to mediate the microbial influence on phagocyte lifespan. 
(A) Quantification of cell survival ex vivo (Annexin V-, % Viable) among neutrophils 
(PMNs) and inflammatory monocytes (IMs) from the bone marrow (24 hours) and 
spleens (B, 6 hours) of conventional WT, Nod1-/-, neomycin (NEO)-treated Nod1-/-, 
Nod2Tlr2-/-, and Tlr4-/- mice. Cellular lifespan was measured similarly for phagocytes 
obtained from CNV and NEO-treated mice after intraperitoneal injection of the Nod1 
ligand C12-iE-DAP (Ligand), with 100 μg doses given 12 and 2 hours before sacrifice. (C) 
BrdU pulse-chase assays. BrdU+ frequency among PMNs and IMs from the bloodstream 
of CNV (black), NEO (grey), and Nod1-/- mice (open), measured on days 2-5 after 
systemic BrdU administration. Mice received injections of vehicle (1% DMSO in PBS, 
solid curves) or 100 μg C12-iE-DAP (Ligand, hashed curves) on days 2 and 3 after 
injection of BrdU. (D) Rate constants (k, day-1) for one-phase exponential decay 
quantified from BrdU+ frequencies depicted in (C). All data presented as mean ± SEM 
with ≥ 5 mice per group. Statistical significance was assessed by Student’s t test for 
pairwise comparisons and one-way ANOVA with Newman-Keuls post-test for 
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comparisons of >2 conditions. NS = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 
0.001. 
 
Figure 5.  Neutralization of IL-17A abrogates the impact of the microbiota 
and Nod1 on phagocyte lifespan. 
(A) Assessment of cellular lifespan ex vivo (Annexin V-, % Viable) among neutrophils 
(PMNs) and inflammatory monocytes (IMs). Survival of cells from the bone marrow (24 
hours) and spleens (B, 6 hours) was quantified for WT, neomycin-treated WT, and Nod1-
/- mice after 100 µg injections of IgG1 isotype control (Isotype) or neutralizing anti-IL-
17A antibody (α-IL-17A), given 12 and 2 hours before sacrifice. (C) BrdU pulse-chase 
assays. Quantification of BrdU+ frequency among PMNs and IMs from the bloodstream 
of CNV (black), NEO (grey), and Nod1-/- mice (open). Mice received injections of 100 μg 
of IgG1 isotype control (solid curves) or IL-17A-neutralizing antibody (hashed curves) on 
days 2 and 3 after administration of BrdU. BrdU+ frequency was assessed on days 2, 4, 
and 5 after BrdU injection. (D) Rate constants (k, day-1) for one-phase exponential decay 
quantified from BrdU+ frequencies depicted in (C). All data presented as mean ± SEM 
with ≥ 4 mice per group. Statistical significance was assessed by Student’s t test for 
pairwise comparisons and one-way ANOVA with Newman-Keuls post-test for 
comparisons of >2 conditions. NS = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 
0.001. 
 
Figure S1. Gating strategies for circulating neutrophils and inflammatory 
monocytes. 
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Neutrophils (PMNs) and inflammatory monocytes (IMs) were gated by the following 
heuristic: (I) Leukocytes gated from erythrocytes by forward- and side-scatter; (II) 
CD45+CD11b+ to gate mature myeloid cells; (III) PMNs gated by Ly6C+Ly6G+ and IMs 
gated by Ly6C+Ly6G-.  
 
Figure S2.  Effects of neomycin treatment on apoptosis among splenic 
lymphocytes, endothelial cells, fibroblasts, and macrophages.  
Assessment of Annexin V- event frequency (% viable) among: (A) Lymphocytes (CD45+ 
events that are CD4+, CD8+, or B220+), endothelial cells (CD45-CD90.2+), fibroblasts 
(CD45-CD31+); or (B) macrophages (CD45+F4/80hi) from the splenic parenchyma of 
conventional (black) or neomycin-treated mice (grey) after 6 hours’ incubation ex vivo.  
All data presented as mean ± SEM with 4 mice per group. Statistical significance was 
assessed by Student’s t test. NS = not significant, * = p < 0.05. 
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Figure 3, continued. 
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Bacterial Exploitation of Phosphorylcholine Mimicry Suppresses 
Inflammation to Promote Airway Infection. 
While prolonged pneumococcal infection of the upper airway was known to require 
efficient evasion of acute, neutrophil-mediated phagocytosis, the mechanism underlying 
this phenomenon remained unknown. We found that the pneumococcus disarms the 
functional capacity of responding neutrophils through hydrolysis of platelet-activating 
factor (PAF), a secreted inflammatory phospholipid essential for neutrophil activation, 
viability, and phagocytic capability in the airway. PAF hydrolysis relies upon molecular 
mimicry between phosphorylcholine (ChoP) residues present on the pneumococcal 
surface and within PAF, allowing the microbe to leverage a surface ChoP hydrolase, Pce, 
to remove PAF from the airway. 
 
We found that pneumococci deficient in Pce were cleared rapidly from the upper airway 
over the first week of infection, corresponding with the period of maximal neutrophil 
influx into the airway (366). This survival defect was in agreement with previous findings 
in infant rats over the first two days of infection, though no mechanistic explanation was 
explored in that study (129). Further evidence linking Pce to neutrophil evasion was 
provided by a previously completed in vitro genomic screen for anti-phagocytic factors 
in which the gene encoding Pce was detected (81). Purified Pce enzyme had also been 
shown to mediate ChoP hydrolysis from artificial substrates in vitro, suggesting this 
catalytic activity was likely responsible for its immune evasion properties (340). Whether 
ChoP hydrolysis from the cell wall or another substrate remained less clear.  
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Using bacterial flow cytometry, we assessed whether ChoP abundance on the exterior of 
the pneumococcus was modified in the presence or absence of Pce and found no 
difference.  Furthermore, we noted that the neutrophils recruited to pneumococci 
lacking Pce were both more abundant and more activated despite the mutant’s enhanced 
clearance from the airway, suggesting that Pce may modulate the physiology of 
responding neutrophils directly. Given previous in vitro evidence that Pce is capable of 
hydrolyzing ChoP from PAF, along with the well-known stimulatory activity of PAF on 
neutrophils, we hypothesized that this exploitation of phosphorylcholine mimicry 
governed pneumococcal neutrophil evasion in the upper airway (144, 178).  
 
Systemic neutrophil depletion with monoclonal antibodies demonstrated that 
neutrophils were responsible the survival defect observed among Pce-deficient 
pneumococci. Pce was also rendered unnecessary for pneumococcal survival in mice 
lacking PAFR or treated with PAFR inhibitors, suggesting that the enzyme targets PAF 
signaling to disable responding neutrophils in the upper airway. These findings stand in 
contrast to previous investigations of PAFR in pneumococcal infections, carried out 
primarily in pneumonia, sepsis, and meningitis models. Previous conceptions of PAFR-
pneumococcus interactions focused on the receptor’s role as a bacterial adhesin, binding 
cell wall ChoP to enhance bacterial persistence at the mucosa and invasion across 
mucosal barriers (76). Accordingly, PAFR-deficient mice showed impaired 
pneumococcal dissemination in these models, though PAFR exerted little effect on 
intravascular bacterial survival (47, 48). In contrast, we found that PAFR exerts no role 
in governing wild type pneumococcal persistence in the upper airway and exerts a 
protective effect against Pce-deficient pneumococci.  Furthermore, we determined that 
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Pce inhibits bacterial invasion into the blood from the upper airway, suggesting that 
enhanced PAF signaling protects the host from systemic pneumococcal dissemination.  
These results indicate that the primary function for PAFR in the upper airway is 
responding to cognate ligand binding and stimulating neutrophil-mediated clearance, 
rather than serving as a receptor for direct binding by microbial ChoP.  Given that nearly 
all invasive pneumococci arise from localized infections of the upper airway, we propose 
that the cognate ligand “signaling” paradigm reflects a more physiologically relevant 
function of PAFR than the microbial “binding” paradigm in the natural course of 
infection (154). 
 
The wide range of extracellular bacteria that display surface ChoP, including H. 
influenzae and N. meningitidis, led us to hypothesize that similar PAF mimicry may be 
utilized by other microbes (350). Despite the lack of a direct homolog for Pce, we 
uncovered a functional analog on the surface of H. influenzae named GlpQ.  Like Pce, 
GlpQ hydrolyzes phosphorylcholine from conjugated substrates and inhibits acute, 
neutrophil-mediated clearance of the microbe during upper airway infection. Future 
work will focus on expanding the repertoire of undiscovered PAF-cleaving enzymes 
expressed on the exterior of ChoP-expressing microbes. This can proceed without need 
for genetic similarity to Pce and in a high-throughput manner, as our in vitro 
chromogenic assay for ChoP hydrolysis provides a functional, quantifiable readout for 
this catalytic activity. Transposon libraries can be generated in suspected microbes, 
similar to that performed previously for the pneumococcus in anti-phagocytosis screens 
(81).  Insertion mutants showing diminished ChoP hydrolysis activity can be explored 
mechanistically and in mouse infection models. A potential complication of this method 
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is that other microbes may possess multiple enzymes functioning in parallel to hydrolyze 
ChoP efficiently. Indeed, while no residual activity remained in the pneumococcus after 
deletion of Pce, ~20% of ChoP hydrolysis remained for H. influenzae after deletion of 
GlpQ.  Thus, muti-gene deletions or bioinformatics queries for the active site structure in 
question may be required to elucidate the full complement of unknown PAF-hydrolyzing 
enzymes in other bacterial species. 
 
The main clinical relevance of this work arises from the finding that a critical threshold 
of PAF concentration exists for clearance of both S. pneumoniae and H. influenzae, 
above which neither pathogen can evade acute neutrophil responses. This may 
illuminate a potentially actionable target for intervening in upper airway infection before 
the onset of invasive disease, especially among individuals at elevated risk of 
dissemination (e.g. children, the elderly, the immunocompromised). If PAF levels can be 
safely elevated in the upper airway, clearance of a wide spectrum respiratory pathogens 
may accelerate. One potentially promising avenue for elevating PAF levels is the 
inhibition of a host enzyme, called PAF acetylhydrolase, charged with hydrolyzing PAF 
as a negative feedback mechanism to promote resolution of inflammation. PAF 
acetylhydrolase is secreted into the airway lumen during infection and inhibits 
respiratory tract neutrophil responses (188, 331). Preliminary experiments suggest mice 
lacking PAF acetylhydrolase clear colonizing pneumococci entirely within a few days, 
accompanied by an abundant influx of activated neutrophils (data not shown). 
Importantly, the safety of a PAF acetylhydrolase inhibitor (named darapladib) has 
already been demonstrated in human clinical trials and no systemic inflammatory 
symptoms were observed (153). If proven to be efficacious in inhibiting airway bacterial 
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infection, darapladib could represent a broadly-acting, host-directed antibacterial 
therapeutic less susceptible to bacterial escape than drugs targeting microbial structures. 
 
Macrophage Migration Inhibitory Factor Promotes Clearance of 
Pneumococcal Colonization 
A sustained influx of macrophages is required for definitive elimination of pneumococci 
from the upper airway (366). However, which factors mediate macrophage persistence in 
the respiratory tract and how such factors are elicited by the microbe have remained less 
clear. We demonstrated that macrophage persistence in the upper airway lumen requires 
the cytokine macrophage migration inhibitory factor (MIF). Colonizing pneumococci 
stimulate MIF secretion through the action of its pore-forming toxin pneumolysin, which 
triggers pro-inflammatory p38-MAPK signaling in tissue-resident macrophages. MIF 
liberated into airway stimulates the durability and phagocytic capacity of recruited 
macrophages. MIF also facilitates secretion of CCL2, the key chemokine governing 
macrophage recruitment.  Collectively, these functions markedly accelerate 
pneumococcal clearance from the respiratory tract. 
 
Stable colonization of the upper respiratory tract is a prerequisite for the development of 
pneumococcal pneumonia and disseminated disease (348). We found that mice lacking 
MIF exhibit higher bacterial burdens in the upper airway and reduced abundance of 
airway luminal macrophages. These experiments are in agreement with population-
based studies showing decreased incidence of pneumococcal pneumonia among adults 
with activating polymorphisms in the gene encoding MIF (362). Increasingly, genetic 
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screens for genetic polymorphisms provide an empiric basis upon which to design 
mechanistic investigations.  Traditionally restricted to monogenic disorders with readily 
apparent clinical phenotypes, modern sequencing technologies have allowed detailed 
analysis of patient genotype information as individuals are monitored for susceptibility 
to infectious disease. In the past 15 years, functional polymorphisms have been 
discovered within a range of factors governing microbial detection and response, 
including TLR2, TLR4, NOD1, TNFα, and IL-1β (174, 290, 335).  In addition to providing 
a platform for scientific study, these genetic variants may delineate patients that are 
particularly susceptible to infectious diseases and may therefore require more careful 
clinical monitoring and/or prophylaxis.  
 
We found that MIF is released into the respiratory tract by pneumococci through the 
action of its pore-forming toxin, pneumolysin. Originally thought to function chiefly 
through lysis of host cells, this toxin is also capable of modulating intracellular signaling 
pathways, inhibiting bactericidal mechanisms, and impairing phagocyte trafficking to 
disable phagocytic responses (234). However, its role in pneumococcal colonization is 
less clear. As shown in Figure 4A, pneumolysin-deficient bacteria persist at higher loads 
than wild type bacteria at two weeks post-inoculation. Thus, pneumolysin seems to 
confer detrimental effects to the microbe in the upper airway, accompanied by the more 
robust macrophage response it initiates. Whether the poor survival of pneumolysin-
positive pneumococci belies some other evolutionary benefit remains unclear.  One 
possible interpretation is that pneumolysin functions primarily in the lower airway tract, 
where it is essential for maintaining bacterial persistence (33).  Expectoration of 
persistent organisms from the lung may continually re-seed the upper respiratory tract, 
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providing an ongoing platform from which the robust immunity of the lower airway can 
be evaded. Alternatively, pneumolysin may provide some yet-unknown advantage to 
pneumococci during transmission from host to host.  Disabling and destroying leukocyte 
aggregates by pneumolysin may free the pneumococcus to be shed in respiratory 
droplets and more readily acquired by a new host. Finally, recent evidence suggests the 
elicitation of inflammation can provide direct nutritional benefits to colonizing 
pneumococci, potentially yielding a smaller population of bacteria that exhibit enhanced 
fitness within the nutrient-limiting conditions inherent to respiratory droplet 
transmission (305).  
 
Our findings also illuminate a potentially cooperative relationship between luminal 
cytokines and systemic chemokines in generating enduring macrophage responses to 
pneumococcal colonization. Previous findings have demonstrated that detection of the 
pneumococcus in the upper airway by TLR2 and NOD2 stimulated release of CCL2, the 
key chemokine governing initial macrophage recruitment into the tissues (87).  The 
present study expands this paradigm by showing that MIF governs the sustained 
presence of these cells in the lumen of the airway, where they persist and clear bacteria 
more readily. Additionally, we found that MIF binding to resident macrophages 
stimulates additional secretion of CCL2 from the airway, generating a positive feedback 
loop of macrophage recruitment and retention. Accordingly, mice lacking either CCR2 
(the receptor for CCL2) or MIF exhibit macrophage responses with lower cell abundance 
and qualitative phagocytic defects. 
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Macrophage Migration Inhibitory Factor is Detrimental in Pneumococcal 
Pneumonia and a Target for Therapeutic Immunomodulation 
While MIF-stimulated macrophage persistence is essential for pneumococcal clearance 
from the upper airway, it remained unclear whether this host-protective effect also 
functioned during fulminant pneumonia. In contrast its impact in the upper airway, we 
found that MIF signaling precipitated more rapid host mortality, impaired bacterial 
clearance, and substantial pulmonary tissue damage during pneumococcal pneumonia. 
These findings corresponded with enhanced viability of resident alveolar macrophages 
and increased recruitment of neutrophils and inflammatory monocytes to the lungs of 
wild type mice when compared to MIF-deficient mice.  
 
We discovered that the detrimental consequences of MIF signaling in pneumococcal 
pneumonia were incongruent with the beneficial impact observed during upper 
respiratory tract clearance. However, our findings suggested that MIF stimulates similar 
functional changes in macrophages residing at both anatomic sites. In the upper 
respiratory tract, MIF augments bacterial clearance by enhancing the duration of 
macrophage responses in the airway lumen.  Similarly, alveolar macrophages from wild 
type mice exhibit significantly enhanced cellular viability during pneumococcal 
pneumonia compared to similarly infected MIF-deficient animals. These results are 
consistent with well-described mechanisms through which MIF signaling delays 
apoptotic cell death by suppressing nitric oxide production and p53 signaling (240). 
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In our study, MIF-driven delays in alveolar macrophage apoptosis were accompanied by 
substantially increased pulmonary recruitment of neutrophils and inflammatory 
monocytes, along with elevated pneumococcal burden and accelerated host mortality. 
Multiple previous studies have demonstrated a host-protective role for apoptotic cell 
death among alveolar macrophages during pneumococcal pneumonia (93, 94). Inversely, 
inhibition of alveolar macrophage apoptosis (e.g. in iNOS-deficient mice) corresponds 
with drastically enhanced pulmonary inflammation, bacteremia, and host demise. 
Activated neutrophils recruited to the lungs confer the bulk of tissue damage in these 
infection models, responsible for liberating a plethora of proteases, reactive oxygen 
species, and other cytotoxic mediators that spur further inflammation and disrupt 
vascular integrity (136).  
 
We also found that treating mice systemically with a small-molecule inhibitor of MIF 
called MIF098 reduced inflammatory leukocyte infiltration and augmented 
pneumococcal clearance from the lungs. Like the inhibitors of PAF acetylhydrolase, MIF 
antagonists present an opportunity for broadly efficacious, host-directed 
immunomodulatory therapy potentially more resistant to microbial evolutionary escape. 
While MIF-directed small molecules have shown some efficacy in combating animal 
models of inflammatory diseases, they remain largely undeveloped in the context of 
bacterial infections (198). Our results in pneumococcal pneumonia may be particularly 
promising because the drug is efficacious against fulminant, ongoing disease. This may 
help preclude the need for the difficult patient monitoring inherent in detecting nascent 
infections before they develop into readily detectable clinical entities. 
171 
 
Detection of peptidoglycan from the gut microbiota governs the lifespan of  
circulating phagocytes at homeostasis. 
It is now widely appreciated that the gut commensal flora regulates systemic innate 
immunity, yet the mechanisms driving many of these stimulatory influences remain 
poorly understood. We showed that the gut microbiota regulates the viability and 
circulating lifespan of neutrophils and inflammatory monocytes at homeostasis. 
Microbial effects were dependent upon a distinct community of neomycin-sensitive 
microbes in the intestine, required host signaling through the cytoplasmic peptidoglycan 
sensor Nod1, and necessitated IL-17A liberation to relay commensal signals to circulating 
phagocytes. 
 
Most investigations into the impact of the commensal flora on phagocytes have focused 
on the influence of these signals on their hematopoietic development or bactericidal 
capacity (91, 173).  However, the rate at which phagocytes turn over in the tissues 
continuously instruct these other parameters. Persistence in the vasculature and in the 
tissues dictates the window in which phagocytes can combat pathogenic threats (206). 
Phagocyte turnover also restrains the rate of new phagocyte development during 
homeostasis through suppression of IL-17A and IL-23 release (315). Tight regulation of 
phagocyte lifespan becomes particularly important in inflammatory environments, in 
which the cells must exert their functions efficiently but undergo apoptosis with 
sufficient rapidity to facilitate resolution (103). Dysregulated persistence of phagocytes 
at inflammatory sites leads to tissue damage and, if the threat is infectious, suboptimal 
pathogen control (104).  Phagocyte turnover kinetics remain important even at rest, as 
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continuous disposal and degradation of aged cells regulates the size of periperhal organs 
and inhibits spontaneous auto-inflammation (206).  
 
Our results reveal that neutrophil and inflammatory monocyte lifespans are dictated at 
homeostasis by tonic and systemically disseminated signals from the gut microbiota. 
Broad-spectrum antibiotic treatment accelerated the exit of circulating phagocytes from 
the bloodstream and accelerated their spontaneous cell death ex vivo. The turnover and 
apoptosis kinetics among cells from control mice resembled those seen in previous 
studies, reinforcing that our assays accurately reflect physiologic phagocyte lifespan 
ranges (364). We also sought to identify a particular microbial community responsible 
these stimulatory signals by narrowing the coverage of our antibiotic treatment. 
Neomycin recapitulated the impact of the broad antibiotic cocktail, a finding congruent 
with previous analyses of the microbiota and antiviral pulmonary responses (152).  
 
Neomycin is an aminoglycoside antibiotic that absorbs poorly into systemic circulation 
when given orally. It exhibits strong activity against gram-negative bacteria with less 
consistent coverage among gram-positive bacteria and little impact on anaerobes (78). 
We characterized the community architecture of the intestinal microbiota before and 
after neomycin treatment. We found that while facultative gram-negative taxa were 
relatively rare in all conditions, gram-positive lactobacilli were depleted particularly well 
upon drug treatment. This finding was consistent with previous studies reporting high 
sensitivity of lactobacilli to neomycin (251). Furthermore, the peptidoglycan of multiple 
lactobacilli express iE-DAP, the cardinal ligand for Nod1 and the first signal connecting 
the microbes to systemic phagocyte responses (31). Accordingly, we found that Nod1 
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signaling is both necessary and sufficient to mediate microbial extension of phagocyte 
lifespan. 
 
The path by which iE-DAP transits from the bacterial cell wall in the gut lumen to Nod1 
within the cytoplasm of host cells remains incompletely understood. Intact bacteria or 
cell wall components shed during microbial fission are taken into sensing cells through 
endosomal compartments, from which they traffic into the cytosol through the peptide 
transporters SLC15A3 and SLC15A1, meeting and binding to Nod1 on the cytoplasmic 
leaflet of the endosomal membrane (61). Binding of ligand to Nod1 triggers 
oligomerization of the sensor, which facilitates downstream signaling through 
downstream kinases to activate NF-κB (318).  
 
In addition to stimulating the release of cytokines and neutrophil chemokines, Nod1 
signaling also promotes the differentiation of IL-17A-producing T cells in the intestinal 
lamina propria (119). Our results demonstrate that IL-17A is essential for mediating 
microbial and Nod1-dependent signals to stimulate phagocyte lifespan. Systemic 
neutralization of IL-17A renders cells from control, knockout, and antibiotic-treated mice 
nearly equivalent in persistence and turnover kinetics. How IL-17A instructs phagocyte 
lifespan is likely complex and multifactorial. While it remains possible that IL-17A acts 
on neutrophils and inflammatory monocytes directly, the majority of evidence suggests 
that IL-17A instead stimulates the lifespan of these cells through additional cytokine 
intermediates. The best-studied terminal cytokine for neutrophil lifespan extension is G-
CSF (201).  G-CSF binding to its receptor (G-CSFR1) on neutrophils triggers diverse 
intracellular signaling pathways that converge to block the activation of caspase 3 (212). 
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Monocytes also receive signals from GM-CSF, though the two cytokines are by no means 
mutually exclusive (43). Collectively, these signals integrate to inhibit pro-apoptotic 
machinery with phagocytes and promote their persistence in the periphery. 
 
Future directions for this project will focus on determining whether microbiota-
mediated stimulation of phagocyte lifespan manifests as a differential outcome in some 
clinically significant disease scenario. Preliminary data suggests that mice treated with 
neomycin or lacking Nod1 exhibit impaired bacterial clearance of S. pneumoniae and S. 
aureus (data not shown).  This is consistent with previous reports showing accelerated 
sepsis from these pathogens among Nod1-deficient mice, though the present results 
suggest this is directly attributable to the neomycin-sensitive cohort of microbes. 
However, host defense phenotypes among Nod1-deficient mice are not necessarily 
caused by differential phagocyte lifespan, especially since Nod1-mediated stimulation 
also impacts neutrophil phagocytic capacity (70).    
 
Dissecting whether a causal relationship exists between phagocyte lifespan and infection 
outcome in vivo would require isolated manipulation of lifespan determinants without 
confounding effects on phagocytic capacity. One potentially promising strategy for 
investigating this in neutrophils is using myeloid-specific Mcl-1 knockout mice. Mcl-1 
has been termed the “master regulator” of intracellular neutrophil apoptotic signaling is 
essential for maintaining normal neutrophil (but not macrophage) lifespan (98, 239). 
Myeloid-specific depletion of Mcl-1 (by Cre recombinase under the LysM promoter) 
accelerates the turnover of neutrophils so sharply as to render mice nearly devoid of 
neutrophils successfully recruited to gastrointestinal infections (167). This result 
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supports the overarching hypothesis that neutrophil lifespan is central to its role in host 
defense, but does not dissect the role of the flora in governing these changes. Because 
these mice are functionally neutropenic, there may be a very narrow window in which to 
analyze the effects of neomycin treatment or Nod1 deletion on a background of myeloid 
Mcl-1 deficiency. 
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